<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Oncolytic virus - Wikipedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Oncolytic_virus","wgTitle":"Oncolytic virus","wgCurRevisionId":754177403,"wgRevisionId":754177403,"wgArticleId":1723667,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Wikipedia articles needing page number citations from January 2014","Articles needing more detailed references","Pages using ISBN magic links","All articles with unsourced statements","Articles with unsourced statements from January 2014","Articles with unsourced statements from October 2016","Articles with unsourced statements from October 2014","CS1 maint: Multiple names: authors list","Use dmy dates from May 2012","Biotechnology","Emerging technologies","Experimental cancer treatments","Virotherapy","Viruses"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Oncolytic_virus","wgRelevantArticleId":1723667,"wgRequestId":"WE0C4wpAMCUAACr8D7MAAAAD","wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgPreferredVariant":"en","wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgCentralNoticeCookiesToDelete":[],"wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgWikibaseItemId":"Q1560099","wgCentralAuthMobileDomain":false,"wgVisualEditorToolbarScrollOffset":0,"wgEditSubmitButtonLabelPublish":false});mw.loader.state({"ext.globalCssJs.user.styles":"ready","ext.globalCssJs.site.styles":"ready","site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","user.tokens":"loading","ext.cite.styles":"ready","wikibase.client.init":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","ext.wikimediaBadges":"ready","mediawiki.legacy.shared":"ready","mediawiki.legacy.commonPrint":"ready","mediawiki.sectionAnchor":"ready","mediawiki.skinning.interface":"ready","skins.vector.styles":"ready","ext.globalCssJs.user":"ready","ext.globalCssJs.site":"ready"});mw.loader.implement("user.options@0j3lz3q",function($,jQuery,require,module){mw.user.options.set({"variant":"en"});});mw.loader.implement("user.tokens@1dqfd7l",function ( $, jQuery, require, module ) {
mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});/*@nomin*/;

});mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","site","mediawiki.page.startup","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.legacy.wikibits","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.watchlist-notice","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.extra-toolbar-buttons","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.centralauth.centralautologin","mmv.head","mmv.bootstrap.autostart","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.navigationTiming","ext.uls.eventlogger","ext.uls.init","ext.uls.interface","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp","skins.vector.js"]);});</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.29.0-wmf.5"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Oncolytic_virus"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Oncolytic_virus&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Oncolytic_virus&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Oncolytic_virus"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Oncolytic_virus rootpage-Oncolytic_virus skin-vector action-view">		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Oncolytic virus</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><p>An <b>oncolytic virus</b> is a <a href="/wiki/Virus" title="Virus">virus</a> that preferentially infects and kills <a href="/wiki/Cancer_cell" title="Cancer cell">cancer cells</a>.<sup id="cite_ref-Oncolytic_viruses_1-0" class="reference"><a href="#cite_note-Oncolytic_viruses-1">[1]</a></sup><sup id="cite_ref-2" class="reference"><a href="#cite_note-2">[2]</a></sup> As the infected cancer cells are destroyed by <a href="/wiki/Lysis#Oncolysis" title="Lysis">oncolysis</a>, they release new infectious virus particles or <a href="/wiki/Virus" title="Virus">virions</a> to help destroy the remaining tumour.<sup id="cite_ref-ReferenceB_3-0" class="reference"><a href="#cite_note-ReferenceB-3">[3]</a></sup><sup id="cite_ref-4" class="reference"><a href="#cite_note-4">[4]</a></sup> Oncolytic viruses are thought not only to cause direct destruction of the <a href="/wiki/Tumour" class="mw-redirect" title="Tumour">tumour</a> cells, but also to stimulate host anti-tumour <a href="/wiki/Innate_immune_system" title="Innate immune system">immune responses</a>.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">[5]</a></sup><sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup></p>
<p>The potential of viruses as anti-cancer agents was first realised in the early twentieth century, although coordinated research efforts did not begin until the 1960s.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">[7]</a></sup> A number of viruses including <a href="/wiki/Adenoviridae" title="Adenoviridae">adenovirus</a>, <a href="/wiki/Reoviridae" title="Reoviridae">reovirus</a>, <a href="/wiki/Measles_virus" title="Measles virus">measles</a>, <a href="/wiki/Herpes_simplex_virus" title="Herpes simplex virus">herpes simplex</a>, <a href="/wiki/Newcastle_disease" title="Newcastle disease">Newcastle disease virus</a> and <a href="/wiki/Vaccinia" title="Vaccinia">vaccinia</a> have now been clinically tested as oncolytic agents.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8">[8]</a></sup> Most current oncolytic viruses are engineered for tumour selectivity, although there are naturally occurring examples such as <a href="/wiki/Reovirus" class="mw-redirect" title="Reovirus">reovirus</a> and the <a href="/wiki/Senecavirus" title="Senecavirus">senecavirus</a>,<sup id="cite_ref-Rudin2014_9-0" class="reference"><a href="#cite_note-Rudin2014-9">[9]</a></sup> resulting in <a href="/wiki/Clinical_trials" class="mw-redirect" title="Clinical trials">clinical trials</a>.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">[10]</a></sup></p>
<p>The first oncolytic virus approved by a national regulatory agency is genetically not modified ECHO-7 strain <a href="/wiki/Enterovirus" title="Enterovirus">enterovirus</a> <a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a>, approved in <a href="/wiki/Latvia" title="Latvia">Latvia</a> in 2004 for treatment of skin <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>.<sup id="cite_ref-latvia2004_11-0" class="reference"><a href="#cite_note-latvia2004-11">[11]</a></sup> Later (in 2015 and 2016 respectively) it was also approved in <a href="/wiki/Georgia_(country)" title="Georgia (country)">Georgia (country)</a><sup id="cite_ref-Georgia_Today_12-0" class="reference"><a href="#cite_note-Georgia_Today-12">[12]</a></sup> and <a rel="nofollow" class="external text" href="http://www.baltic-course.com/eng/good_for_business/?doc=120586"></a><a href="/wiki/Armenia" title="Armenia">Armenia</a>. In 2005 Chinese company, Shanghai Sunway Biotech registered an <a href="/wiki/Oncolytic_adenovirus" title="Oncolytic adenovirus">oncolytic adenovirus</a>, a <a href="/wiki/Genetic_engineering" title="Genetic engineering">genetically modified</a> adenovirus named <a href="/wiki/H101_virus" class="mw-redirect" title="H101 virus">H101</a>. It gained regulatory approval in 2005 from the <a href="/wiki/China_Food_and_Drug_Administration" title="China Food and Drug Administration">CFDA</a>, for the treatment of head and neck cancer.<sup id="cite_ref-pmid18183014_13-0" class="reference"><a href="#cite_note-pmid18183014-13">[13]</a></sup> The drug <a href="/wiki/Talimogene_laherparepvec" title="Talimogene laherparepvec">talimogene laherparepvec</a> (OncoVex, T-VEC) was the first <a href="/wiki/Oncolytic_herpes_virus" title="Oncolytic herpes virus">oncolytic herpes virus</a> ( a modified herpes simplex virus), approved for use by the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">USFDA</a> and by the <a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">EMA</a> in the <a href="/wiki/EU" class="mw-redirect" title="EU">EU</a> in 2015 for the treatment of advanced inoperable <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>. In a combined decision, members of the FDA's <a href="/wiki/Oncology_Drug_Advisory_Committee" title="Oncology Drug Advisory Committee">Oncology Drug Advisory Committee</a> and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic <a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">immunotherapy</a>.<sup id="cite_ref-Broderick_14-0" class="reference"><a href="#cite_note-Broderick-14">[14]</a></sup></p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Herpes_simplex_virus"><span class="tocnumber">1.1</span> <span class="toctext">Herpes simplex virus</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Oncorine_.28H101.29"><span class="tocnumber">1.2</span> <span class="toctext">Oncorine (H101)</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Mechanisms_of_action"><span class="tocnumber">2</span> <span class="toctext">Mechanisms of action</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#Direct_oncolysis"><span class="tocnumber">2.1</span> <span class="toctext">Direct oncolysis</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Immunotherapy"><span class="tocnumber">2.2</span> <span class="toctext">Immunotherapy</span></a>
<ul>
<li class="toclevel-3 tocsection-7"><a href="#Immunity_as_an_obstacle"><span class="tocnumber">2.2.1</span> <span class="toctext">Immunity as an obstacle</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Immunity_as_an_ally"><span class="tocnumber">2.2.2</span> <span class="toctext">Immunity as an ally</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-9"><a href="#Oncolytic_behaviour_of_wild-type_viruses"><span class="tocnumber">3</span> <span class="toctext">Oncolytic behaviour of wild-type viruses</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#Vesicular_stomatitis_virus"><span class="tocnumber">3.1</span> <span class="toctext">Vesicular stomatitis virus</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Poliovirus"><span class="tocnumber">3.2</span> <span class="toctext">Poliovirus</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Reovirus"><span class="tocnumber">3.3</span> <span class="toctext">Reovirus</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Senecavirus"><span class="tocnumber">3.4</span> <span class="toctext">Senecavirus</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#RIGVIR"><span class="tocnumber">3.5</span> <span class="toctext">RIGVIR</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Semliki_Forest_virus"><span class="tocnumber">3.6</span> <span class="toctext">Semliki Forest virus</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Other"><span class="tocnumber">3.7</span> <span class="toctext">Other</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Engineering_oncolytic_viruses"><span class="tocnumber">4</span> <span class="toctext">Engineering oncolytic viruses</span></a>
<ul>
<li class="toclevel-2 tocsection-18"><a href="#Directed_evolution"><span class="tocnumber">4.1</span> <span class="toctext">Directed evolution</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Attenuation"><span class="tocnumber">4.2</span> <span class="toctext">Attenuation</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Tumour_targeting"><span class="tocnumber">4.3</span> <span class="toctext">Tumour targeting</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Reporter_genes"><span class="tocnumber">4.4</span> <span class="toctext">Reporter genes</span></a></li>
<li class="toclevel-2 tocsection-22"><a href="#Modifications_to_improve_oncolytic_activity"><span class="tocnumber">4.5</span> <span class="toctext">Modifications to improve oncolytic activity</span></a>
<ul>
<li class="toclevel-3 tocsection-23"><a href="#Suicide_genes"><span class="tocnumber">4.5.1</span> <span class="toctext">Suicide genes</span></a></li>
<li class="toclevel-3 tocsection-24"><a href="#Suppression_of_angiogenesis"><span class="tocnumber">4.5.2</span> <span class="toctext">Suppression of angiogenesis</span></a></li>
<li class="toclevel-3 tocsection-25"><a href="#Radioiodine"><span class="tocnumber">4.5.3</span> <span class="toctext">Radioiodine</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-26"><a href="#Approved_therapeutic_agents"><span class="tocnumber">5</span> <span class="toctext">Approved therapeutic agents</span></a></li>
<li class="toclevel-1 tocsection-27"><a href="#Clinical_research"><span class="tocnumber">6</span> <span class="toctext">Clinical research</span></a>
<ul>
<li class="toclevel-2 tocsection-28"><a href="#Approved_somewhere"><span class="tocnumber">6.1</span> <span class="toctext">Approved somewhere</span></a></li>
<li class="toclevel-2 tocsection-29"><a href="#Started_phase_III"><span class="tocnumber">6.2</span> <span class="toctext">Started phase III</span></a></li>
<li class="toclevel-2 tocsection-30"><a href="#Started_phase_II"><span class="tocnumber">6.3</span> <span class="toctext">Started phase II</span></a></li>
<li class="toclevel-2 tocsection-31"><a href="#Started_phase_I"><span class="tocnumber">6.4</span> <span class="toctext">Started phase I</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-32"><a href="#Oncolytic_viruses_in_conjunction_with_existing_cancer_therapies"><span class="tocnumber">7</span> <span class="toctext">Oncolytic viruses in conjunction with existing cancer therapies</span></a>
<ul>
<li class="toclevel-2 tocsection-33"><a href="#Clinical_trials"><span class="tocnumber">7.1</span> <span class="toctext">Clinical trials</span></a></li>
<li class="toclevel-2 tocsection-34"><a href="#Pre-clinical_research"><span class="tocnumber">7.2</span> <span class="toctext">Pre-clinical research</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-35"><a href="#In_fiction"><span class="tocnumber">8</span> <span class="toctext">In fiction</span></a></li>
<li class="toclevel-1 tocsection-36"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-37"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-38"><a href="#Further_reading"><span class="tocnumber">11</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-39"><a href="#External_links"><span class="tocnumber">12</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=1" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>A connection between cancer <a href="/wiki/Regression_(medicine)" title="Regression (medicine)">regression</a> and viruses has long been theorised, and case reports of regression noted in <a href="/wiki/Cervical_cancer" title="Cervical cancer">cervical cancer</a>, <a href="/wiki/Burkitt_lymphoma" class="mw-redirect" title="Burkitt lymphoma">Burkitt lymphoma</a> and <a href="/wiki/Hodgkin_lymphoma" class="mw-redirect" title="Hodgkin lymphoma">Hodgkin lymphoma</a>, after immunisation or infection with an unrelated virus appeared at the beginning of the 20th century.<sup id="cite_ref-pmid15917655_15-0" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup> Efforts to treat cancer through <a href="/wiki/Immunisation" class="mw-redirect" title="Immunisation">immunisation</a> or <a href="/wiki/Virotherapy" title="Virotherapy">virotherapy</a> (deliberate infection with a virus), began in the mid-20th century.<sup id="cite_ref-pmid15917655_15-1" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup><sup id="cite_ref-pmid2555836_16-0" class="reference"><a href="#cite_note-pmid2555836-16">[16]</a></sup> As the technology for creating a custom virus did not exist, all early efforts focused on finding natural oncolytic viruses. During the 1960s, promising research involved using <a href="/wiki/Poliovirus" title="Poliovirus">poliovirus</a>,<sup id="cite_ref-pmid14202523_17-0" class="reference"><a href="#cite_note-pmid14202523-17">[17]</a></sup> <a href="/wiki/Adenovirus" class="mw-redirect" title="Adenovirus">adenovirus</a>,<sup id="cite_ref-pmid15917655_15-2" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup> <a href="/wiki/Coxsackie_virus" class="mw-redirect" title="Coxsackie virus">Coxsackie virus</a>,<sup id="cite_ref-pmid14244713_18-0" class="reference"><a href="#cite_note-pmid14244713-18">[18]</a></sup> <a href="/wiki/Echovirus" title="Echovirus">ECHO enterovirus</a> <a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a><sup id="cite_ref-virotherapy.eu_19-0" class="reference"><a href="#cite_note-virotherapy.eu-19">[19]</a></sup> and others.<sup id="cite_ref-pmid2555836_16-1" class="reference"><a href="#cite_note-pmid2555836-16">[16]</a></sup> The early complications were occasional cases of uncontrolled infection, resulting in significant morbidity and mortality; the very frequent development of an immune response, while harmless to the patient,<sup id="cite_ref-pmid15917655_15-3" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup> destroyed the virus and thus prevented it from destroying the cancer.<sup id="cite_ref-pmid14202523_17-1" class="reference"><a href="#cite_note-pmid14202523-17">[17]</a></sup> Only certain cancers could be treated through <a href="/wiki/Virotherapy" title="Virotherapy">virotherapy</a> was also recognised very early.<sup id="cite_ref-pmid14244713_18-1" class="reference"><a href="#cite_note-pmid14244713-18">[18]</a></sup> Even when a response was seen, these responses were neither complete nor durable.<sup id="cite_ref-pmid15917655_15-4" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup> The field of <a href="/wiki/Virotherapy" title="Virotherapy">virotherapy</a> was nearly abandoned for a time, as the technology required to modify viruses didn't exist and chemotherapy and radiotherapy technology enjoyed early success. However, now these technologies have been thoroughly developed, cancer is still a major cause of mortality and there is still a need for novel cancer therapies, hence the return to this sidelined therapy now using the recently developed genetic technology required to engineer viruses.<sup id="cite_ref-pmid15917655_15-5" class="reference"><a href="#cite_note-pmid15917655-15">[15]</a></sup><sup id="cite_ref-20" class="reference"><a href="#cite_note-20">[20]</a></sup></p>
<h3><span class="mw-headline" id="Herpes_simplex_virus">Herpes simplex virus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=2" title="Edit section: Herpes simplex virus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote">Main article: <a href="/wiki/Oncolytic_herpes_virus" title="Oncolytic herpes virus">Oncolytic herpes virus</a></div>
<p><a href="/wiki/Herpes_simplex_virus" title="Herpes simplex virus">Herpes simplex virus</a> (HSV) was one of the first viruses to be adapted to attack cancer cells selectively, because it was well understood, easy to manipulate and relatively harmless in its natural state (merely causing <a href="/wiki/Cold_sore" class="mw-redirect" title="Cold sore">cold sores</a>) so likely to pose fewer risks. The herpes simplex virus type 1 (HSV-1) mutant 1716 lacks both copies of the ICP34.5 gene, and as a result is no longer able to replicate in terminally <a href="/wiki/Cellular_differentiation" title="Cellular differentiation">differentiated</a> and non-<a href="/wiki/Cell_division" title="Cell division">dividing cells</a> but will infect and cause <a href="/wiki/Lysis" title="Lysis">lysis</a> very efficiently in cancer cells, and this has proved to be an effective tumour-targeting strategy.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup><sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup> In a wide range of <a href="/wiki/In_vivo" title="In vivo">in vivo</a> cancer models, the <a href="/wiki/HSV1716" class="mw-redirect" title="HSV1716">HSV1716</a> virus has induced tumour <a href="/wiki/Regression_(medicine)" title="Regression (medicine)">regression</a> and increased survival times.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24">[24]</a></sup><sup id="cite_ref-25" class="reference"><a href="#cite_note-25">[25]</a></sup></p>
<p>In 1996, the first approval was given in Europe for a <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trial</a> using the oncolytic virus HSV1716. From 1997 to 2003, strain HSV1716 was injected into tumours of patients with <a href="/wiki/Glioblastoma_multiforme" class="mw-redirect" title="Glioblastoma multiforme">glioblastoma multiforme</a>, a highly <a href="/wiki/Malignancy" title="Malignancy">malignant</a> brain tumour, with no evidence of toxicity or side effects, and some long-term survivors.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">[26]</a></sup><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">[27]</a></sup><sup id="cite_ref-28" class="reference"><a href="#cite_note-28">[28]</a></sup> Other safety trials have used HSV1716 to treat patients with <a href="/wiki/Melanoma" title="Melanoma">melanoma</a> and <a href="/wiki/Squamous-cell_carcinoma" class="mw-redirect" title="Squamous-cell carcinoma">squamous-cell carcinoma</a> of head and neck.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">[29]</a></sup><sup id="cite_ref-30" class="reference"><a href="#cite_note-30">[30]</a></sup> Since then other studies have shown that the outer coating of HSV1716 variants can be targeted to specific types of cancer cells,<sup id="cite_ref-31" class="reference"><a href="#cite_note-31">[31]</a></sup> and can be used to deliver a variety of additional genes into cancer cells, such as genes to split a harmless <a href="/wiki/Prodrug" title="Prodrug">prodrug</a> inside cancer cells to release toxic chemotherapy,<sup id="cite_ref-Braidwood-2009_32-0" class="reference"><a href="#cite_note-Braidwood-2009-32">[32]</a></sup> or genes which command infected cancer cells to concentrate <a href="/wiki/Protein_tag" title="Protein tag">protein tagged</a> with <a href="/wiki/Radioactive_iodine#Medical_and_pharmaceutical_uses" class="mw-redirect" title="Radioactive iodine">radioactive iodine</a>, so that individual cancer cells are killed by micro-dose radiation as well as by virus-induced cell lysis.<sup id="cite_ref-Sorensen-2012_33-0" class="reference"><a href="#cite_note-Sorensen-2012-33">[33]</a></sup></p>
<p>Other oncolytic viruses based on HSV have also been developed and are in clinical trials, most notably <a href="/wiki/OncoVex_GM-CSF" class="mw-redirect" title="OncoVex GM-CSF">OncoVex GM-CSF</a>, developed by Amgen, which has successfully completed a pivotal <a href="/wiki/Clinical_trials#Phases" class="mw-redirect" title="Clinical trials">Phase III trial</a> for advanced melanoma. This study met its primary endpoint (durable response rate) with a very high degree of statistical significance in March 2013, the first positive phase 3 study for an oncolytic virus in the western world.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (January 2014)">citation needed</span></a></i>]</sup></p>
<h3><span class="mw-headline" id="Oncorine_.28H101.29">Oncorine (H101)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=3" title="Edit section: Oncorine (H101)">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The first oncolytic virus to be approved by a regulatory agency was a genetically modified adenovirus named <a href="/wiki/H101_virus" class="mw-redirect" title="H101 virus">H101</a> by Shanghai Sunway Biotech. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.<sup id="cite_ref-pmid18183014_13-1" class="reference"><a href="#cite_note-pmid18183014-13">[13]</a></sup><sup id="cite_ref-pmid16507823_34-0" class="reference"><a href="#cite_note-pmid16507823-34">[34]</a></sup> Sunway's <a href="/wiki/H101_virus" class="mw-redirect" title="H101 virus">H101</a> and the very similar <a href="/wiki/Onyx-15" class="mw-redirect" title="Onyx-15">Onyx-15</a> have been engineered to remove a viral defense mechanism that interacts with a normal human gene <i><a href="/wiki/P53" class="mw-redirect" title="P53">p53</a></i>, which is very frequently dysregulated in cancer cells.<sup id="cite_ref-pmid16507823_34-1" class="reference"><a href="#cite_note-pmid16507823-34">[34]</a></sup> Despite the promises of early <i>in vivo</i> lab work, these viruses do not specifically infect cancer cells, but they still kill cancer cells preferentially.<sup id="cite_ref-pmid16507823_34-2" class="reference"><a href="#cite_note-pmid16507823-34">[34]</a></sup> While overall survival rates are not known, short-term response rates are approximately doubled for H101 plus chemotherapy when compared to chemotherapy alone.<sup id="cite_ref-pmid16507823_34-3" class="reference"><a href="#cite_note-pmid16507823-34">[34]</a></sup> It appears to work best when injected directly into a tumour, and when any resulting fever is not suppressed.<sup id="cite_ref-pmid16507823_34-4" class="reference"><a href="#cite_note-pmid16507823-34">[34]</a></sup> Systemic therapy (such as through infusion through an intravenous line) is desirable for treating metastatic disease.<sup id="cite_ref-pmid18167474_35-0" class="reference"><a href="#cite_note-pmid18167474-35">[35]</a></sup> It is now marketed under the brand name Oncorine.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup></p>
<h2><span class="mw-headline" id="Mechanisms_of_action">Mechanisms of action</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=4" title="Edit section: Mechanisms of action">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Direct_oncolysis">Direct oncolysis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=5" title="Edit section: Direct oncolysis">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Direct oncolysis, the cell killing effect produced by viral infection of cancer cells, was the original concept of oncolytic viruses.<sup id="cite_ref-Oncolytic_viruses_1-1" class="reference"><a href="#cite_note-Oncolytic_viruses-1">[1]</a></sup><sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup> By specific infection of a tumour cell, the virus multiplies within it until it causes cell <a href="/wiki/Lysis" title="Lysis">lysis</a>, releasing a second generation of virus to then infect surrounding cells.<sup id="cite_ref-ReferenceB_3-1" class="reference"><a href="#cite_note-ReferenceB-3">[3]</a></sup></p>
<h3><span class="mw-headline" id="Immunotherapy">Immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=6" title="Edit section: Immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>With advances in <a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">cancer immunotherapy</a> such as immune checkpoint inhibitors, increased interest was given to the prospect of oncolytic viruses as immunotherapies. There are two main considerations of the interaction between oncolytic viruses and the immune system.</p>
<h4><span class="mw-headline" id="Immunity_as_an_obstacle">Immunity as an obstacle</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=7" title="Edit section: Immunity as an obstacle">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>A major obstacle to the success of oncolytic viruses is the patient immune system which naturally attempts to deactivate any virus. This can be a particular problem for intravenous injection, where the virus must first survive interactions with the blood complement and neutralising antibodies.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">[38]</a></sup> It has been shown that <a href="/wiki/Immunosuppression" title="Immunosuppression">immunosuppression</a> by chemotherapy and inhibition of the <a href="/wiki/Complement_system" title="Complement system">complement system</a> can enhance oncolytic virus therapy.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">[39]</a></sup><sup id="cite_ref-40" class="reference"><a href="#cite_note-40">[40]</a></sup><sup id="cite_ref-41" class="reference"><a href="#cite_note-41">[41]</a></sup></p>
<p>Pre-existing immunity can be partly avoided by using viruses that are not common human pathogens. However, this does not avoid subsequent <a href="/wiki/Antibody" title="Antibody">antibody</a> generation. However, some studies have shown that pre-immunity to oncolytic viruses doesn't cause a significant reduction in efficacy.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup></p>
<p>Alternatively, the viral vector can be coated with a <a href="/wiki/Polymer" title="Polymer">polymer</a> such as <a href="/wiki/Polyethylene_glycol" title="Polyethylene glycol">polyethylene glycol</a>, shielding it from antibodies, but this also prevents viral coat proteins adhering to host cells.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43">[43]</a></sup></p>
<p>Another way to help oncolytic viruses reach cancer growths after intravenous injection, is to hide them inside <a href="/wiki/Macrophage" title="Macrophage">macrophages</a> (a type of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a>). Macrophages automatically migrate to areas of tissue destruction, especially where oxygen levels are low, characteristic of cancer growths, and have been used successfully to deliver oncolytic viruses to <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> in animals.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">[44]</a></sup></p>
<h4><span class="mw-headline" id="Immunity_as_an_ally">Immunity as an ally</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=8" title="Edit section: Immunity as an ally">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Although it poses a hurdle by inactivating viruses, the patient's immune system can also act as an ally against tumors; infection attracts the attention of the immune system to the tumour and may help to generate useful and long-lasting antitumor immunity.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup><sup id="cite_ref-46" class="reference"><a href="#cite_note-46">[46]</a></sup> This essentially produces a personalised <a href="/wiki/Cancer_vaccine" title="Cancer vaccine">Cancer vaccine</a>.</p>
<p>Many cases of spontaneous remission of cancer have been recorded, though not fully understood, they are thought likely to be a result of a sudden immune response or infection.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47">[47]</a></sup> Efforts to induce this phenomenon have used cancer vaccines (derived from cancer cells or selected cancer <a href="/wiki/Antigens" class="mw-redirect" title="Antigens">antigens</a>), or direct treatment with immune-stimulating factors on skin cancers.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48">[48]</a></sup> Some oncolytic viruses are very immunogenic and may by infection of the tumour, elicit an anti-tumor immune response, especially viruses delivering <a href="/wiki/Cytokines" class="mw-redirect" title="Cytokines">cytokines</a> or other immune stimulating factors.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49">[49]</a></sup></p>
<h2><span class="mw-headline" id="Oncolytic_behaviour_of_wild-type_viruses">Oncolytic behaviour of wild-type viruses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=9" title="Edit section: Oncolytic behaviour of wild-type viruses">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Vesicular_stomatitis_virus">Vesicular stomatitis virus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=10" title="Edit section: Vesicular stomatitis virus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Vesicular_stomatitis_virus" title="Vesicular stomatitis virus">Vesicular stomatitis virus</a> (VSV) is a rhabdovirus, consisting of 5 genes encoded by a negative sense, single-stranded RNA genome. In nature, VSV infects insects as well as livestock, where it causes a relatively localized and non-fatal illness. The low pathogenicity of this virus is due in large part to its sensitivity to interferons, a class of proteins that are released into the tissues and bloodstream during infection. These molecules activate genetic anti-viral defence programs that protect cells from infection and prevent spread of the virus. However, in 2000, Stojdl, Lichty et al.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">[50]</a></sup> demonstrated that defects in these pathways render cancer cells unresponsive to the protective effects of interferons and therefore highly sensitive to infection with VSV. Since VSV undergoes a rapid cytolytic replication cycle, infection leads to death of the malignant cell and roughly a 1000-fold amplification of virus within 24h. VSV is therefore highly suitable for therapeutic application, and several groups have gone on to show that systemically administered VSV can be delivered to a tumour site, where it replicates and induces disease regression, often leading to durable cures.<sup id="cite_ref-Stojdl03_51-0" class="reference"><a href="#cite_note-Stojdl03-51">[51]</a></sup><sup id="cite_ref-52" class="reference"><a href="#cite_note-52">[52]</a></sup><sup id="cite_ref-53" class="reference"><a href="#cite_note-53">[53]</a></sup><sup id="cite_ref-54" class="reference"><a href="#cite_note-54">[54]</a></sup> Attenuation of the virus by engineering a deletion of Met-51 of the matrix protein ablates virtually all infection of normal tissues, while replication in tumour cells is unaffected.<sup id="cite_ref-Stojdl03_51-1" class="reference"><a href="#cite_note-Stojdl03-51">[51]</a></sup></p>
<p>Recent research has shown that this virus has the potential to cure <a href="/wiki/Brain_tumor#Research_to_treatment_with_the_VSV-virus" title="Brain tumor">brain tumours</a>, thanks to its oncolytic properties.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55">[55]</a></sup></p>
<h3><span class="mw-headline" id="Poliovirus">Poliovirus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=11" title="Edit section: Poliovirus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote">Main article: <a href="/wiki/PVSRIPO" title="PVSRIPO">PVSRIPO</a></div>
<p><a href="/wiki/Poliovirus" title="Poliovirus">Poliovirus</a> is a natural neuropathogen, making it the obvious choice for selective replication in tumours derived from neuronal cells. Poliovirus has a plus-strand RNA genome, the <a href="/wiki/Translation_(biology)" title="Translation (biology)">translation</a> of which depends on a tissue-specific <a href="/wiki/Internal_ribosome_entry_site" title="Internal ribosome entry site">internal ribosome entry site</a> (IRES) within the 5' untranslated region of the viral genome, which is active in cells of neuronal origin and allows translation of the viral genome without a 5' cap. <a href="/wiki/Matthias_Gromeier" title="Matthias Gromeier">Gromeier</a> et al. (2000)<sup id="cite_ref-56" class="reference"><a href="#cite_note-56">[56]</a></sup> replaced the normal poliovirus IRES with a <a href="/wiki/Rhinovirus" title="Rhinovirus">rhinovirus</a> IRES, altering tissue specificity. The resulting <i>PV1(RIPO)</i> virus was able to selectively destroy <a href="/wiki/Malignant_glioma" class="mw-redirect" title="Malignant glioma">malignant glioma</a> cells, while leaving normal neuronal cells untouched.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">[57]</a></sup></p>
<h3><span class="mw-headline" id="Reovirus">Reovirus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=12" title="Edit section: Reovirus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Reoviridae" title="Reoviridae">Reoviruses</a>, an acronym for respiratory enteric orphan virus, generally infect mammalian respiratory and bowel systems. Most people have been exposed to reovirus by adulthood; however, the infection does not typically produce symptoms. The link to the reovirus' oncolytic ability was established after it was discovered to reproduce well in various cancer cell lines and lyses these cells.<sup id="cite_ref-pmid19806501_58-0" class="reference"><a href="#cite_note-pmid19806501-58">[58]</a></sup></p>
<p><a href="/wiki/Reolysin" title="Reolysin">Reolysin</a> is a formulation of reovirus that is currently in clinical trials for the treatment of various cancers.<sup id="cite_ref-pmid19565924_59-0" class="reference"><a href="#cite_note-pmid19565924-59">[59]</a></sup></p>
<h3><span class="mw-headline" id="Senecavirus">Senecavirus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=13" title="Edit section: Senecavirus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Seneca_Valley_virus" class="mw-redirect" title="Seneca Valley virus">Senecavirus</a>, also known as Seneca Valley Virus, is a naturally occurring wild-type oncolytic <a href="/wiki/Picornavirus" title="Picornavirus">picornavirus</a> discovered in 2001 as a tissue culture contaminate at Genetic Therapy, Inc. The initial isolate, SVV-001, is being developed as an anti-cancer therapeutic by Neotropix, Inc. under the name NTX-010 for cancers with neuroendocrine features including small cell lung cancer and a variety of pediatric solid tumours.</p>
<h3><span class="mw-headline" id="RIGVIR">RIGVIR</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=14" title="Edit section: RIGVIR">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote">Main article: <a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a></div>
<p>In the 1960s, a group of scientists in <a href="/wiki/Latvia" title="Latvia">Latvia</a> led by Dr. <a href="/wiki/Aina_Muceniece" title="Aina Muceniece">Aina Muceniece</a> studied oncolytic activity of ECHO viruses, but in 1968 a clinical trial of 5 ECHO enterovirus strains began (in trials participated stage-IV cancer patients volunteers). Scientists decided to continue researching ECHO-7 strain of ECHO virus (later called <a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a>), because it showed the most pronounced oncolytic properties. III-phase trials started in 1988 with the aim to compare effect of RIGVIR therapy with results of chemotherapy and radiation therapy. In 2004 RIGVIR was patented and registered in Latvia and since then it has been used in cancer therapy.<sup id="cite_ref-virotherapy.eu_19-1" class="reference"><a href="#cite_note-virotherapy.eu-19">[19]</a></sup> <a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a> virus was approved in Georgia in February 2015,<sup id="cite_ref-Georgia_Today_12-1" class="reference"><a href="#cite_note-Georgia_Today-12">[12]</a></sup> but in 2016 it was approved also in Armenia. Recent retrospective study published in Melanoma Research revealed that IB-IIC melanoma patients treated with oncolytic virus RIGVIR were 4.39–6.57-fold lower mortality than those, who according to melanoma treatment guidelines did not receive virotherapy and were only observed.<sup id="cite_ref-ReferenceA_60-0" class="reference"><a href="#cite_note-ReferenceA-60">[60]</a></sup> In 2015 <a href="/wiki/RIGVIR" title="RIGVIR">Rigvir</a> was included into the Latvian National guidelines for treatment of skin cancer and melanoma, developed by the Riga Eastern Clinical University Hospital Task Force.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">[61]</a></sup> In July 2016 new positive results were published in APMIS journal about RIGVIR efficacy in treatment of lung cancer and histiocytic sarcoma.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">[62]</a></sup></p>
<h3><span class="mw-headline" id="Semliki_Forest_virus">Semliki Forest virus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=15" title="Edit section: Semliki Forest virus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Semliki_Forest_virus" title="Semliki Forest virus">Semliki Forest virus</a> (SFV) is a virus that naturally infects cells of the central nervous system and causes <a href="/wiki/Encephalitis" title="Encephalitis">encephalitis</a>. A <a href="/wiki/Genetic_engineering" title="Genetic engineering">genetically engineered</a> form has been <a href="/wiki/Pre-clinical_development" title="Pre-clinical development">pre-clinically tested</a> as an oncolytic virus against the severe brain tumour type <a href="/wiki/Glioblastoma" title="Glioblastoma">glioblastoma</a>. The SFV was genetically modified with <a href="/wiki/MicroRNA" title="MicroRNA">microRNA</a> target sequences so that it only replicated in brain tumour cells and not in normal brain cells. The modified virus reduced tumour growth and prolonged survival of mice with brain tumours.<sup id="cite_ref-Ramachandran_clincanres.0925.2016_63-0" class="reference"><a href="#cite_note-Ramachandran_clincanres.0925.2016-63">[63]</a></sup> The modified virus was also found to efficiently kill human glioblastoma tumour cell lines.<sup id="cite_ref-Ramachandran_clincanres.0925.2016_63-1" class="reference"><a href="#cite_note-Ramachandran_clincanres.0925.2016-63">[63]</a></sup></p>
<h3><span class="mw-headline" id="Other">Other</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=16" title="Edit section: Other">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/Vesiculovirus" title="Vesiculovirus">maraba virus</a>, first identified in Brazilian sandflies, is being tested clinically.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">[64]</a></sup><sup id="cite_ref-65" class="reference"><a href="#cite_note-65">[65]</a></sup></p>
<h2><span class="mw-headline" id="Engineering_oncolytic_viruses">Engineering oncolytic viruses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=17" title="Edit section: Engineering oncolytic viruses">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Directed_evolution">Directed evolution</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=18" title="Edit section: Directed evolution">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>An innovative approach of drug development termed "<a href="/wiki/Directed_evolution" title="Directed evolution">directed evolution</a>" involves the creation of new viral variants or serotypes specifically directed against tumour cells via rounds of directed selection using large populations of randomly generated recombinant precursor viruses. The increased biodiversity produced by the initial <a href="/wiki/Homologous_recombination" title="Homologous recombination">homologous recombination</a> step provides a large random pool of viral candidates which can then be passed through a series of selection steps designed to lead towards a pre-specified outcome (e.g. higher tumor specific activity) without requiring any previous knowledge of the resultant viral mechanisms that are responsible for that outcome. The pool of resultant oncolytic viruses can then be further screened in pre-clinical models to select an oncolytic virus with the desired therapeutic characteristics.<sup id="cite_ref-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409_66-0" class="reference"><a href="#cite_note-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409-66">[66]</a></sup></p>
<p>Directed evolution was applied on human <a href="/wiki/Adenovirus" class="mw-redirect" title="Adenovirus">adenovirus</a>, one of many viruses that are being developed as oncolytic agents, to create a highly selective and yet potent oncolytic vaccine. As a result of this process, <a href="/wiki/ColoAd1" class="mw-redirect" title="ColoAd1">ColoAd1</a> (a novel chimeric member of the group B adenoviruses) was generated. This hybrid of adenovirus serotypes Ad11p and Ad3 shows much higher potency and tumour selectivity than the control viruses (including Ad5, Ad11p and Ad3) and was confirmed to generate approximately two logs more viral progeny on freshly isolated human colon tumour tissue than on matching normal tissue.<sup id="cite_ref-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409_66-1" class="reference"><a href="#cite_note-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409-66">[66]</a></sup></p>
<h3><span class="mw-headline" id="Attenuation">Attenuation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=19" title="Edit section: Attenuation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Attenuation involves deleting viral genes, or gene regions, to eliminate viral functions that are expendable in tumour cells, but not in normal cells, thus making the virus safer and more tumour-specific. Cancer cells and virus-infected cells have similar alterations in their cell signalling pathways, particularly those that govern progression through the <a href="/wiki/Cell_cycle" title="Cell cycle">cell cycle</a>.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67">[67]</a></sup> A viral gene whose function is to alter a pathway is dispensable in cells where the pathway is defective, but not in cells where the pathway is active.</p>
<p>The enzymes <a href="/wiki/Thymidine_kinase" title="Thymidine kinase">thymidine kinase</a> and <a href="/wiki/Ribonucleotide_reductase" title="Ribonucleotide reductase">ribonucleotide reductase</a> in cells are responsible for <a href="/wiki/DNA_replication" title="DNA replication">DNA synthesis</a> and are only expressed in cells which are actively replicating.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">[68]</a></sup> These <a href="/wiki/Enzymes" class="mw-redirect" title="Enzymes">enzymes</a> also exist in the genomes of certain viruses (E.g. HSV, vaccinia) and allow viral replication in <a href="/wiki/G0_phase" title="G0 phase">quiescent</a>(non-replicating) cells,<sup id="cite_ref-69" class="reference"><a href="#cite_note-69">[69]</a></sup> so if they are inactivated by mutation the virus will only be able to replicate in proliferating cells, such as cancer cells.</p>
<h3><span class="mw-headline" id="Tumour_targeting">Tumour targeting</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=20" title="Edit section: Tumour targeting">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>There are two main approaches for generating tumour selectivity: transductional and non-transductional targeting.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (October 2016)">citation needed</span></a></i>]</sup></p>
<ul>
<li>Transductional targeting involves modifying the viral coat proteins to target tumour cells while reducing entry to non-tumour cells. This approach to tumour selectivity has mainly focused on adenoviruses and HSV-1, although it is entirely viable with other viruses.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (October 2016)">citation needed</span></a></i>]</sup></li>
<li>Non-transductional targeting involves altering the genome of the virus so it can only replicate in cancer cells, most frequently as part of the attenuation of the virus.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (October 2016)">citation needed</span></a></i>]</sup>
<ul>
<li><a href="/wiki/Transcription_(genetics)" class="mw-redirect" title="Transcription (genetics)">Transcription</a> targeting can also be used, where critical parts of the viral genome are placed under the control of a tumour-specific <a href="/wiki/Promoter_(biology)" class="mw-redirect" title="Promoter (biology)">promoter</a>. A suitable promoter should be active in the tumour but inactive in the majority of normal tissue, particularly the <a href="/wiki/Liver" title="Liver">liver</a>, which is the organ that is most exposed to blood born viruses. Many such promoters have been identified and studied for the treatment of a range of cancers.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (October 2016)">citation needed</span></a></i>]</sup></li>
<li>Similarly, viral replication can be finely tuned with the use of <a href="/wiki/MicroRNA" title="MicroRNA">microRNAs</a> (miRNA) artificial target sites or miRNA response elements (MREs). Differential expression of miRNAs between healthy tissues and tumors permit to engineer oncolytic viruses detargeted from certain tissues of interest while allowing its replication in the tumor cells.</li>
</ul>
</li>
</ul>
<p>Double targeting with both transductional and non-transductional targeting methods is more effective than any one form of targeting alone.<sup id="cite_ref-Davydova04_70-0" class="reference"><a href="#cite_note-Davydova04-70">[70]</a></sup></p>
<div role="note" class="hatnote">Further information: <a href="/wiki/Oncolytic_adenovirus" title="Oncolytic adenovirus">Oncolytic adenovirus</a></div>
<h3><span class="mw-headline" id="Reporter_genes">Reporter genes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=21" title="Edit section: Reporter genes">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tleft">
<div class="thumbinner" style="width:122px;"><a href="/wiki/File:Viral_luciferase_expression_in_a_mouse_tumour.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/3a/Viral_luciferase_expression_in_a_mouse_tumour.jpg/120px-Viral_luciferase_expression_in_a_mouse_tumour.jpg" width="120" height="181" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/3a/Viral_luciferase_expression_in_a_mouse_tumour.jpg/180px-Viral_luciferase_expression_in_a_mouse_tumour.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/3/3a/Viral_luciferase_expression_in_a_mouse_tumour.jpg 2x" data-file-width="229" data-file-height="346" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Viral_luciferase_expression_in_a_mouse_tumour.jpg" class="internal" title="Enlarge"></a></div>
Viral luciferase expression in a mouse tumour</div>
</div>
</div>
<p>Both in the laboratory and in the clinic it is useful to have a simple means of identifying cells infected by the experimental virus. This can be done by equipping the virus with '<a href="/wiki/Reporter_gene" title="Reporter gene">reporter genes</a>' not normally present in viral genomes, which encode easily identifiable protein markers. One example of such proteins is GFP (<a href="/wiki/Green_fluorescent_protein" title="Green fluorescent protein">Green fluorescent protein</a>) which, when present in infected cells, will cause a fluorescent green light to be emitted when stimulated by blue light.<sup id="cite_ref-Haddad_2012_e41647_71-0" class="reference"><a href="#cite_note-Haddad_2012_e41647-71">[71]</a></sup><sup id="cite_ref-72" class="reference"><a href="#cite_note-72">[72]</a></sup> An advantage of this method is that it can be used on live cells and in patients with superficial infected lesions, it enables rapid non-invasive confirmation of viral infection.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73">[73]</a></sup> Another example of a visual marker useful in living cells is <a href="/wiki/Luciferase" title="Luciferase">luciferase</a>, an enzyme from the firefly which in the presence of <a href="/wiki/Luciferin" title="Luciferin">luciferin</a>, emits light detectable by specialized cameras.<sup id="cite_ref-Haddad_2012_e41647_71-1" class="reference"><a href="#cite_note-Haddad_2012_e41647-71">[71]</a></sup></p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Viral_LACZ_gene_expression.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/9f/Viral_LACZ_gene_expression.JPG/220px-Viral_LACZ_gene_expression.JPG" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/9f/Viral_LACZ_gene_expression.JPG/330px-Viral_LACZ_gene_expression.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/9f/Viral_LACZ_gene_expression.JPG/440px-Viral_LACZ_gene_expression.JPG 2x" data-file-width="640" data-file-height="480" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Viral_LACZ_gene_expression.JPG" class="internal" title="Enlarge"></a></div>
Vaccinia virus infected cells expressing beta-glucuronidase (blue colour)</div>
</div>
</div>
<p>The <i><a href="/wiki/E._coli" class="mw-redirect" title="E. coli">E. coli</a></i> enzymes <a href="/wiki/Beta-glucuronidase" title="Beta-glucuronidase">beta-glucuronidase</a> and <a href="/wiki/Beta-galactosidase" title="Beta-galactosidase">beta-galactosidase</a> can also be encoded by some viruses. These enzymes, in the presence of certain substrates, can produce intense colored compounds useful for visualizing infected cells and also for quantifying gene expression.</p>
<h3><span class="mw-headline" id="Modifications_to_improve_oncolytic_activity">Modifications to improve oncolytic activity</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=22" title="Edit section: Modifications to improve oncolytic activity">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Oncolytic viruses can be used against cancers in ways that are additional to lysis of infected cells.</p>
<h4><span class="mw-headline" id="Suicide_genes">Suicide genes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=23" title="Edit section: Suicide genes">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Viruses can be used as vectors for delivery of suicide genes, encoding enzymes that can metabolise a separately administered non-toxic <a href="/wiki/Pro-drug" class="mw-redirect" title="Pro-drug">pro-drug</a> into a potent <a href="/wiki/Cytotoxin" class="mw-redirect" title="Cytotoxin">cytotoxin</a>, which can diffuse to and kill neighbouring cells. One herpes simplex virus, encoding a thymidine kinase suicide gene, has progressed to phase III clinical trials. The herpes simplex virus thymidine kinase phosphorylates the <a href="/wiki/Pro-drug" class="mw-redirect" title="Pro-drug">pro-drug</a>, ganciclovir, which is then incorporated into <a href="/wiki/DNA" title="DNA">DNA</a>, blocking DNA synthesis.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">[74]</a></sup> The tumour selectivity of oncolytic viruses ensures that the suicide genes are only expressed in cancer cells, however a 'bystander effect' on surrounding tumour cells has been described with several suicide gene systems.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75">[75]</a></sup></p>
<h4><span class="mw-headline" id="Suppression_of_angiogenesis">Suppression of angiogenesis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=24" title="Edit section: Suppression of angiogenesis">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Angiogenesis" title="Angiogenesis">Angiogenesis</a> (blood vessel formation) is an essential part of the formation of large tumour masses. Angiogenesis can be inhibited by the expression of several genes, which can be delivered to cancer cells in <a href="/wiki/Viral_vector" title="Viral vector">viral vectors</a>, resulting in suppression of angiogenesis, and oxygen starvation in the tumour. The infection of cells with viruses containing the genes for angiostatin and endostatin synthesis inhibited tumour growth in mice. Enhanced antitumour activities have been demonstrated in a recombinant vaccinia virus encoding anti-angiogenic therapeutic antibody and with an HSV1716 variant expressing an inhibitor of angiogenesis.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76">[76]</a></sup><sup id="cite_ref-77" class="reference"><a href="#cite_note-77">[77]</a></sup></p>
<h4><span class="mw-headline" id="Radioiodine">Radioiodine</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=25" title="Edit section: Radioiodine">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/7/75/Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg/220px-Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg" width="220" height="100" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/7/75/Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg/330px-Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/75/Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg/440px-Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg 2x" data-file-width="992" data-file-height="452" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Adenoviral_NIS_gene_expression_in_a_mouse_tumour.jpg" class="internal" title="Enlarge"></a></div>
Adenoviral NIS gene expression in a mouse tumour (Located at the crosshairs) following intravenous delivery of virus (Left) compared to an uninfected control mouse (Right)</div>
</div>
</div>
<p>Addition of the <a href="/wiki/Sodium-iodide_symporter" title="Sodium-iodide symporter">sodium-iodide symporter</a> (NIS) gene to the viral genome causes infected tumour cells to express NIS and accumulate iodine. When combined with <a href="/wiki/Radioiodine" class="mw-redirect" title="Radioiodine">radioiodine</a> therapy it allows local radiotherapy of the tumour, as used to treat thyroid cancer. The radioiodine can also be used to visualise viral replication within the body by the use of a <a href="/wiki/Gamma_camera" title="Gamma camera">gamma camera</a>.<sup id="cite_ref-Haddad_2012_e41647_71-2" class="reference"><a href="#cite_note-Haddad_2012_e41647-71">[71]</a></sup> This approach has been used successfully preclinically with adenovirus, measles virus and vaccinia virus.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78">[78]</a></sup><sup id="cite_ref-79" class="reference"><a href="#cite_note-79">[79]</a></sup><sup id="cite_ref-80" class="reference"><a href="#cite_note-80">[80]</a></sup></p>
<h2><span class="mw-headline" id="Approved_therapeutic_agents">Approved therapeutic agents</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=26" title="Edit section: Approved therapeutic agents">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Talimogene_laherparepvec" title="Talimogene laherparepvec">Talimogene laherparepvec</a> (<a href="/wiki/OncoVEX_GM-CSF" class="mw-redirect" title="OncoVEX GM-CSF">OncoVEX GM-CSF</a>), aka T-vec, by <a href="/wiki/Amgen" title="Amgen">Amgen</a>, successfully completed phase III trials for advanced <a href="/wiki/Melanoma" title="Melanoma">melanoma</a> in March 2013.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81">[81]</a></sup> In October 2015, the <a href="/wiki/US_FDA" class="mw-redirect" title="US FDA">US FDA</a> approved T-VEC, with the brand name <b>Imlygic</b>, for the treatment of melanoma in patients with inoperable tumors.<sup id="cite_ref-Reuters_82-0" class="reference"><a href="#cite_note-Reuters-82">[82]</a></sup> becoming the first approved oncolytic agent in the western world.<sup id="cite_ref-Sheridan2015_83-0" class="reference"><a href="#cite_note-Sheridan2015-83">[83]</a></sup> It is based on <a href="/wiki/Herpes_simplex_virus" title="Herpes simplex virus">herpes simplex virus</a> (HSV-1).<sup id="cite_ref-Amgen-Jan-2012-8-K_84-0" class="reference"><a href="#cite_note-Amgen-Jan-2012-8-K-84">[84]</a></sup> It has also been tested in a Phase I trial for <a href="/wiki/Pancreatic_cancer" title="Pancreatic cancer">pancreatic cancer</a> and a Phase III trial in <a href="/wiki/Head_and_neck_cancer" title="Head and neck cancer">head and neck cancer</a> together with <a href="/wiki/Cisplatin" title="Cisplatin">Cisplatin</a> chemotherapy and radiotherapy.<sup id="cite_ref-85" class="reference"><a href="#cite_note-85">[85]</a></sup></li>
</ul>
<h2><span class="mw-headline" id="Clinical_research">Clinical research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=27" title="Edit section: Clinical research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>In 2014-2015 period a number of <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a> were initiated for a wide range of oncolytic virus products, reflecting the ongoing clinical development of this class of therapy.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">[86]</a></sup></p>
<table class="wikitable">
<tr>
<th scope="col">Agent</th>
<th scope="col">Indication</th>
<th scope="col">Phase</th>
<th scope="col">Status</th>
<th scope="col">Route</th>
<th scope="col">Notes</th>
<th scope="col">Ref</th>
</tr>
<tr>
<td>Ad5-yCD/mutTKSR39rep-hIL12</td>
<td>Prostate carcinoma</td>
<td>I</td>
<td>Recruiting</td>
<td>Intraprostatic</td>
<td>As single agent</td>
<td>NCT02555397</td>
</tr>
<tr>
<td><a href="/wiki/Cavatak" class="mw-redirect" title="Cavatak">Cavatak</a>™</td>
<td>Bladder carcinoma</td>
<td>I</td>
<td>Recruiting</td>
<td>Intravesical</td>
<td>Optionally combined with low-dose mitomycin C</td>
<td>NCT02316171</td>
</tr>
<tr>
<td></td>
<td>Melanoma</td>
<td>I</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>Combined with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a></td>
<td>NCT02307149</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Combined with <a href="/wiki/Pembrolizumab" title="Pembrolizumab">pembrolizumab</a></td>
<td>NCT02565992</td>
</tr>
<tr>
<td>CG0070</td>
<td>Bladder carcinoma</td>
<td>II</td>
<td>No longer available</td>
<td>Intravesical</td>
<td>As single agent</td>
<td>NCT02143804</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Recruiting</td>
<td>Intravesical</td>
<td>As single agent</td>
<td>NCT02365818</td>
</tr>
<tr>
<td>DNX-2401</td>
<td>Brain tumors</td>
<td>I</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>Combined with <a href="/wiki/IFN%CE%B3" class="mw-redirect" title="IFNγ">IFNγ</a></td>
<td>NCT02197169</td>
</tr>
<tr>
<td><a href="/wiki/G207" class="mw-redirect" title="G207">G207</a></td>
<td>Brain tumors</td>
<td>I</td>
<td>Not yet recruiting</td>
<td>Intratumoral</td>
<td>Optionally combined with radiation therapy</td>
<td>NCT02457845</td>
</tr>
<tr>
<td><a href="/w/index.php?title=HF10&amp;action=edit&amp;redlink=1" class="new" title="HF10 (page does not exist)">HF10</a></td>
<td>Melanoma</td>
<td>II</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>Combined with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a></td>
<td>NCT02272855</td>
</tr>
<tr>
<td></td>
<td>Solid tumors</td>
<td>I</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02428036</td>
</tr>
<tr>
<td><a href="/wiki/Imlygic" class="mw-redirect" title="Imlygic">Imlygic</a>®</td>
<td>Hepatocellular carcinoma</td>
<td>I</td>
<td>Not yet recruiting</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02509507</td>
</tr>
<tr>
<td></td>
<td>Melanoma</td>
<td>n.a.</td>
<td>Enrolling by invitation</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02173171</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02366195</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Combined with surgery</td>
<td>NCT02211131</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>Active, not recruiting</td>
<td>Intratumoral</td>
<td>Combined with <a href="/wiki/Pembrolizumab" title="Pembrolizumab">pembrolizumab</a></td>
<td>NCT02263508</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Available</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02147951</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NCT02297529</td>
</tr>
<tr>
<td></td>
<td>Soft tissue sarcoma</td>
<td>I/II</td>
<td>Recruiting</td>
<td>Intratumoral</td>
<td>Combined with radiotherapy</td>
<td>NCT02453191</td>
</tr>
<tr>
<td><a href="/wiki/JX-594" class="mw-redirect" title="JX-594">JX-594</a></td>
<td>Hepatocellular carcinoma</td>
<td>III</td>
<td>Not yet recruiting</td>
<td>Intratumoral</td>
<td>Combined with <a href="/wiki/Sorafenib" title="Sorafenib">sorafenib</a></td>
<td>NCT02562755</td>
</tr>
<tr>
<td>MG1-MA3</td>
<td>Solid tumors</td>
<td>I/II</td>
<td>Recruiting</td>
<td>Intravenous</td>
<td>Combined with a MAGEA3-encoding <a href="/wiki/Adenovirus" class="mw-redirect" title="Adenovirus">adenovirus</a></td>
<td>NCT02285816</td>
</tr>
<tr>
<td>MV-NIS</td>
<td>Gynecological tumors</td>
<td>II</td>
<td>Recruiting</td>
<td>Intraperitoneal</td>
<td>As single agent</td>
<td>NCT02364713</td>
</tr>
<tr>
<td></td>
<td>Multiple myeloma</td>
<td>II</td>
<td>Recruiting</td>
<td>Intravenous</td>
<td>Combined with <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a></td>
<td>NCT02192775</td>
</tr>
<tr>
<td>OBP-301</td>
<td>Solid tumors</td>
<td>I</td>
<td>Not yet recruiting</td>
<td>Intratumoral</td>
<td>As single agent</td>
<td>NCT02293850</td>
</tr>
<tr>
<td><a href="/wiki/Reolysin" title="Reolysin">Reolysin</a>®</td>
<td>Brain tumors</td>
<td>I</td>
<td>Recruiting</td>
<td>Intravenous</td>
<td>Combined with <a href="/wiki/GM-CSF" class="mw-redirect" title="GM-CSF">GM-CSF</a>&#160;s.c.</td>
<td>NCT02444546</td>
</tr>
<tr>
<td></td>
<td>Multiple myeloma</td>
<td>I</td>
<td>Recruiting</td>
<td>Intravenous</td>
<td>Combined with <a href="/wiki/Dexamethasone" title="Dexamethasone">dexamethasone</a> plus a proteasomal inhibitor</td>
<td>NCT02101944</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NCT02514382</td>
</tr>
<tr>
<td>Toca 511</td>
<td>Brain tumors</td>
<td>II/III</td>
<td>Not yet recruiting</td>
<td>Intratumoral</td>
<td>Combined with 5-FC and standard chemotherapy</td>
<td>NCT02414165</td>
</tr>
<tr>
<td></td>
<td>Solid tumors</td>
<td>I/II</td>
<td>Recruiting</td>
<td>Intratumoral Intravenous</td>
<td>Combined with 5-FC</td>
<td>NCT02576665</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</table>
<p>Abbreviations: 5-FC, <a href="/wiki/5-fluorocytosine" class="mw-redirect" title="5-fluorocytosine">5-fluorocytosine</a>; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNγ, interferon γ; MAGEA3, melanoma antigen family A3; s.c.,sub cutem.*initiated between 2014, March 1 and 2015, October 31.</p>
<h3><span class="mw-headline" id="Approved_somewhere">Approved somewhere</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=28" title="Edit section: Approved somewhere">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li><a href="/wiki/Talimogene_laherparepvec" title="Talimogene laherparepvec">Talimogene laherparepvec</a> was approved by the <a href="/wiki/US_FDA" class="mw-redirect" title="US FDA">US FDA</a> in 2015, with the brand name <b>Imlygic</b>, for the treatment of melanoma in patients with inoperable tumors.<sup id="cite_ref-Reuters_82-1" class="reference"><a href="#cite_note-Reuters-82">[82]</a></sup> In Jan 2016 it was approved in Europe for some inoperable melanoma.<sup id="cite_ref-EUAp_87-0" class="reference"><a href="#cite_note-EUAp-87">[87]</a></sup></li>
<li><a href="/wiki/Oncorine" class="mw-redirect" title="Oncorine">Oncorine</a>, by Shanghai Sunway Biotech, was approved in China for Head and neck cancer in 2005.<sup id="cite_ref-Nat2011_88-0" class="reference"><a href="#cite_note-Nat2011-88">[88]</a></sup> It is based on the adenovirus H101.</li>
<li><a href="/wiki/RIGVIR" title="RIGVIR">RIGVIR</a>, approved for use in Latvia and Georgia for melanoma treatment.</li>
</ul>
<h3><span class="mw-headline" id="Started_phase_III">Started phase III</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=29" title="Edit section: Started phase III">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li><a href="/wiki/Reolysin" title="Reolysin">Reolysin</a>, by <a href="/wiki/Oncolytics_Biotech" title="Oncolytics Biotech">Oncolytics Biotech</a>, is in phase III for head and neck cancer.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89">[89]</a></sup> An interim data release showed that this phase III had already obtained statistically significant tumor shrinkage in patients at their 6-week scan,<sup id="cite_ref-90" class="reference"><a href="#cite_note-90">[90]</a></sup> although the trial will not be complete until the overall survival data matures. Encouraging early results in colorectal cancer.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91">[91]</a></sup><sup id="cite_ref-92" class="reference"><a href="#cite_note-92">[92]</a></sup> In total there are 31 clinical studies either completed or ongoing, including many testing Reolysin alongside standard chemotherapies in a variety of solid cancers.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93">[93]</a></sup></li>
</ul>
<h3><span class="mw-headline" id="Started_phase_II">Started phase II</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=30" title="Edit section: Started phase II">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li><a href="/wiki/JX-594" class="mw-redirect" title="JX-594">JX-594</a>, by <a href="/wiki/Jennerex" title="Jennerex">Jennerex</a>, is currently in phase II for <a href="/wiki/Hepatocellular_carcinoma" title="Hepatocellular carcinoma">hepatocellular carcinoma</a>.<sup id="cite_ref-94" class="reference"><a href="#cite_note-94">[94]</a></sup> JX-594 is a thymidine kinase-deleted <a href="/wiki/Vaccinia_virus" class="mw-redirect" title="Vaccinia virus">Vaccinia virus</a> plus <a href="/wiki/GM-CSF" class="mw-redirect" title="GM-CSF">GM-CSF</a>.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">[95]</a></sup><sup id="cite_ref-96" class="reference"><a href="#cite_note-96">[96]</a></sup></li>
<li><a href="/wiki/Seneca_Valley_virus" class="mw-redirect" title="Seneca Valley virus">Seneca Valley virus</a> (NTX-010) and (<a href="/wiki/Seneca_Valley_virus-001" class="mw-redirect" title="Seneca Valley virus-001">SVV-001</a>), oncolytic <a href="/wiki/Picornavirus" title="Picornavirus">picornavirus</a>, is in phase II for <a href="/wiki/Small_cell_lung_cancer" class="mw-redirect" title="Small cell lung cancer">small cell lung cancer</a> and <a href="/wiki/Neuroblastoma" title="Neuroblastoma">neuroblastoma</a>.<sup id="cite_ref-Rudin2014_9-1" class="reference"><a href="#cite_note-Rudin2014-9">[9]</a></sup><sup id="cite_ref-Nat2011_88-1" class="reference"><a href="#cite_note-Nat2011-88">[88]</a></sup><sup id="cite_ref-97" class="reference"><a href="#cite_note-97">[97]</a></sup><sup id="cite_ref-98" class="reference"><a href="#cite_note-98">[98]</a></sup></li>
<li><a href="/wiki/ColoAd1" class="mw-redirect" title="ColoAd1">ColoAd1</a> was developed by Psioxus Therapeutics Ltd using the process of directed evolution. ColoAd1 has successfully completed recruitment in a Phase I clinical trials of ColoAd1.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (October 2014)">citation needed</span></a></i>]</sup> The trial involved recruiting patients with metastatic solid tumours where no standard treatment options were applicable. Samples from these patients showed evidence of virus replication within tumour sites after intravenous delivery. The second phase of the ColoAd1 study is planned to commence in 2014 and will examine efficacy in patients with metastatic colorectal cancer. Unlike many other oncolytic viruses, ColoAd1 can be administered by intravenous injection rather than requiring intra-tumoral injection. A second trial is comparing the efficacy of the intravenous approach versus direct intra-tumoural injection to assess the most effective method of delivering ColoAd1 to cancer patients (see the EU Clinical Trials Register for further details). A third trial is examining the intra-peritoneal route of delivery for women with late stage ovarian cancer.</li>
<li><a href="/wiki/Cavatak" class="mw-redirect" title="Cavatak">Cavatak</a><sup id="cite_ref-99" class="reference"><a href="#cite_note-99">[99]</a></sup><sup id="cite_ref-100" class="reference"><a href="#cite_note-100">[100]</a></sup> is a coxsackie virus which is in phase II clinical trials for the treatment of malignant melanoma.<sup id="cite_ref-101" class="reference"><a href="#cite_note-101">[101]</a></sup></li>
</ul>
<h3><span class="mw-headline" id="Started_phase_I">Started phase I</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=31" title="Edit section: Started phase I">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li><a href="/wiki/SEPREHVIR" class="mw-redirect" title="SEPREHVIR">SEPREHVIR</a> (HSV-1716), by Virttu Biologics,<sup id="cite_ref-102" class="reference"><a href="#cite_note-102">[102]</a></sup> completed phase I in glioblastoma, in squamous cell carcinoma of head and neck, and in melanoma. Ongoing phase I dose escalation study of intratumoral HSV-1716 in pediatric/young adult patients with non–central nervous system solid tumours and a new phase I/IIa study in <a href="/wiki/Mesothelioma" title="Mesothelioma">mesothelioma</a> commenced in 2012.<sup id="cite_ref-103" class="reference"><a href="#cite_note-103">[103]</a></sup><sup id="cite_ref-104" class="reference"><a href="#cite_note-104">[104]</a></sup></li>
<li><a href="/wiki/CGTG-102" title="CGTG-102">CGTG-102</a> (<a href="/w/index.php?title=Ad5/3&amp;action=edit&amp;redlink=1" class="new" title="Ad5/3 (page does not exist)">Ad5/3</a>-D24-<a href="/wiki/GM-CSF" class="mw-redirect" title="GM-CSF">GMCSF</a>), by <a href="/w/index.php?title=Oncos_Therapeutics&amp;action=edit&amp;redlink=1" class="new" title="Oncos Therapeutics (page does not exist)">Oncos Therapeutics</a>,<sup id="cite_ref-105" class="reference"><a href="#cite_note-105">[105]</a></sup> while in phase I was already used to treat 200 advanced cancer patients in the company's Advanced Therapy Access Program.<sup id="cite_ref-106" class="reference"><a href="#cite_note-106">[106]</a></sup></li>
<li><a href="/wiki/GL-ONC1" title="GL-ONC1">GL-ONC1</a>, by Genelux, is in phase I administered intravenously for <a href="/wiki/Solid_tumours" class="mw-redirect" title="Solid tumours">solid tumours</a>.<sup id="cite_ref-107" class="reference"><a href="#cite_note-107">[107]</a></sup> Additional trials are ongoing utilising alternative methods of administration including <a href="/wiki/Intrapleural" class="mw-redirect" title="Intrapleural">intrapleural</a> administration for patients with malignant <a href="/wiki/Pleural_effusion" title="Pleural effusion">pleural effusion</a>,<sup id="cite_ref-108" class="reference"><a href="#cite_note-108">[108]</a></sup> <a href="/wiki/Intraperitoneal_injection" title="Intraperitoneal injection">intraperitoneal injection</a> for patients with advanced peritoneal carcinomatosis,<sup id="cite_ref-109" class="reference"><a href="#cite_note-109">[109]</a></sup> and in combination therapy in head and neck cancers.<sup id="cite_ref-110" class="reference"><a href="#cite_note-110">[110]</a></sup></li>
<li><a href="/wiki/MV-NIS" class="mw-redirect" title="MV-NIS">MV-NIS</a>, an engineered measles virus has shown to be effective in targeted destruction of myeloma plasma cells. Radioactive Iodine imaging provides a novel technique for NIS gene expression monitoring.<sup id="cite_ref-russell2014_111-0" class="reference"><a href="#cite_note-russell2014-111">[111]</a></sup></li>
<li><a href="/wiki/DNX-2401" class="mw-redirect" title="DNX-2401">DNX-2401</a> is an oncolytic adenovirus with US Orphan drug status for <a href="/wiki/Glioma" title="Glioma">glioma</a>.<sup id="cite_ref-112" class="reference"><a href="#cite_note-112">[112]</a></sup></li>
<li><a href="/wiki/ONCOS-102" class="mw-redirect" title="ONCOS-102">ONCOS-102</a> is an engineered human serotype 5/3 adenovirus coding for human GM-CSF optimized to induce systemic anti-tumor T cell response in cancer patients. It has completed a phase I trial and is starting another for <a href="/wiki/Malignant_pleural_mesothelioma" class="mw-redirect" title="Malignant pleural mesothelioma">malignant pleural mesothelioma</a> (MPM).<sup id="cite_ref-113" class="reference"><a href="#cite_note-113">[113]</a></sup></li>
</ul>
<h2><span class="mw-headline" id="Oncolytic_viruses_in_conjunction_with_existing_cancer_therapies">Oncolytic viruses in conjunction with existing cancer therapies</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=32" title="Edit section: Oncolytic viruses in conjunction with existing cancer therapies">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>It is in conjunction with conventional cancer therapies that oncolytic viruses have often showed the most promise, since combined therapies operate synergistically with no apparent negative effects.<sup id="cite_ref-114" class="reference"><a href="#cite_note-114">[114]</a></sup></p>
<h3><span class="mw-headline" id="Clinical_trials">Clinical trials</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=33" title="Edit section: Clinical trials">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Onyx-015" class="mw-redirect" title="Onyx-015">Onyx-015</a> underwent trials in conjunction with chemotherapy before it was abandoned in the early 2000s. The combined treatment gave a greater response than either treatment alone, but the results were not entirely conclusive.<sup id="cite_ref-115" class="reference"><a href="#cite_note-115">[115]</a></sup></p>
<h3><span class="mw-headline" id="Pre-clinical_research">Pre-clinical research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=34" title="Edit section: Pre-clinical research">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Chen et al. (2001)<sup id="cite_ref-116" class="reference"><a href="#cite_note-116">[116]</a></sup> used CV706, a prostate-specific adenovirus, in conjunction with <a href="/wiki/Radiotherapy" class="mw-redirect" title="Radiotherapy">radiotherapy</a> on prostate cancer in mice. The combined treatment resulted in a synergistic increase in cell death, as well as a significant increase in viral burst size (the number of virus particles released from each cell lysis). No alteration in viral specificity was observed.</p>
<p>SEPREHVIR (HSV-1716) has also shown synergy in pre-clinical research when used in combination with several cancer chemotherapies.<sup id="cite_ref-117" class="reference"><a href="#cite_note-117">[117]</a></sup><sup id="cite_ref-118" class="reference"><a href="#cite_note-118">[118]</a></sup></p>
<p>The anti-<a href="/wiki/Angiogenesis" title="Angiogenesis">angiogenesis</a> drug <a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a> (anti-<a href="/wiki/VEGF" class="mw-redirect" title="VEGF">VEGF</a> antibody) has been shown to reduce the inflammatory response to oncolytic HSV and improve virotherapy in mice.<sup id="cite_ref-119" class="reference"><a href="#cite_note-119">[119]</a></sup></p>
<h2><span class="mw-headline" id="In_fiction">In fiction</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=35" title="Edit section: In fiction">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>In science fiction, the concept of an oncolytic virus was first introduced to the public in <a href="/wiki/Jack_Williamson" title="Jack Williamson">Jack Williamson</a>'s novel <i>Dragon's Island</i>, published in 1951, although Williamson's imaginary virus was based on a <a href="/wiki/Bacteriophage" title="Bacteriophage">bacteriophage</a> rather than a mammalian virus.<sup id="cite_ref-120" class="reference"><a href="#cite_note-120">[120]</a></sup> <i>Dragon's Island</i> is also known for being the source of the term "<a href="/wiki/Genetic_engineering" title="Genetic engineering">genetic engineering</a>".<sup id="cite_ref-121" class="reference"><a href="#cite_note-121">[121]</a></sup></p>
<p>The plot of the Hollywood film <i><a href="/wiki/I_Am_Legend_(film)" title="I Am Legend (film)">I Am Legend</a></i> is based on the premise that a worldwide epidemic was caused by a viral cure for cancer.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (January 2014)">citation needed</span></a></i>]</sup></p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=36" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Oncovirus" title="Oncovirus">Oncovirus</a>, virus that can cause cancer</li>
<li><a href="/wiki/Measles_virus_encoding_the_human_thyroidal_sodium_iodide_symporter_(MV-NIS)" title="Measles virus encoding the human thyroidal sodium iodide symporter (MV-NIS)">Measles virus encoding the human thyroidal sodium iodide symporter (MV-NIS)</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=37" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-count references-column-count-3" style="-moz-column-count: 3; -webkit-column-count: 3; column-count: 3; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-Oncolytic_viruses-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Oncolytic_viruses_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Oncolytic_viruses_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Nemunaitis, John (1999). "Oncolytic viruses". <i>Investigational New Drugs</i>. <b>17</b> (4): 375–86. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1023%2FA%3A1006334404767">10.1023/A:1006334404767</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10759404">10759404</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+viruses&amp;rft.aufirst=John&amp;rft.aulast=Nemunaitis&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1023%2FA%3A1006334404767&amp;rft_id=info%3Apmid%2F10759404&amp;rft.issue=4&amp;rft.jtitle=Investigational+New+Drugs&amp;rft.pages=375-86&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><cite class="citation journal">Fillat, Cristina (2010). <a rel="nofollow" class="external text" href="http://benthamopen.com/contents/pdf/TOGTJ/TOGTJ-3-15.pdf">"Controlling Adenoviral Replication to Induce Oncolytic Efficacy"</a> <span style="font-size:85%;">(PDF)</span>. <i>The Open Gene Therapy Journal</i>. <b>3</b>: 15–23. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F1875037001003010015">10.2174/1875037001003010015</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Controlling+Adenoviral+Replication+to+Induce+Oncolytic+Efficacy&amp;rft.aufirst=Cristina&amp;rft.aulast=Fillat&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbenthamopen.com%2Fcontents%2Fpdf%2FTOGTJ%2FTOGTJ-3-15.pdf&amp;rft_id=info%3Adoi%2F10.2174%2F1875037001003010015&amp;rft.jtitle=The+Open+Gene+Therapy+Journal&amp;rft.pages=15-23&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ReferenceB-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-ReferenceB_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ReferenceB_3-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Ferguson, Mark S.; Lemoine, Nicholas R.; Wang, Yaohe (2012). "Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles". <i>Advances in Virology</i>. <b>2012</b>: 1–14. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1155%2F2012%2F805629">10.1155/2012/805629</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Systemic+Delivery+of+Oncolytic+Viruses%3A+Hopes+and+Hurdles&amp;rft.aufirst=Mark+S.&amp;rft.aulast=Ferguson&amp;rft.au=Lemoine%2C+Nicholas+R.&amp;rft.au=Wang%2C+Yaohe&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1155%2F2012%2F805629&amp;rft.jtitle=Advances+in+Virology&amp;rft.pages=1-14&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2012" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><span class="citation">Casjens S. In: Mahy BWJ and Van Regenmortel MHV. <i>Desk Encyclopedia of General Virology</i>. Boston: Academic Press; 2010. <a href="/wiki/Special:BookSources/0123751462" class="internal mw-magiclink-isbn">ISBN 0-12-375146-2</a>. p. 167.</span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><cite class="citation journal">Melcher, Alan; Parato, Kelley; Rooney, Cliona M; Bell, John C (2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3129809">"Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide"</a>. <i>Molecular Therapy</i>. <b>19</b> (6): 1008–16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fmt.2011.65">10.1038/mt.2011.65</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3129809">3129809</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21505424">21505424</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Thunder+and+Lightning%3A+Immunotherapy+and+Oncolytic+Viruses+Collide&amp;rft.au=Bell%2C+John+C&amp;rft.aufirst=Alan&amp;rft.aulast=Melcher&amp;rft.au=Parato%2C+Kelley&amp;rft.au=Rooney%2C+Cliona+M&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3129809&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3129809&amp;rft_id=info%3Adoi%2F10.1038%2Fmt.2011.65&amp;rft_id=info%3Apmid%2F21505424&amp;rft.issue=6&amp;rft.jtitle=Molecular+Therapy&amp;rft.pages=1008-16&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lichty, Brian D.; Breitbach, Caroline J.; Stojdl, David F.; Bell, John C. (2014). "Going viral with cancer immunotherapy". <i>Nat Rev Cancer</i>. <b>14</b> (8): 559–67. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrc3770">10.1038/nrc3770</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24990523">24990523</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Going+viral+with+cancer+immunotherapy&amp;rft.au=Bell%2C+John+C.&amp;rft.au=Breitbach%2C+Caroline+J.&amp;rft.aufirst=Brian+D.&amp;rft.aulast=Lichty&amp;rft.au=Stojdl%2C+David+F.&amp;rft.date=2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc3770&amp;rft_id=info%3Apmid%2F24990523&amp;rft.issue=8&amp;rft.jtitle=Nat+Rev+Cancer&amp;rft.pages=559-67&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=14" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation journal">Alemany, R. (2012). "Viruses in cancer treatment". <i>Clinical and Translational Oncology</i>. <b>15</b> (3): 182–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs12094-012-0951-7">10.1007/s12094-012-0951-7</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23143950">23143950</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Viruses+in+cancer+treatment&amp;rft.aufirst=R.&amp;rft.aulast=Alemany&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs12094-012-0951-7&amp;rft_id=info%3Apmid%2F23143950&amp;rft.issue=3&amp;rft.jtitle=Clinical+and+Translational+Oncology&amp;rft.pages=182-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation journal">g. Donnelly, O.; Errington-Mais, F.; Prestwich, R.; Harrington, K.; Pandha, H.; Vile, R.; Melcher, A. (2012). "Recent Clinical Experience with Oncolytic Viruses". <i>Current Pharmaceutical Biotechnology</i>. <b>13</b> (9): 1834–41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F138920112800958904">10.2174/138920112800958904</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21740364">21740364</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Recent+Clinical+Experience+with+Oncolytic+Viruses&amp;rft.au=Errington-Mais%2C+F.&amp;rft.aufirst=O.&amp;rft.au=Harrington%2C+K.&amp;rft.aulast=g.+Donnelly&amp;rft.au=Melcher%2C+A.&amp;rft.au=Pandha%2C+H.&amp;rft.au=Prestwich%2C+R.&amp;rft.au=Vile%2C+R.&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2174%2F138920112800958904&amp;rft_id=info%3Apmid%2F21740364&amp;rft.issue=9&amp;rft.jtitle=Current+Pharmaceutical+Biotechnology&amp;rft.pages=1834-41&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Rudin2014-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Rudin2014_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Rudin2014_9-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Roberts, MS; Lorence, RM; Groene, WS; Bamat, MK (2006). "Naturally oncolytic viruses". <i>Current opinion in molecular therapeutics</i>. <b>8</b> (4): 314–21. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16955694">16955694</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Naturally+oncolytic+viruses&amp;rft.au=Bamat%2C+MK&amp;rft.aufirst=MS&amp;rft.au=Groene%2C+WS&amp;rft.aulast=Roberts&amp;rft.au=Lorence%2C+RM&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F16955694&amp;rft.issue=4&amp;rft.jtitle=Current+opinion+in+molecular+therapeutics&amp;rft.pages=314-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rudin, Charles M.; John T. Poirier; Neil N. Senzer; Joseph Stephenson; David Loesch; Kevin D. Burroughs; P. Seshidhar Reddy; Christine L. Hann; Paul L. Hallenbeck (2011-02-15). "Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features". <i>Clinical Cancer Research</i>. <b>17</b> (4): 888–895. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F1078-0432.CCR-10-1706">10.1158/1078-0432.CCR-10-1706</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1078-0432">1078-0432</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21304001">21304001</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Phase+I+clinical+study+of+Seneca+Valley+Virus+%28SVV-001%29%2C+a+replication-competent+picornavirus%2C+in+advanced+solid+tumors+with+neuroendocrine+features&amp;rft.au=Christine+L.+Hann&amp;rft.au=David+Loesch&amp;rft.aufirst=Charles+M.&amp;rft.au=John+T.+Poirier&amp;rft.au=Joseph+Stephenson&amp;rft.au=Kevin+D.+Burroughs&amp;rft.aulast=Rudin&amp;rft.au=Neil+N.+Senzer&amp;rft.au=Paul+L.+Hallenbeck&amp;rft.au=P.+Seshidhar+Reddy&amp;rft.date=2011-02-15&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-10-1706&amp;rft_id=info%3Apmid%2F21304001&amp;rft.issn=1078-0432&amp;rft.issue=4&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.pages=888-895&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-latvia2004-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-latvia2004_11-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.zva.gov.lv/zalu-registrs/?iss=1&amp;lang=en&amp;q=Rigvir&amp;ON=&amp;SN=&amp;">"Rigvir šķīdums injekcijām"</a>. <i>Medicinal product register of the Republic of Latvia</i>. 2004-04-29<span class="reference-accessdate">. Retrieved <span class="nowrap">2016-12-08</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Rigvir+%C5%A1%C4%B7%C4%ABdums+injekcij%C4%81m&amp;rft.date=2004-04-29&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.zva.gov.lv%2Fzalu-registrs%2F%3Fiss%3D1%26lang%3Den%26q%3DRigvir%26ON%3D%26SN%3D%26&amp;rft.jtitle=Medicinal+product+register+of+the+Republic+of+Latvia&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Georgia_Today-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Georgia_Today_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Georgia_Today_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://georgiatoday.ge/news/507/Georgia%E2%80%99s-Aversi-Now-Selling-Riga-Virus-Cancer-Treatment">"Georgia Today"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Georgia+Today&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fgeorgiatoday.ge%2Fnews%2F507%2FGeorgia%25E2%2580%2599s-Aversi-Now-Selling-Riga-Virus-Cancer-Treatment&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18183014-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid18183014_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18183014_13-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Frew, Sarah E; Sammut, Stephen M; Shore, Alysha F; Ramjist, Joshua K; Al-Bader, Sara; Rezaie, Rahim; Daar, Abdallah S; Singer, Peter A (2008). "Chinese health biotech and the billion-patient market". <i>Nature Biotechnology</i>. <b>26</b> (1): 37–53. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnbt0108-37">10.1038/nbt0108-37</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18183014">18183014</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Chinese+health+biotech+and+the+billion-patient+market&amp;rft.au=Al-Bader%2C+Sara&amp;rft.au=Daar%2C+Abdallah+S&amp;rft.aufirst=Sarah+E&amp;rft.aulast=Frew&amp;rft.au=Ramjist%2C+Joshua+K&amp;rft.au=Rezaie%2C+Rahim&amp;rft.au=Sammut%2C+Stephen+M&amp;rft.au=Shore%2C+Alysha+F&amp;rft.au=Singer%2C+Peter+A&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0108-37&amp;rft_id=info%3Apmid%2F18183014&amp;rft.issue=1&amp;rft.jtitle=Nature+Biotechnology&amp;rft.pages=37-53&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Broderick-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-Broderick_14-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Broderick, Jason. <a rel="nofollow" class="external text" href="http://www.onclive.com/web-exclusives/FDA-Panels-Support-Approval-of-T-VEC-in-Melanoma">"FDA Panels Support Approval of T-VEC in Melanoma"</a>. OncLive<span class="reference-accessdate">. Retrieved <span class="nowrap">24 Aug</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=Jason&amp;rft.aulast=Broderick&amp;rft.btitle=FDA+Panels+Support+Approval+of+T-VEC+in+Melanoma&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.onclive.com%2Fweb-exclusives%2FFDA-Panels-Support-Approval-of-T-VEC-in-Melanoma&amp;rft.pub=OncLive&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15917655-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15917655_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15917655_15-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid15917655_15-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid15917655_15-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid15917655_15-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid15917655_15-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Kuruppu, Darshini; Tanabe, Kenneth K. (2005). "Viral oncolysis by herpes simplex virus and other viruses". <i>Cancer Biology &amp; Therapy</i>. <b>4</b> (5): 524–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.4161%2Fcbt.4.5.1820">10.4161/cbt.4.5.1820</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15917655">15917655</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Viral+oncolysis+by+herpes+simplex+virus+and+other+viruses&amp;rft.aufirst=Darshini&amp;rft.aulast=Kuruppu&amp;rft.au=Tanabe%2C+Kenneth+K.&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.4161%2Fcbt.4.5.1820&amp;rft_id=info%3Apmid%2F15917655&amp;rft.issue=5&amp;rft.jtitle=Cancer+Biology+%26+Therapy&amp;rft.pages=524-31&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid2555836-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid2555836_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid2555836_16-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Voroshilova, MK (1989). "Potential use of nonpathogenic enteroviruses for control of human disease". <i>Progress in medical virology</i>. <b>36</b>: 191–202. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2555836">2555836</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Potential+use+of+nonpathogenic+enteroviruses+for+control+of+human+disease&amp;rft.aufirst=MK&amp;rft.aulast=Voroshilova&amp;rft.date=1989&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F2555836&amp;rft.jtitle=Progress+in+medical+virology&amp;rft.pages=191-202&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=36" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14202523-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid14202523_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid14202523_17-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Pond, AR; Manuelidis, EE (1964). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1907181">"Oncolytic Effect of Poliomyelitis Virus on Human Epidermoid Carcinoma (Hela Tumor) Heterologously Transplanted to Guinea Pigs"</a>. <i>The American Journal of Pathology</i>. <b>45</b> (2): 233–49. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1907181">1907181</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14202523">14202523</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+Effect+of+Poliomyelitis+Virus+on+Human+Epidermoid+Carcinoma+%28Hela+Tumor%29+Heterologously+Transplanted+to+Guinea+Pigs&amp;rft.aufirst=AR&amp;rft.aulast=Pond&amp;rft.au=Manuelidis%2C+EE&amp;rft.date=1964&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1907181&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1907181&amp;rft_id=info%3Apmid%2F14202523&amp;rft.issue=2&amp;rft.jtitle=The+American+Journal+of+Pathology&amp;rft.pages=233-49&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=45" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14244713-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid14244713_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid14244713_18-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Kunin, CM (1964). <a rel="nofollow" class="external text" href="http://mmbr.asm.org/cgi/pmidlookup?view=long&amp;pmid=14244713">"Cellular Susceptibility to Enterovirus"</a>. <i>Bacteriological reviews</i>. <b>28</b> (4): 382–90. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC441234">441234</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14244713">14244713</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Cellular+Susceptibility+to+Enterovirus&amp;rft.aufirst=CM&amp;rft.aulast=Kunin&amp;rft.date=1964&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC441234&amp;rft_id=http%3A%2F%2Fmmbr.asm.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D14244713&amp;rft_id=info%3Apmid%2F14244713&amp;rft.issue=4&amp;rft.jtitle=Bacteriological+reviews&amp;rft.pages=382-90&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-virotherapy.eu-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-virotherapy.eu_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-virotherapy.eu_19-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Chumakov P, Morozova V, Babkin I, Baikov I, Netesov S, Tikunova N (2012). <a rel="nofollow" class="external text" href="http://www.virotherapy.eu/publications/preclinical/oncolytic-enteroviruses-2012.pdf">"Oncolytic enteroviruses"</a> <span style="font-size:85%;">(PDF)</span>. <i>Molecular Biology</i>. <b>46</b> (5): 639–650. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1134%2Fs0026893312050032">10.1134/s0026893312050032</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+enteroviruses&amp;rft.au=Babkin%2C+I&amp;rft.au=Baikov%2C+I&amp;rft.aufirst=P&amp;rft.aulast=Chumakov&amp;rft.au=Morozova%2C+V&amp;rft.au=Netesov%2C+S&amp;rft.au=Tikunova%2C+N&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.virotherapy.eu%2Fpublications%2Fpreclinical%2Foncolytic-enteroviruses-2012.pdf&amp;rft_id=info%3Adoi%2F10.1134%2Fs0026893312050032&amp;rft.issue=5&amp;rft.jtitle=Molecular+Biology&amp;rft.pages=639-650&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=46" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kelly, Elizabeth; Russell, Stephen J (2007). "History of Oncolytic Viruses: Genesis to Genetic Engineering". <i>Molecular Therapy</i>. <b>15</b> (4): 651–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.mt.6300108">10.1038/sj.mt.6300108</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17299401">17299401</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=History+of+Oncolytic+Viruses%3A+Genesis+to+Genetic+Engineering&amp;rft.aufirst=Elizabeth&amp;rft.aulast=Kelly&amp;rft.au=Russell%2C+Stephen+J&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.mt.6300108&amp;rft_id=info%3Apmid%2F17299401&amp;rft.issue=4&amp;rft.jtitle=Molecular+Therapy&amp;rft.pages=651-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation journal">MacLean, A. R.; Ul-Fareed, M.; Robertson, L.; Harland, J.; Brown, S. M. (1991). "Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence". <i>Journal of General Virology</i>. <b>72</b> (3): 631–639. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1099%2F0022-1317-72-3-631">10.1099/0022-1317-72-3-631</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Herpes+simplex+virus+type+1+deletion+variants+1714+and+1716+pinpoint+neurovirulence-related+sequences+in+Glasgow+strain+17%2B+between+immediate+early+gene+1+and+the+%27a%27+sequence&amp;rft.au=Brown%2C+S.+M.&amp;rft.aufirst=A.+R.&amp;rft.au=Harland%2C+J.&amp;rft.aulast=MacLean&amp;rft.au=Robertson%2C+L.&amp;rft.au=Ul-Fareed%2C+M.&amp;rft.date=1991&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1099%2F0022-1317-72-3-631&amp;rft.issue=3&amp;rft.jtitle=Journal+of+General+Virology&amp;rft.pages=631-639&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation journal">Brown, S. M.; Harland, J.; MacLean, A. R.; Podlech, J.; Clements, J. B. (1994). "Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2". <i>Journal of General Virology</i>. <b>75</b> (9): 2367–2377. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1099%2F0022-1317-75-9-2367">10.1099/0022-1317-75-9-2367</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Cell+type+and+cell+state+determine+differential+in+vitro+growth+of+non-neurovirulent+ICP34.5-negative+herpes+simplex+virus+types+1+and+2&amp;rft.au=Clements%2C+J.+B.&amp;rft.aufirst=S.+M.&amp;rft.au=Harland%2C+J.&amp;rft.aulast=Brown&amp;rft.au=MacLean%2C+A.+R.&amp;rft.au=Podlech%2C+J.&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1099%2F0022-1317-75-9-2367&amp;rft.issue=9&amp;rft.jtitle=Journal+of+General+Virology&amp;rft.pages=2367-2377&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=75" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kesari, S; Randazzo, BP; Valyi-Nagy, T; Huang, QS; Brown, SM; MacLean, AR; Lee, VM; Trojanowski, JQ; Fraser, NW (1995). "Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant". <i>Laboratory investigation</i>. <b>73</b> (5): 636–48. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7474937">7474937</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Therapy+of+experimental+human+brain+tumors+using+a+neuroattenuated+herpes+simplex+virus+mutant&amp;rft.au=Brown%2C+SM&amp;rft.aufirst=S&amp;rft.au=Fraser%2C+NW&amp;rft.au=Huang%2C+QS&amp;rft.aulast=Kesari&amp;rft.au=Lee%2C+VM&amp;rft.au=MacLean%2C+AR&amp;rft.au=Randazzo%2C+BP&amp;rft.au=Trojanowski%2C+JQ&amp;rft.au=Valyi-Nagy%2C+T&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F7474937&amp;rft.issue=5&amp;rft.jtitle=Laboratory+investigation&amp;rft.pages=636-48&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=73" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation journal">McKie, EA; MacLean, AR; Lewis, AD; Cruickshank, G; Rampling, R; Barnett, SC; Kennedy, PGE; Brown, SM (1996). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2074706">"Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy"</a>. <i>British Journal of Cancer</i>. <b>74</b> (5): 745–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fbjc.1996.431">10.1038/bjc.1996.431</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2074706">2074706</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8795577">8795577</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Selective+in+vitro+replication+of+herpes+simplex+virus+type+1+%28HSV-1%29+ICP34.5+null+mutants+in+primary+human+CNS+tumours+-+evaluation+of+a+potentially+effective+clinical+therapy&amp;rft.au=Barnett%2C+SC&amp;rft.au=Brown%2C+SM&amp;rft.au=Cruickshank%2C+G&amp;rft.aufirst=EA&amp;rft.au=Kennedy%2C+PGE&amp;rft.aulast=McKie&amp;rft.au=Lewis%2C+AD&amp;rft.au=MacLean%2C+AR&amp;rft.au=Rampling%2C+R&amp;rft.date=1996&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2074706&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2074706&amp;rft_id=info%3Adoi%2F10.1038%2Fbjc.1996.431&amp;rft_id=info%3Apmid%2F8795577&amp;rft.issue=5&amp;rft.jtitle=British+Journal+of+Cancer&amp;rft.pages=745-52&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><cite class="citation journal">Randazzo, Bruce P; Bhat, Mulki G; Kesari, Santosh; Fraser, Nigel W; Brown, S Moira (1997). "Treatment of Experimental Subcutaneous Human Melanoma with a Replication-Restricted Herpes Simplex Virus Mutant". <i>Journal of Investigative Dermatology</i>. <b>108</b> (6): 933–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2F1523-1747.ep12295238">10.1111/1523-1747.ep12295238</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9182825">9182825</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Treatment+of+Experimental+Subcutaneous+Human+Melanoma+with+a+Replication-Restricted+Herpes+Simplex+Virus+Mutant&amp;rft.au=Bhat%2C+Mulki+G&amp;rft.au=Brown%2C+S+Moira&amp;rft.aufirst=Bruce+P&amp;rft.au=Fraser%2C+Nigel+W&amp;rft.au=Kesari%2C+Santosh&amp;rft.aulast=Randazzo&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2F1523-1747.ep12295238&amp;rft_id=info%3Apmid%2F9182825&amp;rft.issue=6&amp;rft.jtitle=Journal+of+Investigative+Dermatology&amp;rft.pages=933-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=108" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rampling, R; Cruickshank, G; Papanastassiou, V; Nicoll, J; Hadley, D; Brennan, D; Petty, R; MacLean, A; Harland, J; McKie, E; Mabbs, R; Brown, M (2000). "Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma". <i>Gene Therapy</i>. <b>7</b> (10): 859–66. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.gt.3301184">10.1038/sj.gt.3301184</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10845724">10845724</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Toxicity+evaluation+of+replication-competent+herpes+simplex+virus+%28ICP+34.5+null+mutant+1716%29+in+patients+with+recurrent+malignant+glioma&amp;rft.au=Brennan%2C+D&amp;rft.au=Brown%2C+M&amp;rft.au=Cruickshank%2C+G&amp;rft.aufirst=R&amp;rft.au=Hadley%2C+D&amp;rft.au=Harland%2C+J&amp;rft.aulast=Rampling&amp;rft.au=Mabbs%2C+R&amp;rft.au=MacLean%2C+A&amp;rft.au=McKie%2C+E&amp;rft.au=Nicoll%2C+J&amp;rft.au=Papanastassiou%2C+V&amp;rft.au=Petty%2C+R&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.gt.3301184&amp;rft_id=info%3Apmid%2F10845724&amp;rft.issue=10&amp;rft.jtitle=Gene+Therapy&amp;rft.pages=859-66&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation journal">Papanastassiou, V; Rampling, R; Fraser, M; Petty, R; Hadley, D; Nicoll, J; Harland, J; Mabbs, R; Brown, M (2002). "The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study". <i>Gene Therapy</i>. <b>9</b> (6): 398–406. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.gt.3301664">10.1038/sj.gt.3301664</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11960316">11960316</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=The+potential+for+efficacy+of+the+modified+%28ICP+34.5%88%92%29+herpes+simplex+virus+HSV1716+following+intratumoural+injection+into+human+malignant+glioma%3A+A+proof+of+principle+study&amp;rft.au=Brown%2C+M&amp;rft.aufirst=V&amp;rft.au=Fraser%2C+M&amp;rft.au=Hadley%2C+D&amp;rft.au=Harland%2C+J&amp;rft.aulast=Papanastassiou&amp;rft.au=Mabbs%2C+R&amp;rft.au=Nicoll%2C+J&amp;rft.au=Petty%2C+R&amp;rft.au=Rampling%2C+R&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.gt.3301664&amp;rft_id=info%3Apmid%2F11960316&amp;rft.issue=6&amp;rft.jtitle=Gene+Therapy&amp;rft.pages=398-406&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation journal">Harrow, S; Papanastassiou, V; Harland, J; Mabbs, R; Petty, R; Fraser, M; Hadley, D; Patterson, J; Brown, S M; Rampling, R (2004). "HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival". <i>Gene Therapy</i>. <b>11</b> (22): 1648–58. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.gt.3302289">10.1038/sj.gt.3302289</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15334111">15334111</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=HSV1716+injection+into+the+brain+adjacent+to+tumour+following+surgical+resection+of+high-grade+glioma%3A+Safety+data+and+long-term+survival&amp;rft.au=Brown%2C+S+M&amp;rft.aufirst=S&amp;rft.au=Fraser%2C+M&amp;rft.au=Hadley%2C+D&amp;rft.au=Harland%2C+J&amp;rft.aulast=Harrow&amp;rft.au=Mabbs%2C+R&amp;rft.au=Papanastassiou%2C+V&amp;rft.au=Patterson%2C+J&amp;rft.au=Petty%2C+R&amp;rft.au=Rampling%2C+R&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.gt.3302289&amp;rft_id=info%3Apmid%2F15334111&amp;rft.issue=22&amp;rft.jtitle=Gene+Therapy&amp;rft.pages=1648-58&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><cite class="citation journal">MacKie, Rona M; Stewart, Barry; Brown, S Moira (2001). "Intralesional injection of herpes simplex virus 1716 in metastatic melanoma". <i>The Lancet</i>. <b>357</b> (9255): 525–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2800%2904048-4">10.1016/S0140-6736(00)04048-4</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11229673">11229673</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Intralesional+injection+of+herpes+simplex+virus+1716+in+metastatic+melanoma&amp;rft.au=Brown%2C+S+Moira&amp;rft.aufirst=Rona+M&amp;rft.aulast=MacKie&amp;rft.au=Stewart%2C+Barry&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2800%2904048-4&amp;rft_id=info%3Apmid%2F11229673&amp;rft.issue=9255&amp;rft.jtitle=The+Lancet&amp;rft.pages=525-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=357" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation journal">Mace, Alastair T. M.; Ganly, Ian; Soutar, David S.; Brown, S. Moira (2008). "Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma". <i>Head &amp; Neck</i>. <b>30</b> (8): 1045–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fhed.20840">10.1002/hed.20840</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18615711">18615711</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Potential+for+efficacy+of+the+oncolytic+Herpes+simplex+virus+1716+in+patients+with+oral+squamous+cell+carcinoma&amp;rft.au=Brown%2C+S.+Moira&amp;rft.aufirst=Alastair+T.+M.&amp;rft.au=Ganly%2C+Ian&amp;rft.aulast=Mace&amp;rft.au=Soutar%2C+David+S.&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fhed.20840&amp;rft_id=info%3Apmid%2F18615711&amp;rft.issue=8&amp;rft.jtitle=Head+%26+Neck&amp;rft.pages=1045-51&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation journal">Conner, J; Braidwood, L; Brown, S M (2008). "A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein". <i>Gene Therapy</i>. <b>15</b> (24): 1579–92. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fgt.2008.121">10.1038/gt.2008.121</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18701918">18701918</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=A+strategy+for+systemic+delivery+of+the+oncolytic+herpes+virus+HSV1716%3A+Redirected+tropism+by+antibody-binding+sites+incorporated+on+the+virion+surface+as+a+glycoprotein+D+fusion+protein&amp;rft.au=Braidwood%2C+L&amp;rft.au=Brown%2C+S+M&amp;rft.aufirst=J&amp;rft.aulast=Conner&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fgt.2008.121&amp;rft_id=info%3Apmid%2F18701918&amp;rft.issue=24&amp;rft.jtitle=Gene+Therapy&amp;rft.pages=1579-92&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Braidwood-2009-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-Braidwood-2009_32-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Braidwood, L; Dunn, PD; Hardy, S; Evans, TR; Brown, SM (2009). "Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy". <i>Anticancer research</i>. <b>29</b> (6): 2159–66. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19528476">19528476</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Antitumor+activity+of+a+selectively+replication+competent+herpes+simplex+virus+%28HSV%29+with+enzyme+prodrug+therapy&amp;rft.au=Brown%2C+SM&amp;rft.au=Dunn%2C+PD&amp;rft.au=Evans%2C+TR&amp;rft.aufirst=L&amp;rft.au=Hardy%2C+S&amp;rft.aulast=Braidwood&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F19528476&amp;rft.issue=6&amp;rft.jtitle=Anticancer+research&amp;rft.pages=2159-66&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Sorensen-2012-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-Sorensen-2012_33-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sorensen, A.; Mairs, R. J.; Braidwood, L.; Joyce, C.; Conner, J.; Pimlott, S.; Brown, M.; Boyd, M. (2012). "In Vivo Evaluation of a Cancer Therapy Strategy Combining HSV1716-Mediated Oncolysis with Gene Transfer and Targeted Radiotherapy". <i>Journal of Nuclear Medicine</i>. <b>53</b> (4): 647–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2967%2Fjnumed.111.090886">10.2967/jnumed.111.090886</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22414636">22414636</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=In+Vivo+Evaluation+of+a+Cancer+Therapy+Strategy+Combining+HSV1716-Mediated+Oncolysis+with+Gene+Transfer+and+Targeted+Radiotherapy&amp;rft.au=Boyd%2C+M.&amp;rft.au=Braidwood%2C+L.&amp;rft.au=Brown%2C+M.&amp;rft.au=Conner%2C+J.&amp;rft.aufirst=A.&amp;rft.au=Joyce%2C+C.&amp;rft.aulast=Sorensen&amp;rft.au=Mairs%2C+R.+J.&amp;rft.au=Pimlott%2C+S.&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2967%2Fjnumed.111.090886&amp;rft_id=info%3Apmid%2F22414636&amp;rft.issue=4&amp;rft.jtitle=Journal+of+Nuclear+Medicine&amp;rft.pages=647-54&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=53" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16507823-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16507823_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16507823_34-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid16507823_34-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid16507823_34-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid16507823_34-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Garber, K. (2006). "China Approves World's First Oncolytic Virus Therapy for Cancer Treatment". <i>JNCI Journal of the National Cancer Institute</i>. <b>98</b> (5): 298–300. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fjnci%2Fdjj111">10.1093/jnci/djj111</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16507823">16507823</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=China+Approves+World%27s+First+Oncolytic+Virus+Therapy+for+Cancer+Treatment&amp;rft.aufirst=K.&amp;rft.aulast=Garber&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2Fdjj111&amp;rft_id=info%3Apmid%2F16507823&amp;rft.issue=5&amp;rft.jtitle=JNCI+Journal+of+the+National+Cancer+Institute&amp;rft.pages=298-300&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=98" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18167474-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18167474_35-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ayllón Barbellido, S; Campo Trapero, J; Cano Sánchez, J; Perea García, MA; Escudero Castaño, N; Bascones Martínez, A (2008). <a rel="nofollow" class="external text" href="http://www.medicinaoral.com/medoralfree01/v13i1/medoralv13i1p15.pdf">"Gene therapy in the management of oral cancer: Review of the literature"</a> <span style="font-size:85%;">(PDF)</span>. <i>Medicina oral, patologia oral y cirugia bucal</i>. <b>13</b> (1): E15–21. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18167474">18167474</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Gene+therapy+in+the+management+of+oral+cancer%3A+Review+of+the+literature&amp;rft.au=Bascones+Mart%C3nez%2C+A&amp;rft.au=Campo+Trapero%2C+J&amp;rft.au=Cano+S%C3%A1nchez%2C+J&amp;rft.au=Escudero+Casta%C3%B1o%2C+N&amp;rft.aufirst=S&amp;rft.aulast=Ayll%C3%B3n+Barbellido&amp;rft.au=Perea+Garc%C3a%2C+MA&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.medicinaoral.com%2Fmedoralfree01%2Fv13i1%2Fmedoralv13i1p15.pdf&amp;rft_id=info%3Apmid%2F18167474&amp;rft.issue=1&amp;rft.jtitle=Medicina+oral%2C+patologia+oral+y+cirugia+bucal&amp;rft.pages=E15-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation journal">Guo, J.; Xin, H. (2006). "CHINESE GENE THERAPY: Splicing Out the West?". <i>Science</i>. <b>314</b> (5803): 1232–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1126%2Fscience.314.5803.1232">10.1126/science.314.5803.1232</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17124300">17124300</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=CHINESE+GENE+THERAPY%3A+Splicing+Out+the+West%3F&amp;rft.aufirst=J.&amp;rft.aulast=Guo&amp;rft.au=Xin%2C+H.&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.314.5803.1232&amp;rft_id=info%3Apmid%2F17124300&amp;rft.issue=5803&amp;rft.jtitle=Science&amp;rft.pages=1232-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=314" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation journal">Fillat, Cristina (2010). <a rel="nofollow" class="external text" href="http://benthamopen.com/contents/pdf/TOGTJ/TOGTJ-3-15.pdf">"Controlling Adenoviral Replication to Induce Oncolytic Efficacy"</a> <span style="font-size:85%;">(PDF)</span>. <i>The Open Gene Therapy Journal</i>. <b>3</b>: 15–23. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F1875037001003010015">10.2174/1875037001003010015</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Controlling+Adenoviral+Replication+to+Induce+Oncolytic+Efficacy&amp;rft.aufirst=Cristina&amp;rft.aulast=Fillat&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbenthamopen.com%2Fcontents%2Fpdf%2FTOGTJ%2FTOGTJ-3-15.pdf&amp;rft_id=info%3Adoi%2F10.2174%2F1875037001003010015&amp;rft.jtitle=The+Open+Gene+Therapy+Journal&amp;rft.pages=15-23&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite class="citation journal">Schmidt, C. (2013). "Awaiting a Moment of Truth for Oncolytic Viruses". <i>JNCI Journal of the National Cancer Institute</i>. <b>105</b> (10): 675–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fjnci%2Fdjt111">10.1093/jnci/djt111</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23650626">23650626</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Awaiting+a+Moment+of+Truth+for+Oncolytic+Viruses&amp;rft.aufirst=C.&amp;rft.aulast=Schmidt&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2Fdjt111&amp;rft_id=info%3Apmid%2F23650626&amp;rft.issue=10&amp;rft.jtitle=JNCI+Journal+of+the+National+Cancer+Institute&amp;rft.pages=675-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=105" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kottke, T.; Thompson, J.; Diaz, R. M.; Pulido, J.; Willmon, C.; Coffey, M.; Selby, P.; Melcher, A.; Harrington, K.; Vile, R. G. (2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3046733">"Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2"</a>. <i>Clinical Cancer Research</i>. <b>15</b> (2): 561–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F1078-0432.CCR-08-1688">10.1158/1078-0432.CCR-08-1688</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3046733">3046733</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19147761">19147761</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Improved+Systemic+Delivery+of+Oncolytic+Reovirus+to+Established+Tumors+Using+Preconditioning+with+Cyclophosphamide-Mediated+Treg+Modulation+and+Interleukin-2&amp;rft.au=Coffey%2C+M.&amp;rft.au=Diaz%2C+R.+M.&amp;rft.aufirst=T.&amp;rft.au=Harrington%2C+K.&amp;rft.aulast=Kottke&amp;rft.au=Melcher%2C+A.&amp;rft.au=Pulido%2C+J.&amp;rft.au=Selby%2C+P.&amp;rft.au=Thompson%2C+J.&amp;rft.au=Vile%2C+R.+G.&amp;rft.au=Willmon%2C+C.&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3046733&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3046733&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-08-1688&amp;rft_id=info%3Apmid%2F19147761&amp;rft.issue=2&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.pages=561-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lolkema, M. P.; Arkenau, H.-T.; Harrington, K.; Roxburgh, P.; Morrison, R.; Roulstone, V.; Twigger, K.; Coffey, M.; Mettinger, K.; Gill, G.; Evans, T. R. J.; De Bono, J. S. (2010). "A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer". <i>Clinical Cancer Research</i>. <b>17</b> (3): 581–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F1078-0432.CCR-10-2159">10.1158/1078-0432.CCR-10-2159</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21106728">21106728</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=A+Phase+I+Study+of+the+Combination+of+Intravenous+Reovirus+Type+3+Dearing+and+Gemcitabine+in+Patients+with+Advanced+Cancer&amp;rft.au=Arkenau%2C+H.-T.&amp;rft.au=Coffey%2C+M.&amp;rft.au=De+Bono%2C+J.+S.&amp;rft.au=Evans%2C+T.+R.+J.&amp;rft.aufirst=M.+P.&amp;rft.au=Gill%2C+G.&amp;rft.au=Harrington%2C+K.&amp;rft.aulast=Lolkema&amp;rft.au=Mettinger%2C+K.&amp;rft.au=Morrison%2C+R.&amp;rft.au=Roulstone%2C+V.&amp;rft.au=Roxburgh%2C+P.&amp;rft.au=Twigger%2C+K.&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-10-2159&amp;rft_id=info%3Apmid%2F21106728&amp;rft.issue=3&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.pages=581-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation journal">Magge, D; Guo, Z S; O'Malley, M E; Francis, L; Ravindranathan, R; Bartlett, D L (2013). "Inhibitors of C5 complement enhance vaccinia virus oncolysis". <i>Cancer Gene Therapy</i>. <b>20</b> (6): 342–50. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fcgt.2013.26">10.1038/cgt.2013.26</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23661042">23661042</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Inhibitors+of+C5+complement+enhance+vaccinia+virus+oncolysis&amp;rft.au=Bartlett%2C+D+L&amp;rft.aufirst=D&amp;rft.au=Francis%2C+L&amp;rft.au=Guo%2C+Z+S&amp;rft.aulast=Magge&amp;rft.au=O%27Malley%2C+M+E&amp;rft.au=Ravindranathan%2C+R&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fcgt.2013.26&amp;rft_id=info%3Apmid%2F23661042&amp;rft.issue=6&amp;rft.jtitle=Cancer+Gene+Therapy&amp;rft.pages=342-50&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation journal">Heo, Jeong; Reid, Tony; Ruo, Leyo; Breitbach, Caroline J; Rose, Steven; Bloomston, Mark; Cho, Mong; Lim, Ho Yeong; Chung, Hyun Cheol; Kim, Chang Won; Burke, James; Lencioni, Riccardo; Hickman, Theresa; Moon, Anne; Lee, Yeon Sook; Kim, Mi Kyeong; Daneshmand, Manijeh; Dubois, Kara; Longpre, Lara; Ngo, Minhtran; Rooney, Cliona; Bell, John C; Rhee, Byung-Geon; Patt, Richard; Hwang, Tae-Ho; Kirn, David H (2013). "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer". <i>Nature Medicine</i>. <b>19</b> (3): 329–36. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnm.3089">10.1038/nm.3089</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23396206">23396206</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Randomized+dose-finding+clinical+trial+of+oncolytic+immunotherapeutic+vaccinia+JX-594+in+liver+cancer&amp;rft.au=Bell%2C+John+C&amp;rft.au=Bloomston%2C+Mark&amp;rft.au=Breitbach%2C+Caroline+J&amp;rft.au=Burke%2C+James&amp;rft.au=Cho%2C+Mong&amp;rft.au=Chung%2C+Hyun+Cheol&amp;rft.au=Daneshmand%2C+Manijeh&amp;rft.au=Dubois%2C+Kara&amp;rft.aufirst=Jeong&amp;rft.au=Hickman%2C+Theresa&amp;rft.au=Hwang%2C+Tae-Ho&amp;rft.au=Kim%2C+Chang+Won&amp;rft.au=Kim%2C+Mi+Kyeong&amp;rft.au=Kirn%2C+David+H&amp;rft.aulast=Heo&amp;rft.au=Lee%2C+Yeon+Sook&amp;rft.au=Lencioni%2C+Riccardo&amp;rft.au=Lim%2C+Ho+Yeong&amp;rft.au=Longpre%2C+Lara&amp;rft.au=Moon%2C+Anne&amp;rft.au=Ngo%2C+Minhtran&amp;rft.au=Patt%2C+Richard&amp;rft.au=Reid%2C+Tony&amp;rft.au=Rhee%2C+Byung-Geon&amp;rft.au=Rooney%2C+Cliona&amp;rft.au=Rose%2C+Steven&amp;rft.au=Ruo%2C+Leyo&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnm.3089&amp;rft_id=info%3Apmid%2F23396206&amp;rft.issue=3&amp;rft.jtitle=Nature+Medicine&amp;rft.pages=329-36&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wonganan, Piyanuch; Croyle, Maria A. (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3185605">"PEGylated Adenoviruses: From Mice to Monkeys"</a>. <i>Viruses</i>. <b>2</b> (2): 468–502. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3390%2Fv2020468">10.3390/v2020468</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3185605">3185605</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21994645">21994645</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=PEGylated+Adenoviruses%3A+From+Mice+to+Monkeys&amp;rft.au=Croyle%2C+Maria+A.&amp;rft.aufirst=Piyanuch&amp;rft.aulast=Wonganan&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3185605&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3185605&amp;rft_id=info%3Adoi%2F10.3390%2Fv2020468&amp;rft_id=info%3Apmid%2F21994645&amp;rft.issue=2&amp;rft.jtitle=Viruses&amp;rft.pages=468-502&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><cite class="citation journal">Muthana, M.; Rodrigues, S.; Chen, Y.-Y.; Welford, A.; Hughes, R.; Tazzyman, S.; Essand, M.; Morrow, F.; Lewis, C. E. (2012). "Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation". <i>Cancer Research</i>. <b>73</b> (2): 490–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F0008-5472.CAN-12-3056">10.1158/0008-5472.CAN-12-3056</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23172310">23172310</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Macrophage+Delivery+of+an+Oncolytic+Virus+Abolishes+Tumor+Regrowth+and+Metastasis+after+Chemotherapy+or+Irradiation&amp;rft.au=Chen%2C+Y.-Y.&amp;rft.au=Essand%2C+M.&amp;rft.aufirst=M.&amp;rft.au=Hughes%2C+R.&amp;rft.aulast=Muthana&amp;rft.au=Lewis%2C+C.+E.&amp;rft.au=Morrow%2C+F.&amp;rft.au=Rodrigues%2C+S.&amp;rft.au=Tazzyman%2C+S.&amp;rft.au=Welford%2C+A.&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1158%2F0008-5472.CAN-12-3056&amp;rft_id=info%3Apmid%2F23172310&amp;rft.issue=2&amp;rft.jtitle=Cancer+Research&amp;rft.pages=490-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=73" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><cite class="citation journal">w. Tong, Alex; Senzer, Neil; Cerullo, Vincenzo; Templeton, Nancy; Hemminki, Akseli; Nemunaitis, John (2012). "Oncolytic Viruses for Induction of Anti-Tumor Immunity". <i>Current Pharmaceutical Biotechnology</i>. <b>13</b> (9): 1750–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F138920112800958913">10.2174/138920112800958913</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21740355">21740355</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+Viruses+for+Induction+of+Anti-Tumor+Immunity&amp;rft.au=Cerullo%2C+Vincenzo&amp;rft.aufirst=Alex&amp;rft.au=Hemminki%2C+Akseli&amp;rft.aulast=w.+Tong&amp;rft.au=Nemunaitis%2C+John&amp;rft.au=Senzer%2C+Neil&amp;rft.au=Templeton%2C+Nancy&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2174%2F138920112800958913&amp;rft_id=info%3Apmid%2F21740355&amp;rft.issue=9&amp;rft.jtitle=Current+Pharmaceutical+Biotechnology&amp;rft.pages=1750-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><cite class="citation journal">Naik, J. D.; Twelves, C. J.; Selby, P. J.; Vile, R. G.; Chester, J. D. (2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3131422">"Immune Recruitment and Therapeutic Synergy: Keys to Optimizing Oncolytic Viral Therapy?"</a>. <i>Clinical Cancer Research</i>. <b>17</b> (13): 4214–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F1078-0432.CCR-10-2848">10.1158/1078-0432.CCR-10-2848</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3131422">3131422</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21576084">21576084</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Immune+Recruitment+and+Therapeutic+Synergy%3A+Keys+to+Optimizing+Oncolytic+Viral+Therapy%3F&amp;rft.au=Chester%2C+J.+D.&amp;rft.aufirst=J.+D.&amp;rft.aulast=Naik&amp;rft.au=Selby%2C+P.+J.&amp;rft.au=Twelves%2C+C.+J.&amp;rft.au=Vile%2C+R.+G.&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3131422&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3131422&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-10-2848&amp;rft_id=info%3Apmid%2F21576084&amp;rft.issue=13&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.pages=4214-24&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite class="citation book">O'Regan, Brendan; Hirshberg, Caryle (1993). <a rel="nofollow" class="external text" href="http://noetic.org/library/publication-books/spontaneous-remission-annotated-bibliography/"><i>Spontaneous remission&#160;: an annotated bibliography</i></a>. Sausalito, California: Institute of Noetic Sciences. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0943951178" title="Special:BookSources/0943951178">0943951178</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=Brendan&amp;rft.au=Hirshberg%2C+Caryle&amp;rft.aulast=O%27Regan&amp;rft.btitle=Spontaneous+remission+%3A+an+annotated+bibliography&amp;rft.date=1993&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fnoetic.org%2Flibrary%2Fpublication-books%2Fspontaneous-remission-annotated-bibliography%2F&amp;rft.isbn=0943951178&amp;rft.place=Sausalito%2C+California&amp;rft.pub=Institute+of+Noetic+Sciences&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources"><span title="This citation requires a reference to the specific page or range of pages in which the material appears. (January 2014)">page&#160;needed</span></a></i>]</sup></span></li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><cite class="citation book">Lattime, E (2013). <a rel="nofollow" class="external text" href="http://store.elsevier.com/Gene-Therapy-of-Cancer/isbn-9780123942951/"><i>Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation</i></a>. Academic Press. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0123942950" title="Special:BookSources/0123942950">0123942950</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=E&amp;rft.aulast=Lattime&amp;rft.btitle=Gene+Therapy+of+Cancer%3A+Translational+Approaches+from+Preclinical+Studies+to+Clinical+Implementation&amp;rft.date=2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fstore.elsevier.com%2FGene-Therapy-of-Cancer%2Fisbn-9780123942951%2F&amp;rft.isbn=0123942950&amp;rft.pub=Academic+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources"><span title="This citation requires a reference to the specific page or range of pages in which the material appears. (January 2014)">page&#160;needed</span></a></i>]</sup></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite class="citation journal">Mastrangelo, Michael J; Lattime, Edmund C (2002). "Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors". <i>Cancer Gene Therapy</i>. <b>9</b> (12): 1013–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.cgt.7700538">10.1038/sj.cgt.7700538</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12522440">12522440</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Virotherapy+clinical+trials+for+regional+disease%3A+In+situ+immune+modulation+using+recombinant+poxvirus+vectors&amp;rft.aufirst=Michael+J&amp;rft.aulast=Mastrangelo&amp;rft.au=Lattime%2C+Edmund+C&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.cgt.7700538&amp;rft_id=info%3Apmid%2F12522440&amp;rft.issue=12&amp;rft.jtitle=Cancer+Gene+Therapy&amp;rft.pages=1013-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><cite class="citation journal">Bell, John C.; Lichty, David F.; Knowles, Brian; Marius, Shane; Atkins, Ricardo; Sonenberg, Harold; Bell, Nahum (2000). "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus". <i>Nature Medicine</i>. <b>6</b> (7): 821–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2F77558">10.1038/77558</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10888934">10888934</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Exploiting+tumor-specific+defects+in+the+interferon+pathway+with+a+previously+unknown+oncolytic+virus&amp;rft.au=Atkins%2C+Ricardo&amp;rft.au=Bell%2C+Nahum&amp;rft.aufirst=John+C.&amp;rft.au=Knowles%2C+Brian&amp;rft.aulast=Bell&amp;rft.au=Lichty%2C+David+F.&amp;rft.au=Marius%2C+Shane&amp;rft.au=Sonenberg%2C+Harold&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2F77558&amp;rft_id=info%3Apmid%2F10888934&amp;rft.issue=7&amp;rft.jtitle=Nature+Medicine&amp;rft.pages=821-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Stojdl03-51"><span class="mw-cite-backlink">^ <a href="#cite_ref-Stojdl03_51-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Stojdl03_51-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Stojdl, David F; Lichty, Brian D; Tenoever, Benjamin R; Paterson, Jennifer M; Power, Anthony T; Knowles, Shane; Marius, Ricardo; Reynard, Jennifer; Poliquin, Laurent; Atkins, Harold; Brown, Earl G; Durbin, Russell K; Durbin, Joan E; Hiscott, John; Bell, John C (2003). "VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents". <i>Cancer Cell</i>. <b>4</b> (4): 263–75. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1535-6108%2803%2900241-1">10.1016/S1535-6108(03)00241-1</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14585354">14585354</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=VSV+strains+with+defects+in+their+ability+to+shutdown+innate+immunity+are+potent+systemic+anti-cancer+agents&amp;rft.au=Atkins%2C+Harold&amp;rft.au=Bell%2C+John+C&amp;rft.au=Brown%2C+Earl+G&amp;rft.au=Durbin%2C+Joan+E&amp;rft.au=Durbin%2C+Russell+K&amp;rft.aufirst=David+F&amp;rft.au=Hiscott%2C+John&amp;rft.au=Knowles%2C+Shane&amp;rft.aulast=Stojdl&amp;rft.au=Lichty%2C+Brian+D&amp;rft.au=Marius%2C+Ricardo&amp;rft.au=Paterson%2C+Jennifer+M&amp;rft.au=Poliquin%2C+Laurent&amp;rft.au=Power%2C+Anthony+T&amp;rft.au=Reynard%2C+Jennifer&amp;rft.au=Tenoever%2C+Benjamin+R&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1535-6108%2803%2900241-1&amp;rft_id=info%3Apmid%2F14585354&amp;rft.issue=4&amp;rft.jtitle=Cancer+Cell&amp;rft.pages=263-75&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ahmed, M; Cramer, S; Lyles, D (2004). "Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses". <i>Virology</i>. <b>330</b> (1): 34–49. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.virol.2004.08.039">10.1016/j.virol.2004.08.039</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15527832">15527832</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Sensitivity+of+prostate+tumors+to+wild+type+and+M+protein+mutant+vesicular+stomatitis+viruses&amp;rft.au=Cramer%2C+S&amp;rft.aufirst=M&amp;rft.aulast=Ahmed&amp;rft.au=Lyles%2C+D&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.virol.2004.08.039&amp;rft_id=info%3Apmid%2F15527832&amp;rft.issue=1&amp;rft.jtitle=Virology&amp;rft.pages=34-49&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=330" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ebert, Oliver; Harbaran, Sonal; Shinozaki, Katsunori; Woo, Savio L C (2004). "Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice". <i>Cancer Gene Therapy</i>. <b>12</b> (4): 350–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.cgt.7700794">10.1038/sj.cgt.7700794</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15565179">15565179</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Systemic+therapy+of+experimental+breast+cancer+metastases+by+mutant+vesicular+stomatitis+virus+in+immune-competent+mice&amp;rft.aufirst=Oliver&amp;rft.au=Harbaran%2C+Sonal&amp;rft.aulast=Ebert&amp;rft.au=Shinozaki%2C+Katsunori&amp;rft.au=Woo%2C+Savio+L+C&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.cgt.7700794&amp;rft_id=info%3Apmid%2F15565179&amp;rft.issue=4&amp;rft.jtitle=Cancer+Gene+Therapy&amp;rft.pages=350-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><cite class="citation journal">Porosnicu, M; Mian, A; Barber, GN (2003). <a rel="nofollow" class="external text" href="http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=14678998">"The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene"</a>. <i>Cancer Research</i>. <b>63</b> (23): 8366–76. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14678998">14678998</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=The+oncolytic+effect+of+recombinant+vesicular+stomatitis+virus+is+enhanced+by+expression+of+the+fusion+cytosine+deaminase%2Furacil+phosphoribosyltransferase+suicide+gene&amp;rft.au=Barber%2C+GN&amp;rft.aufirst=M&amp;rft.aulast=Porosnicu&amp;rft.au=Mian%2C+A&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcancerres.aacrjournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D14678998&amp;rft_id=info%3Apmid%2F14678998&amp;rft.issue=23&amp;rft.jtitle=Cancer+Research&amp;rft.pages=8366-76&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=63" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><cite class="citation journal">Bridle, Byram W; Stephenson, Kyle B; Boudreau, Jeanette E; Koshy, Sandeep; Kazdhan, Natasha; Pullenayegum, Eleanor; Brunellière, Jérôme; Bramson, Jonathan L; Lichty, Brian D; Wan, Yonghong (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2927075">"Potentiating Cancer Immunotherapy Using an Oncolytic Virus"</a>. <i>Molecular Therapy</i>. <b>18</b> (8): 1430–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fmt.2010.98">10.1038/mt.2010.98</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2927075">2927075</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20551919">20551919</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Potentiating+Cancer+Immunotherapy+Using+an+Oncolytic+Virus&amp;rft.au=Boudreau%2C+Jeanette+E&amp;rft.au=Bramson%2C+Jonathan+L&amp;rft.au=Brunelli%C3%A8re%2C+J%C3%A9r%C3%B4me&amp;rft.aufirst=Byram+W&amp;rft.au=Kazdhan%2C+Natasha&amp;rft.au=Koshy%2C+Sandeep&amp;rft.aulast=Bridle&amp;rft.au=Lichty%2C+Brian+D&amp;rft.au=Pullenayegum%2C+Eleanor&amp;rft.au=Stephenson%2C+Kyle+B&amp;rft.au=Wan%2C+Yonghong&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2927075&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2927075&amp;rft_id=info%3Adoi%2F10.1038%2Fmt.2010.98&amp;rft_id=info%3Apmid%2F20551919&amp;rft.issue=8&amp;rft.jtitle=Molecular+Therapy&amp;rft.pages=1430-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><cite class="citation journal"><a href="/wiki/Matthias_Gromeier" title="Matthias Gromeier">Gromeier, M.</a>; Lachmann, S.; Rosenfeld, M. R.; Gutin, P. H.; Wimmer, E. (2000). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC18745">"Intergeneric poliovirus recombinants for the treatment of malignant glioma"</a>. <i>Proceedings of the National Academy of Sciences</i>. <b>97</b> (12): 6803–8. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2000PNAS...97.6803G">2000PNAS...97.6803G</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.97.12.6803">10.1073/pnas.97.12.6803</a>. <a href="/wiki/JSTOR" title="JSTOR">JSTOR</a>&#160;<a rel="nofollow" class="external text" href="//www.jstor.org/stable/122718">122718</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC18745">18745</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10841575">10841575</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Intergeneric+poliovirus+recombinants+for+the+treatment+of+malignant+glioma&amp;rft.aufirst=M.&amp;rft.au=Gutin%2C+P.+H.&amp;rft.au=Lachmann%2C+S.&amp;rft.aulast=Gromeier&amp;rft.au=Rosenfeld%2C+M.+R.&amp;rft.au=Wimmer%2C+E.&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.jstor.org%2Fstable%2F122718&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC18745&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC18745&amp;rft_id=info%3Abibcode%2F2000PNAS...97.6803G&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.97.12.6803&amp;rft_id=info%3Apmid%2F10841575&amp;rft.issue=12&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences&amp;rft.pages=6803-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=97" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text"><cite class="citation journal">Goetz, Christian; Gromeier, Matthias (2010). "Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme". <i>Cytokine &amp; Growth Factor Reviews</i>. <b>21</b> (2–3): 197–203. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.cytogfr.2010.02.005">10.1016/j.cytogfr.2010.02.005</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20299272">20299272</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Preparing+an+oncolytic+poliovirus+recombinant+for+clinical+application+against+glioblastoma+multiforme&amp;rft.aufirst=Christian&amp;rft.au=Gromeier%2C+Matthias&amp;rft.aulast=Goetz&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cytogfr.2010.02.005&amp;rft_id=info%3Apmid%2F20299272&amp;rft.issue=2%933&amp;rft.jtitle=Cytokine+%26+Growth+Factor+Reviews&amp;rft.pages=197-203&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19806501-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19806501_58-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lal, R; Harris, D; Postel-Vinay, S; De Bono, J (2009). "Reovirus: Rationale and clinical trial update". <i>Current opinion in molecular therapeutics</i>. <b>11</b> (5): 532–9. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19806501">19806501</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Reovirus%3A+Rationale+and+clinical+trial+update&amp;rft.au=De+Bono%2C+J&amp;rft.aufirst=R&amp;rft.au=Harris%2C+D&amp;rft.aulast=Lal&amp;rft.au=Postel-Vinay%2C+S&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F19806501&amp;rft.issue=5&amp;rft.jtitle=Current+opinion+in+molecular+therapeutics&amp;rft.pages=532-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19565924-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19565924_59-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFThirukkumaranMorris2009" class="citation">Thirukkumaran, Chandini; Morris, Don G. (2009), "Oncolytic Viral Therapy Using Reovirus", <i>Methods in molecular biology</i>, Gene Therapy of Cancer, <b>542</b>: 607–34, <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2F978-1-59745-561-9_31">10.1007/978-1-59745-561-9_31</a>, <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1-934115-85-5" title="Special:BookSources/978-1-934115-85-5">978-1-934115-85-5</a>, <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19565924">19565924</a></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+Viral+Therapy+Using+Reovirus&amp;rft.aufirst=Chandini&amp;rft.aulast=Thirukkumaran&amp;rft.au=Morris%2C+Don+G.&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2F978-1-59745-561-9_31&amp;rft_id=info%3Apmid%2F19565924&amp;rft.isbn=978-1-934115-85-5&amp;rft.jtitle=Methods+in+molecular+biology&amp;rft.pages=607-34&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=542" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ReferenceA-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-ReferenceA_60-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurģis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina (2015). "Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study". <i>Melanoma Research</i>. <b>25</b> (5): 421–426. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FCMR.0000000000000180">10.1097/CMR.0000000000000180</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Adapted+ECHO-7+virus+Rigvir+immunotherapy+%28oncolytic+virotherapy%29+prolongs+survival+in+melanoma+patients+after+surgical+excision+of+the+tumour+in+a+retrospective+study&amp;rft.au=Alberts%2C+P%C4%93teris&amp;rft.au=Auzi%C5%86%C5%A1%2C+Jur%C4%A3is&amp;rft.aufirst=Simona&amp;rft.au=Jonsson%2C+Bj%C3%B6rn&amp;rft.aulast=Doni%C5%86a&amp;rft.au=Muceniece%2C+Aina&amp;rft.au=Proboka%2C+Guna&amp;rft.au=Str%C4%93le%2C+Ieva&amp;rft.au=Venskus%2C+Dite&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FCMR.0000000000000180&amp;rft.issue=5&amp;rft.jtitle=Melanoma+Research&amp;rft.pages=421-426&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text">Cancer Virotherapy Journal | <a rel="nofollow" class="external free" href="https://www.cancervirotherapy.eu/cancer-virotherapy-pdf-version.php">https://www.cancervirotherapy.eu/cancer-virotherapy-pdf-version.php</a> | accessed 23 November 2015</span></li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><cite class="citation journal">Alberts, Pēteris; Olmane, Evija; Brokāne, Linda; Krastiņa, Zanda; Romanovska, Māra; Kupčs, Kārlis; Isajevs, Sergejs; Proboka, Guna; Romualds, Erdmanis; Jurijs, Nazarovs; Dite, Venskus (2016). "Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.". <i>APMIS</i>. <b>124</b> (9). <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fapm.12576">10.1111/apm.12576</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Long-term+treatment+with+the+oncolytic+ECHO-7+virus+Rigvir+of+a+melanoma+stage+IV+M1c+patient%2C+a+small+cell+lung+cancer+stage+IIIA+patient%2C+and+a+histiocytic+sarcoma+stage+IV+patient-three+case+reports.&amp;rft.au=Brok%C4%81ne%2C+Linda&amp;rft.au=Dite%2C+Venskus&amp;rft.aufirst=P%C4%93teris&amp;rft.au=Isajevs%2C+Sergejs&amp;rft.au=Jurijs%2C+Nazarovs&amp;rft.au=Krasti%C5%86a%2C+Zanda&amp;rft.au=Kup%C4s%2C+K%C4%81rlis&amp;rft.aulast=Alberts&amp;rft.au=Olmane%2C+Evija&amp;rft.au=Proboka%2C+Guna&amp;rft.au=Romanovska%2C+M%C4%81ra&amp;rft.au=Romualds%2C+Erdmanis&amp;rft.date=2016&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fapm.12576&amp;rft.issue=9&amp;rft.jtitle=APMIS&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=124" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ramachandran_clincanres.0925.2016-63"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ramachandran_clincanres.0925.2016_63-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ramachandran_clincanres.0925.2016_63-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Ramachandran, Mohanraj; Yu, Di; Dyczynski, Matheus; Baskaran, Sathishkumar; Zhang, Lei; Saul, Sirle; Lulla, Aleksei; Lulla, Valeria; Nelander, Sven (2016-01-01). <a rel="nofollow" class="external text" href="http://clincancerres.aacrjournals.org/content/early/2016/09/16/1078-0432.CCR-16-0925">"Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus"</a>. <i>Clinical Cancer Research</i>: clincanres.0925.2016. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F1078-0432.CCR-16-0925">10.1158/1078-0432.CCR-16-0925</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1078-0432">1078-0432</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27637889">27637889</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Safe+and+effective+treatment+of+experimental+neuroblastoma+and+glioblastoma+using+systemically+administered+triple+microRNA-detargeted+oncolytic+Semliki+Forest+virus&amp;rft.au=Baskaran%2C+Sathishkumar&amp;rft.au=Dyczynski%2C+Matheus&amp;rft.aufirst=Mohanraj&amp;rft.aulast=Ramachandran&amp;rft.au=Lulla%2C+Aleksei&amp;rft.au=Lulla%2C+Valeria&amp;rft.au=Nelander%2C+Sven&amp;rft.au=Saul%2C+Sirle&amp;rft.au=Yu%2C+Di&amp;rft.au=Zhang%2C+Lei&amp;rft.date=2016-01-01&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fclincancerres.aacrjournals.org%2Fcontent%2Fearly%2F2016%2F09%2F16%2F1078-0432.CCR-16-0925&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-16-0925&amp;rft_id=info%3Apmid%2F27637889&amp;rft.issn=1078-0432&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.pages=clincanres.0925.2016&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ottawacommunitynews.com/news-story/6263334-ottawa-research-into-cancer-vaccine-gets-funding-boost/">Ottawa research into cancer vaccine gets funding boost</a></span></li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://clinicaltrials.gov/ct2/show/NCT02285816">MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours (I214)</a></span></li>
<li id="cite_note-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409-66"><span class="mw-cite-backlink">^ <a href="#cite_ref-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409_66-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kuhn_I.2C_Harden_P.2C_Bauzon_M.2C_Chartier_C.2C_Nye_J.2C_Thorne_S.2C_Reid_T.2C_Ni_S.2C_Lieber_A.2C_Fisher_K.2C_Seymour_L.2C_Rubanyi_GM.2C_Harkins_RN.2C_Hermiston_TW_2008_e2409_66-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW (2008). "Directed evolution generates a novel oncolytic virus for the treatment of colon cancer". <i>PLoS ONE</i>. <b>3</b> (6): e2409. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1371%2Fjournal.pone.0002409">10.1371/journal.pone.0002409</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Directed+evolution+generates+a+novel+oncolytic+virus+for+the+treatment+of+colon+cancer&amp;rft.au=Bauzon%2C+M&amp;rft.au=Chartier%2C+C&amp;rft.aufirst=I&amp;rft.au=Fisher%2C+K&amp;rft.au=Harden%2C+P&amp;rft.au=Harkins%2C+RN&amp;rft.au=Hermiston%2C+TW&amp;rft.aulast=Kuhn&amp;rft.au=Lieber%2C+A&amp;rft.au=Ni%2C+S&amp;rft.au=Nye%2C+J&amp;rft.au=Reid%2C+T&amp;rft.au=Rubanyi%2C+GM&amp;rft.au=Seymour%2C+L&amp;rft.au=Thorne%2C+S&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0002409&amp;rft.issue=6&amp;rft.jtitle=PLoS+ONE&amp;rft.pages=e2409&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><cite class="citation web">Chow, Amy. <a rel="nofollow" class="external text" href="http://www.nature.com/scitable/topicpage/cell-cycle-control-by-oncogenes-and-tumor-14191459">"Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells"</a>. Nature Education<span class="reference-accessdate">. Retrieved <span class="nowrap">5 April</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=Amy&amp;rft.aulast=Chow&amp;rft.btitle=Cell+Cycle+Control+by+Oncogenes+and+Tumor+Suppressors%3A+Driving+the+Transformation+of+Normal+Cells+into+Cancerous+Cells&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fscitable%2Ftopicpage%2Fcell-cycle-control-by-oncogenes-and-tumor-14191459&amp;rft.pub=Nature+Education&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.merriam-webster.com/medical/thymidine%20kinase">"Medical Dictionary"</a>. Merriam-Webster<span class="reference-accessdate">. Retrieved <span class="nowrap">5 April</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Medical+Dictionary&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.merriam-webster.com%2Fmedical%2Fthymidine%2520kinase&amp;rft.pub=Merriam-Webster&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><cite class="citation journal">Gentry, Glenn A. (1992). "Viral thymidine kinases and their relatives". <i>Pharmacology &amp; Therapeutics</i>. <b>54</b> (3): 319–355. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0163-7258%2892%2990006-L">10.1016/0163-7258(92)90006-L</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Viral+thymidine+kinases+and+their+relatives&amp;rft.aufirst=Glenn+A.&amp;rft.aulast=Gentry&amp;rft.date=1992&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0163-7258%2892%2990006-L&amp;rft.issue=3&amp;rft.jtitle=Pharmacology+%26+Therapeutics&amp;rft.pages=319-355&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=54" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Davydova04-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-Davydova04_70-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Davydova, J.; Le, LP; Gavrikova, T; Wang, M; Krasnykh, V; Yamamoto, M (2004). "Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment". <i>Cancer Research</i>. <b>64</b> (12): 4319–27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1158%2F0008-5472.CAN-04-0064">10.1158/0008-5472.CAN-04-0064</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15205347">15205347</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Infectivity-Enhanced+Cyclooxygenase-2-Based+Conditionally+Replicative+Adenoviruses+for+Esophageal+Adenocarcinoma+Treatment&amp;rft.aufirst=J.&amp;rft.au=Gavrikova%2C+T&amp;rft.au=Krasnykh%2C+V&amp;rft.aulast=Davydova&amp;rft.au=Le%2C+LP&amp;rft.au=Wang%2C+M&amp;rft.au=Yamamoto%2C+M&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1158%2F0008-5472.CAN-04-0064&amp;rft_id=info%3Apmid%2F15205347&amp;rft.issue=12&amp;rft.jtitle=Cancer+Research&amp;rft.pages=4319-27&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=64" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Haddad_2012_e41647-71"><span class="mw-cite-backlink">^ <a href="#cite_ref-Haddad_2012_e41647_71-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Haddad_2012_e41647_71-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Haddad_2012_e41647_71-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Haddad, Dana; Chen, Chun-Hao; Carlin, Sean; Silberhumer, Gerd; Chen, Nanhai G.; Zhang, Qian; Longo, Valerie; Carpenter, Susanne G.; Mittra, Arjun; Carson, Joshua; Au, Joyce; Gonen, Mithat; Zanzonico, Pat B.; Szalay, Aladar A.; Fong, Yuman (2012). Gelovani, Juri G, ed. <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3422353">"Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter"</a>. <i>PLoS ONE</i>. <b>7</b> (8): e41647. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1371%2Fjournal.pone.0041647">10.1371/journal.pone.0041647</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3422353">3422353</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22912675">22912675</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Imaging+Characteristics%2C+Tissue+Distribution%2C+and+Spread+of+a+Novel+Oncolytic+Vaccinia+Virus+Carrying+the+Human+Sodium+Iodide+Symporter&amp;rft.au=Au%2C+Joyce&amp;rft.au=Carlin%2C+Sean&amp;rft.au=Carpenter%2C+Susanne+G.&amp;rft.au=Carson%2C+Joshua&amp;rft.au=Chen%2C+Chun-Hao&amp;rft.au=Chen%2C+Nanhai+G.&amp;rft.aufirst=Dana&amp;rft.au=Fong%2C+Yuman&amp;rft.au=Gonen%2C+Mithat&amp;rft.aulast=Haddad&amp;rft.au=Longo%2C+Valerie&amp;rft.au=Mittra%2C+Arjun&amp;rft.au=Silberhumer%2C+Gerd&amp;rft.au=Szalay%2C+Aladar+A.&amp;rft.au=Zanzonico%2C+Pat+B.&amp;rft.au=Zhang%2C+Qian&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3422353&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3422353&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0041647&amp;rft_id=info%3Apmid%2F22912675&amp;rft.issue=8&amp;rft.jtitle=PLoS+ONE&amp;rft.pages=e41647&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><cite class="citation journal">Poirier, J. T.; Reddy, P. S.; Idamakanti, N.; Li, S. S.; Stump, K. L.; Burroughs, K. D.; Hallenbeck, P. L.; Rudin, C. M. (2012). "Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001". <i>Journal of General Virology</i>. <b>93</b> (Pt 12): 2606–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1099%2Fvir.0.046011-0">10.1099/vir.0.046011-0</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22971818">22971818</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Characterization+of+a+full-length+infectious+cDNA+clone+and+a+GFP+reporter+derivative+of+the+oncolytic+picornavirus+SVV-001&amp;rft.au=Burroughs%2C+K.+D.&amp;rft.aufirst=J.+T.&amp;rft.au=Hallenbeck%2C+P.+L.&amp;rft.au=Idamakanti%2C+N.&amp;rft.aulast=Poirier&amp;rft.au=Li%2C+S.+S.&amp;rft.au=Reddy%2C+P.+S.&amp;rft.au=Rudin%2C+C.+M.&amp;rft.au=Stump%2C+K.+L.&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1099%2Fvir.0.046011-0&amp;rft_id=info%3Apmid%2F22971818&amp;rft.issue=Pt+12&amp;rft.jtitle=Journal+of+General+Virology&amp;rft.pages=2606-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=93" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><cite class="citation journal">Yu, Yong A; Shabahang, Shahrokh; Timiryasova, Tatyana M; Zhang, Qian; Beltz, Richard; Gentschev, Ivaylo; Goebel, Werner; Szalay, Aladar A (2004). "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins". <i>Nature Biotechnology</i>. <b>22</b> (3): 313–20. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnbt937">10.1038/nbt937</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14990953">14990953</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Visualization+of+tumors+and+metastases+in+live+animals+with+bacteria+and+vaccinia+virus+encoding+light-emitting+proteins&amp;rft.au=Beltz%2C+Richard&amp;rft.aufirst=Yong+A&amp;rft.au=Gentschev%2C+Ivaylo&amp;rft.au=Goebel%2C+Werner&amp;rft.aulast=Yu&amp;rft.au=Shabahang%2C+Shahrokh&amp;rft.au=Szalay%2C+Aladar+A&amp;rft.au=Timiryasova%2C+Tatyana+M&amp;rft.au=Zhang%2C+Qian&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt937&amp;rft_id=info%3Apmid%2F14990953&amp;rft.issue=3&amp;rft.jtitle=Nature+Biotechnology&amp;rft.pages=313-20&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><cite class="citation journal">Freeman, SM; Whartenby, KA; Freeman, JL; Abboud, CN; Marrogi, AJ (1996). "In situ use of suicide genes for cancer therapy". <i>Seminars in oncology</i>. <b>23</b> (1): 31–45. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8607030">8607030</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=In+situ+use+of+suicide+genes+for+cancer+therapy&amp;rft.au=Abboud%2C+CN&amp;rft.aufirst=SM&amp;rft.au=Freeman%2C+JL&amp;rft.aulast=Freeman&amp;rft.au=Marrogi%2C+AJ&amp;rft.au=Whartenby%2C+KA&amp;rft.date=1996&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F8607030&amp;rft.issue=1&amp;rft.jtitle=Seminars+in+oncology&amp;rft.pages=31-45&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=23" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><cite class="citation journal">Duarte, Sónia; Carle, Georges; Faneca, Henrique; De Lima, Maria C. Pedroso de; Pierrefite-Carle, Valérie (2012). "Suicide gene therapy in cancer: Where do we stand now?". <i>Cancer Letters</i>. <b>324</b> (2): 160–70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.canlet.2012.05.023">10.1016/j.canlet.2012.05.023</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22634584">22634584</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Suicide+gene+therapy+in+cancer%3A+Where+do+we+stand+now%3F&amp;rft.au=Carle%2C+Georges&amp;rft.au=De+Lima%2C+Maria+C.+Pedroso+de&amp;rft.au=Faneca%2C+Henrique&amp;rft.aufirst=S%C3%B3nia&amp;rft.aulast=Duarte&amp;rft.au=Pierrefite-Carle%2C+Val%C3%A9rie&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.canlet.2012.05.023&amp;rft_id=info%3Apmid%2F22634584&amp;rft.issue=2&amp;rft.jtitle=Cancer+Letters&amp;rft.pages=160-70&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=324" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><cite class="citation journal">Frentzen, A.; Yu, Y. A.; Chen, N.; Zhang, Q.; Weibel, S.; Raab, V.; Szalay, A. A. (2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2722284">"Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy"</a>. <i>Proceedings of the National Academy of Sciences</i>. <b>106</b> (31): 12915–20. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2009PNAS..10612915F">2009PNAS..10612915F</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.0900660106">10.1073/pnas.0900660106</a>. <a href="/wiki/JSTOR" title="JSTOR">JSTOR</a>&#160;<a rel="nofollow" class="external text" href="//www.jstor.org/stable/40484625">40484625</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2722284">2722284</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19617539">19617539</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Anti-VEGF+single-chain+antibody+GLAF-1+encoded+by+oncolytic+vaccinia+virus+significantly+enhances+antitumor+therapy&amp;rft.au=Chen%2C+N.&amp;rft.aufirst=A.&amp;rft.aulast=Frentzen&amp;rft.au=Raab%2C+V.&amp;rft.au=Szalay%2C+A.+A.&amp;rft.au=Weibel%2C+S.&amp;rft.au=Yu%2C+Y.+A.&amp;rft.au=Zhang%2C+Q.&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.jstor.org%2Fstable%2F40484625&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722284&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722284&amp;rft_id=info%3Abibcode%2F2009PNAS..10612915F&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.0900660106&amp;rft_id=info%3Apmid%2F19617539&amp;rft.issue=31&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences&amp;rft.pages=12915-20&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><cite class="citation journal">Conner, J; Braidwood, L (2012). "Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy". <i>Cancer Gene Therapy</i>. <b>19</b> (7): 499–507. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fcgt.2012.24">10.1038/cgt.2012.24</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22595793">22595793</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Expression+of+inhibitor+of+growth+4+by+HSV1716+improves+oncolytic+potency+and+enhances+efficacy&amp;rft.au=Braidwood%2C+L&amp;rft.aufirst=J&amp;rft.aulast=Conner&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fcgt.2012.24&amp;rft_id=info%3Apmid%2F22595793&amp;rft.issue=7&amp;rft.jtitle=Cancer+Gene+Therapy&amp;rft.pages=499-507&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><cite class="citation journal">Grünwald, G K; Klutz, K; Willhauck, M J; Schwenk, N; Senekowitsch-Schmidtke, R; Schwaiger, M; Zach, C; Göke, B; Holm, P S; Spitzweg, C (2012). "Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus". <i>Gene Therapy</i>. <b>20</b> (6): 625–33. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fgt.2012.79">10.1038/gt.2012.79</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23038026">23038026</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Sodium+iodide+symporter+%28NIS%29-mediated+radiovirotherapy+of+hepatocellular+cancer+using+a+conditionally+replicating+adenovirus&amp;rft.aufirst=G+K&amp;rft.au=G%C3%B6ke%2C+B&amp;rft.au=Holm%2C+P+S&amp;rft.au=Klutz%2C+K&amp;rft.aulast=Gr%C3%BCnwald&amp;rft.au=Schwaiger%2C+M&amp;rft.au=Schwenk%2C+N&amp;rft.au=Senekowitsch-Schmidtke%2C+R&amp;rft.au=Spitzweg%2C+C&amp;rft.au=Willhauck%2C+M+J&amp;rft.au=Zach%2C+C&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fgt.2012.79&amp;rft_id=info%3Apmid%2F23038026&amp;rft.issue=6&amp;rft.jtitle=Gene+Therapy&amp;rft.pages=625-33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><cite class="citation journal">Penheiter, Alan R.; Wegman, Troy R.; Classic, Kelly L.; Dingli, David; Bender, Claire E.; Russell, Stephen J.; Carlson, Stephanie K. (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3117397">"Sodium Iodide Symporter (NIS)-Mediated Radiovirotherapy for Pancreatic Cancer"</a>. <i>American Journal of Roentgenology</i>. <b>195</b> (2): 341–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2214%2FAJR.09.3672">10.2214/AJR.09.3672</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3117397">3117397</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20651188">20651188</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Sodium+Iodide+Symporter+%28NIS%29-Mediated+Radiovirotherapy+for+Pancreatic+Cancer&amp;rft.au=Bender%2C+Claire+E.&amp;rft.au=Carlson%2C+Stephanie+K.&amp;rft.au=Classic%2C+Kelly+L.&amp;rft.au=Dingli%2C+David&amp;rft.aufirst=Alan+R.&amp;rft.aulast=Penheiter&amp;rft.au=Russell%2C+Stephen+J.&amp;rft.au=Wegman%2C+Troy+R.&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3117397&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3117397&amp;rft_id=info%3Adoi%2F10.2214%2FAJR.09.3672&amp;rft_id=info%3Apmid%2F20651188&amp;rft.issue=2&amp;rft.jtitle=American+Journal+of+Roentgenology&amp;rft.pages=341-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=195" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><cite class="citation journal">Li, H; Peng, K-W; Dingli, D; Kratzke, R A; Russell, S J (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2907639">"Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy"</a>. <i>Cancer Gene Therapy</i>. <b>17</b> (8): 550–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fcgt.2010.10">10.1038/cgt.2010.10</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2907639">2907639</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20379224">20379224</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Oncolytic+measles+viruses+encoding+interferon+%CE%B2+and+the+thyroidal+sodium+iodide+symporter+gene+for+mesothelioma+virotherapy&amp;rft.au=Dingli%2C+D&amp;rft.aufirst=H&amp;rft.au=Kratzke%2C+R+A&amp;rft.aulast=Li&amp;rft.au=Peng%2C+K-W&amp;rft.au=Russell%2C+S+J&amp;rft.date=2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2907639&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2907639&amp;rft_id=info%3Adoi%2F10.1038%2Fcgt.2010.10&amp;rft_id=info%3Apmid%2F20379224&amp;rft.issue=8&amp;rft.jtitle=Cancer+Gene+Therapy&amp;rft.pages=550-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT00769704">NCT00769704</a></i> for "Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-Reuters-82"><span class="mw-cite-backlink">^ <a href="#cite_ref-Reuters_82-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Reuters_82-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.reuters.com/article/2015/10/27/us-amgen-fda-idUSKCN0SL2YH20151027">"FDA approves Amgen's Injected Immunotherapy for Melanoma"</a>. Reuters. 27 October 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=FDA+approves+Amgen%27s+Injected+Immunotherapy+for+Melanoma&amp;rft.date=2015-10-27&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.reuters.com%2Farticle%2F2015%2F10%2F27%2Fus-amgen-fda-idUSKCN0SL2YH20151027&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Sheridan2015-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-Sheridan2015_83-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sheridan, Cormac (2015). "First oncolytic virus edges towards approval in surprise vote". <i>Nature Biotechnology</i>. <b>33</b> (6): 569–570. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnbt0615-569">10.1038/nbt0615-569</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1087-0156">1087-0156</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=First+oncolytic+virus+edges+towards+approval+in+surprise+vote&amp;rft.aufirst=Cormac&amp;rft.aulast=Sheridan&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0615-569&amp;rft.issn=1087-0156&amp;rft.issue=6&amp;rft.jtitle=Nature+Biotechnology&amp;rft.pages=569-570&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amgen-Jan-2012-8-K-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-Amgen-Jan-2012-8-K_84-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://pdf.secdatabase.com/2009/0001193125-12-024302.pdf">"Amgen, Form 8-K, Current Report, Filing Date Jan 26, 2012"</a> <span style="font-size:85%;">(PDF)</span>. secdatabase.com<span class="reference-accessdate">. Retrieved <span class="nowrap">Jan 8,</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Amgen%2C+Form+8-K%2C+Current+Report%2C+Filing+Date+Jan+26%2C+2012&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fpdf.secdatabase.com%2F2009%2F0001193125-12-024302.pdf&amp;rft.pub=secdatabase.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01161498">NCT01161498</a></i> for "Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><cite class="citation journal">Pol, Jonathan; Buqué, Aitziber; Aranda, Fernando; Bloy, Norma; Cremer, Isabelle; Eggermont, Alexander; Erbs, Philippe; Fucikova, Jitka; Galon, Jérôme; Limacher, Jean-Marc; Preville, Xavier; Sautès-Fridman, Catherine; Spisek, Radek; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo (8 December 2015). <a rel="nofollow" class="external text" href="http://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1117740">"Trial Watch—Oncolytic viruses and cancer therapy"</a>. <i>OncoImmunology</i>. <b>5</b> (2): e1117740. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F2162402X.2015.1117740">10.1080/2162402X.2015.1117740</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27057469">27057469</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Trial+Watch%94Oncolytic+viruses+and+cancer+therapy&amp;rft.au=Aranda%2C+Fernando&amp;rft.au=Bloy%2C+Norma&amp;rft.au=Buqu%C3%A9%2C+Aitziber&amp;rft.au=Cremer%2C+Isabelle&amp;rft.au=Eggermont%2C+Alexander&amp;rft.au=Erbs%2C+Philippe&amp;rft.aufirst=Jonathan&amp;rft.au=Fucikova%2C+Jitka&amp;rft.au=Galluzzi%2C+Lorenzo&amp;rft.au=Galon%2C+J%C3%A9r%C3%B4me&amp;rft.au=Kroemer%2C+Guido&amp;rft.aulast=Pol&amp;rft.au=Limacher%2C+Jean-Marc&amp;rft.au=Preville%2C+Xavier&amp;rft.au=Saut%C3%A8s-Fridman%2C+Catherine&amp;rft.au=Spisek%2C+Radek&amp;rft.au=Zitvogel%2C+Laurence&amp;rft.date=2015-12-08&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F2162402X.2015.1117740&amp;rft_id=info%3Adoi%2F10.1080%2F2162402X.2015.1117740&amp;rft_id=info%3Apmid%2F27057469&amp;rft.issue=2&amp;rft.jtitle=OncoImmunology&amp;rft.pages=e1117740&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EUAp-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-EUAp_87-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://immuno-oncologynews.com/2016/01/07/metastatic-melanoma-therapy-imlygic-now-available-eu/?utm_source=IO+News&amp;utm_campaign=f957441bf0-RSS_WEEKLY_EMAIL_CAMPAIGN&amp;utm_medium=email&amp;utm_term=0_f04c303b86-f957441bf0-71484089">Metastatic Melanoma Therapy, Imlygic, Now Available in EU</a></span></li>
<li id="cite_note-Nat2011-88"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nat2011_88-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nat2011_88-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Schmidt, Charlie (2011). "Amgen spikes interest in live virus vaccines for hard-to-treat cancers". <i>Nature Biotechnology</i>. <b>29</b> (4): 295–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnbt0411-295">10.1038/nbt0411-295</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21478830">21478830</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Amgen+spikes+interest+in+live+virus+vaccines+for+hard-to-treat+cancers&amp;rft.aufirst=Charlie&amp;rft.aulast=Schmidt&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0411-295&amp;rft_id=info%3Apmid%2F21478830&amp;rft.issue=4&amp;rft.jtitle=Nature+Biotechnology&amp;rft.pages=295-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.oncolytics.com/clinical-trials/8">"Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Platinum-Refractory Head and Neck Cancers"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">31 May</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Intravenous+Administration+of+REOLYSIN%AE+in+Combination+with+Paclitaxel+and+Carboplatin+for+Patients+with+Platinum-Refractory+Head+and+Neck+Cancers&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.oncolytics.com%2Fclinical-trials%2F8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.oncolytics.com/news_items/details?press_release_id=1916">http://www.oncolytics.com/news_items/details?press_release_id=1916</a><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citing_sources#What_information_to_include" title="Wikipedia:Citing sources"><span title="A more detailed citation is required. (January 2014)">full citation needed</span></a></i>]</sup></span></li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://pressroom.ackura.com/biofind/635-Oncolytics-Biotech--announces-positive-data-from-translational-clinical-trial-investigating-REOLYSIN--in-Patients-with-Metastatic-Colorectal-Cancer-.aspx">"Oncolytics Biotech® announces positive data from translational clinical trial investigating REOLYSIN® in Patients with Metastatic Colorectal Cancer"</a> (Press release). Biofind. 21 April 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">7 August</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Oncolytics+Biotech%AE+announces+positive+data+from+translational+clinical+trial+investigating+REOLYSIN%AE+in+Patients+with+Metastatic+Colorectal+Cancer&amp;rft.date=2011-04-21&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fpressroom.ackura.com%2Fbiofind%2F635-Oncolytics-Biotech--announces-positive-data-from-translational-clinical-trial-investigating-REOLYSIN--in-Patients-with-Metastatic-Colorectal-Cancer-.aspx&amp;rft.pub=Biofind&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><cite class="citation journal">Adair, R. A.; Roulstone, V.; Scott, K. J.; Morgan, R.; Nuovo, G. J.; Fuller, M.; Beirne, D.; West, E. J.; Jennings, V. A.; Rose, A.; Kyula, J.; Fraser, S.; Dave, R.; Anthoney, D. A.; Merrick, A.; Prestwich, R.; Aldouri, A.; Donnelly, O.; Pandha, H.; Coffey, M.; Selby, P.; Vile, R.; Toogood, G.; Harrington, K.; Melcher, A. A. (2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3893925">"Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients"</a>. <i>Science Translational Medicine</i>. <b>4</b> (138): 138ra77. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1126%2Fscitranslmed.3003578">10.1126/scitranslmed.3003578</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3893925">3893925</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22700953">22700953</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Cell+Carriage%2C+Delivery%2C+and+Selective+Replication+of+an+Oncolytic+Virus+in+Tumor+in+Patients&amp;rft.au=Aldouri%2C+A.&amp;rft.au=Anthoney%2C+D.+A.&amp;rft.au=Beirne%2C+D.&amp;rft.au=Coffey%2C+M.&amp;rft.au=Dave%2C+R.&amp;rft.au=Donnelly%2C+O.&amp;rft.aufirst=R.+A.&amp;rft.au=Fraser%2C+S.&amp;rft.au=Fuller%2C+M.&amp;rft.au=Harrington%2C+K.&amp;rft.au=Jennings%2C+V.+A.&amp;rft.au=Kyula%2C+J.&amp;rft.aulast=Adair&amp;rft.au=Melcher%2C+A.+A.&amp;rft.au=Merrick%2C+A.&amp;rft.au=Morgan%2C+R.&amp;rft.au=Nuovo%2C+G.+J.&amp;rft.au=Pandha%2C+H.&amp;rft.au=Prestwich%2C+R.&amp;rft.au=Rose%2C+A.&amp;rft.au=Roulstone%2C+V.&amp;rft.au=Scott%2C+K.+J.&amp;rft.au=Selby%2C+P.&amp;rft.au=Toogood%2C+G.&amp;rft.au=Vile%2C+R.&amp;rft.au=West%2C+E.+J.&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3893925&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3893925&amp;rft_id=info%3Adoi%2F10.1126%2Fscitranslmed.3003578&amp;rft_id=info%3Apmid%2F22700953&amp;rft.issue=138&amp;rft.jtitle=Science+Translational+Medicine&amp;rft.pages=138ra77&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span>, cited in <cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.oncolytics.ca/news_items/details?press_release_id=1893">"Oncolytics Biotech® Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine"</a> (Press release). Biofind. 13 June 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">16 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Oncolytics+Biotech%AE+Inc.+Announces+Publication+of+Translational+Clinical+Trial+Results+in+Science+Translational+Medicine&amp;rft.date=2012-06-13&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.oncolytics.ca%2Fnews_items%2Fdetails%3Fpress_release_id%3D1893&amp;rft.pub=Biofind&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://clinicaltrials.gov/ct2/results?term=reolysin">Reolysin Clinical Trials at NIH</a></span></li>
<li id="cite_note-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-94">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01387555">NCT01387555</a></i> for "A Phase 2b Study of Vaccinia Virus to Treat Advanced Liver Cancer (TRAVERSE)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT00625456">NCT00625456</a></i> for "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text"><cite class="citation journal">j. Breitbach, Caroline; Thorne, Steve; Bell, John; Kirn, David (2012). "Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594". <i>Current Pharmaceutical Biotechnology</i>. <b>13</b> (9): 1768–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F138920112800958922">10.2174/138920112800958922</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21740365">21740365</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Targeted+and+Armed+Oncolytic+Poxviruses+for+Cancer%3A+The+Lead+Example+of+JX-594&amp;rft.au=Bell%2C+John&amp;rft.aufirst=Caroline&amp;rft.au=Kirn%2C+David&amp;rft.aulast=j.+Breitbach&amp;rft.au=Thorne%2C+Steve&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2174%2F138920112800958922&amp;rft_id=info%3Apmid%2F21740365&amp;rft.issue=9&amp;rft.jtitle=Current+Pharmaceutical+Biotechnology&amp;rft.pages=1768-72&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01048892">NCT01048892</a></i> for "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a> , October 2012</span></li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01017601">NCT01017601</a></i> for "Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-99">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.viralytics.com/media/presentations/2011-06-23%20Oncolytic%20Activity%20of%20Coxsackievirus%20A21%20%28CAVATAK%29%20in%20Human%20Pancreatic%20Cancer%20WGICC.pdf">Oncolytic activity of Coxsackievirus A21 (CAVATAK™) in human pancreatic cancer. (June 2011 poster)</a></span></li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT00832559">NCT00832559</a></i> for "A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01227551">NCT01227551</a></i> for "A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-102">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.virttu.com/">"Virttu.com"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Virttu.com&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.virttu.com%2F&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.virttu.com/HSV1716">Seprehvir</a>, Virttu Biologics</span></li>
<li id="cite_note-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-104">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.biospace.com/News/oncolytic-virus-specialist-virttu-biologics/272666">Oncolytic Virus Specialist Virttu Biologics Initiates Phase I/II SEPREHVIR™ Study in Mesothelioma</a>, BioSpace, 11 September 2012</span></li>
<li id="cite_note-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-105">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.oncos.net/">"Oncos.net"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Oncos.net&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.oncos.net%2F&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-106">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.realwire.com/release_detail.asp?ReleaseID=18698">"Oncolytic viruses mediating anti-tumor immunity in human cancer patients"</a> (Press release). Oncos Therapeutics. 19 May 2010.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.btitle=Oncolytic+viruses+mediating+anti-tumor+immunity+in+human+cancer+patients&amp;rft.date=2010-05-19&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.realwire.com%2Frelease_detail.asp%3FReleaseID%3D18698&amp;rft.pub=Oncos+Therapeutics&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-107">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT00794131">NCT00794131</a></i> for "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-108"><span class="mw-cite-backlink"><b><a href="#cite_ref-108">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01766739">NCT01766739</a></i> for "Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-109">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01443260">NCT01443260</a></i> for "A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-110"><span class="mw-cite-backlink"><b><a href="#cite_ref-110">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01584284">NCT01584284</a></i> for "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head &amp; Neck Cancer" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-russell2014-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-russell2014_111-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A (2014-07-01). <a rel="nofollow" class="external text" href="http://www.mayoclinicproceedings.org/article/S0025619614003322/abstract">"Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy"</a>. <i>Mayo Clinic Proceedings</i>. <b>89</b> (7): 926–933. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.mayocp.2014.04.003">10.1016/j.mayocp.2014.04.003</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0025-6196">0025-6196</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24835528">24835528</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2014-08-21</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Remission+of+Disseminated+Cancer+After+Systemic+Oncolytic+Virotherapy&amp;rft.au=Buadi%2C+FK&amp;rft.au=Dingli%2C+D&amp;rft.au=Dispenzieri%2C+A&amp;rft.au=Federspiel%2C+MJ&amp;rft.aufirst=SJ&amp;rft.au=Gertz%2C+MA&amp;rft.au=Kyle%2C+RA&amp;rft.au=Lacy%2C+MQ&amp;rft.aulast=Russell&amp;rft.au=Leung%2C+N&amp;rft.au=Lowe%2C+V&amp;rft.au=Morice%2C+WG&amp;rft.au=O%27Connor%2C+MK&amp;rft.au=Peng%2C+KW&amp;rft.au=Rajkumar%2C+SV&amp;rft.au=Tong%2C+C&amp;rft.date=2014-07-01&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.mayoclinicproceedings.org%2Farticle%2FS0025619614003322%2Fabstract&amp;rft_id=info%3Adoi%2F10.1016%2Fj.mayocp.2014.04.003&amp;rft_id=info%3Apmid%2F24835528&amp;rft.issn=0025-6196&amp;rft.issue=7&amp;rft.jtitle=Mayo+Clinic+Proceedings&amp;rft.pages=926-933&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-112"><span class="mw-cite-backlink"><b><a href="#cite_ref-112">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external autonumber" href="http://www.prnewswire.com/news-releases/dnatrixs-oncolytic-immunotherapy-dnx-2401-awarded-eu-orphan-medicine-designation-for-treating-malignant-brain-tumors-300217118.html">[1]</a></span></li>
<li id="cite_note-113"><span class="mw-cite-backlink"><b><a href="#cite_ref-113">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://finance.yahoo.com/news/targovax-recruits-first-patient-trial-052103439.html">Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma</a></span></li>
<li id="cite_note-114"><span class="mw-cite-backlink"><b><a href="#cite_ref-114">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ottolino-Perry, Kathryn; Diallo, Jean-Simon; Lichty, Brian D; Bell, John C; McCart, J (2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2839289">"Intelligent Design: Combination Therapy with Oncolytic Viruses"</a>. <i>Molecular Therapy</i>. <b>18</b> (2): 251–63. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fmt.2009.283">10.1038/mt.2009.283</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2839289">2839289</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20029399">20029399</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Intelligent+Design%3A+Combination+Therapy+with+Oncolytic+Viruses&amp;rft.au=Bell%2C+John+C&amp;rft.au=Diallo%2C+Jean-Simon&amp;rft.aufirst=Kathryn&amp;rft.aulast=Ottolino-Perry&amp;rft.au=Lichty%2C+Brian+D&amp;rft.au=McCart%2C+J&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2839289&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2839289&amp;rft_id=info%3Adoi%2F10.1038%2Fmt.2009.283&amp;rft_id=info%3Apmid%2F20029399&amp;rft.issue=2&amp;rft.jtitle=Molecular+Therapy&amp;rft.pages=251-63&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-115"><span class="mw-cite-backlink"><b><a href="#cite_ref-115">^</a></b></span> <span class="reference-text"><cite class="citation journal">Khuri, Fadlo R.; Nemunaitis, John; Ganly, Ian; Arseneau, James; Tannock, Ian F.; Romel, Larry; Gore, Martin; Ironside, Janet; MacDougall, R.H.; Heise, Carla; Randlev, Britta; Gillenwater, Ann M.; Bruso, Patricia; Kaye, Stanley B.; Hong, Waun Ki; Kirn, David H. (2000). "A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer". <i>Nature Medicine</i>. <b>6</b> (8): 879–85. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2F78638">10.1038/78638</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10932224">10932224</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=A+controlled+trial+of+intratumoral+ONYX-015%2C+a+selectively-replicating+adenovirus%2C+in+combination+with+cisplatin+and+5-fluorouracil+in+patients+with+recurrent+head+and+neck+cancer&amp;rft.au=Arseneau%2C+James&amp;rft.au=Bruso%2C+Patricia&amp;rft.aufirst=Fadlo+R.&amp;rft.au=Ganly%2C+Ian&amp;rft.au=Gillenwater%2C+Ann+M.&amp;rft.au=Gore%2C+Martin&amp;rft.au=Heise%2C+Carla&amp;rft.au=Hong%2C+Waun+Ki&amp;rft.au=Ironside%2C+Janet&amp;rft.au=Kaye%2C+Stanley+B.&amp;rft.au=Kirn%2C+David+H.&amp;rft.aulast=Khuri&amp;rft.au=MacDougall%2C+R.H.&amp;rft.au=Nemunaitis%2C+John&amp;rft.au=Randlev%2C+Britta&amp;rft.au=Romel%2C+Larry&amp;rft.au=Tannock%2C+Ian+F.&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2F78638&amp;rft_id=info%3Apmid%2F10932224&amp;rft.issue=8&amp;rft.jtitle=Nature+Medicine&amp;rft.pages=879-85&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-116"><span class="mw-cite-backlink"><b><a href="#cite_ref-116">^</a></b></span> <span class="reference-text"><cite class="citation journal">Chen, Y; Deweese, T; Dilley, J; Zhang, Y; Li, Y; Ramesh, N; Lee, J; Pennathur-Das, R; Radzyminski, J; Wypych, J; Brignetti, D; Scott, S; Stephens, J; Karpf, DB; Henderson, DR; Yu, DC (2001). <a rel="nofollow" class="external text" href="http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=11454691">"CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity"</a>. <i>Cancer Research</i>. <b>61</b> (14): 5453–60. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11454691">11454691</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=CV706%2C+a+prostate+cancer-specific+adenovirus+variant%2C+in+combination+with+radiotherapy+produces+synergistic+antitumor+efficacy+without+increasing+toxicity&amp;rft.au=Brignetti%2C+D&amp;rft.au=Deweese%2C+T&amp;rft.au=Dilley%2C+J&amp;rft.aufirst=Y&amp;rft.au=Henderson%2C+DR&amp;rft.au=Karpf%2C+DB&amp;rft.aulast=Chen&amp;rft.au=Lee%2C+J&amp;rft.au=Li%2C+Y&amp;rft.au=Pennathur-Das%2C+R&amp;rft.au=Radzyminski%2C+J&amp;rft.au=Ramesh%2C+N&amp;rft.au=Scott%2C+S&amp;rft.au=Stephens%2C+J&amp;rft.au=Wypych%2C+J&amp;rft.au=Yu%2C+DC&amp;rft.au=Zhang%2C+Y&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcancerres.aacrjournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D11454691&amp;rft_id=info%3Apmid%2F11454691&amp;rft.issue=14&amp;rft.jtitle=Cancer+Research&amp;rft.pages=5453-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-117"><span class="mw-cite-backlink"><b><a href="#cite_ref-117">^</a></b></span> <span class="reference-text"><cite class="citation journal">Mace, A.T.M.; Harrow, S.J.; Ganly, I.; Brown, S.M. (2007). "Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma". <i>Acta Oto-laryngologica</i>. <b>127</b> (8): 880–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F00016480601075381">10.1080/00016480601075381</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17763002">17763002</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Cytotoxic+effects+of+the+oncolytic+herpes+simplex+virus+HSV1716+alone+and+in+combination+with+cisplatin+in+head+and+neck+squamous+cell+carcinoma&amp;rft.au=Brown%2C+S.M.&amp;rft.aufirst=A.T.M.&amp;rft.au=Ganly%2C+I.&amp;rft.au=Harrow%2C+S.J.&amp;rft.aulast=Mace&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1080%2F00016480601075381&amp;rft_id=info%3Apmid%2F17763002&amp;rft.issue=8&amp;rft.jtitle=Acta+Oto-laryngologica&amp;rft.pages=880-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=127" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-118"><span class="mw-cite-backlink"><b><a href="#cite_ref-118">^</a></b></span> <span class="reference-text"><cite class="citation journal">Toyoizumi, Takane; Mick, Rosemarie; Abbas, Abbas E.; Kang, Eugene H.; Kaiser, Larry R.; Molnar-Kimber, Katherine L. (1999). "Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer". <i>Human Gene Therapy</i>. <b>10</b> (18): 3013–29. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1089%2F10430349950016410">10.1089/10430349950016410</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10609661">10609661</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=Combined+Therapy+with+Chemotherapeutic+Agents+and+Herpes+Simplex+Virus+Type+1+ICP34.5+Mutant+%28HSV-1716%29+in+Human+Non-Small+Cell+Lung+Cancer&amp;rft.au=Abbas%2C+Abbas+E.&amp;rft.aufirst=Takane&amp;rft.au=Kaiser%2C+Larry+R.&amp;rft.au=Kang%2C+Eugene+H.&amp;rft.aulast=Toyoizumi&amp;rft.au=Mick%2C+Rosemarie&amp;rft.au=Molnar-Kimber%2C+Katherine+L.&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1089%2F10430349950016410&amp;rft_id=info%3Apmid%2F10609661&amp;rft.issue=18&amp;rft.jtitle=Human+Gene+Therapy&amp;rft.pages=3013-29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-119">^</a></b></span> <span class="reference-text"><cite class="citation journal">Currier, Mark A; Eshun, Francis K; Sholl, Allyson; Chernoguz, Artur; Crawford, Kelly; Divanovic, Senad; Boon, Louis; Goins, William F; Frischer, Jason S; Collins, Margaret H; Leddon, Jennifer L; Baird, William H; Haseley, Amy; Streby, Keri A; Wang, Pin-Yi; Hendrickson, Brett W; Brekken, Rolf A; Kaur, Balveen; Hildeman, David; Cripe, Timothy P (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666636">"VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells"</a>. <i>Molecular Therapy</i>. <b>21</b> (5): 1014–23. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fmt.2013.39">10.1038/mt.2013.39</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666636">3666636</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23481323">23481323</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.atitle=VEGF+Blockade+Enables+Oncolytic+Cancer+Virotherapy+in+Part+by+Modulating+Intratumoral+Myeloid+Cells&amp;rft.au=Baird%2C+William+H&amp;rft.au=Boon%2C+Louis&amp;rft.au=Brekken%2C+Rolf+A&amp;rft.au=Chernoguz%2C+Artur&amp;rft.au=Collins%2C+Margaret+H&amp;rft.au=Crawford%2C+Kelly&amp;rft.au=Cripe%2C+Timothy+P&amp;rft.au=Divanovic%2C+Senad&amp;rft.au=Eshun%2C+Francis+K&amp;rft.aufirst=Mark+A&amp;rft.au=Frischer%2C+Jason+S&amp;rft.au=Goins%2C+William+F&amp;rft.au=Haseley%2C+Amy&amp;rft.au=Hendrickson%2C+Brett+W&amp;rft.au=Hildeman%2C+David&amp;rft.au=Kaur%2C+Balveen&amp;rft.aulast=Currier&amp;rft.au=Leddon%2C+Jennifer+L&amp;rft.au=Sholl%2C+Allyson&amp;rft.au=Streby%2C+Keri+A&amp;rft.au=Wang%2C+Pin-Yi&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3666636&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3666636&amp;rft_id=info%3Adoi%2F10.1038%2Fmt.2013.39&amp;rft_id=info%3Apmid%2F23481323&amp;rft.issue=5&amp;rft.jtitle=Molecular+Therapy&amp;rft.pages=1014-23&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-120"><span class="mw-cite-backlink"><b><a href="#cite_ref-120">^</a></b></span> <span class="reference-text"><cite class="citation book">Williamson, Jack (2002). <i>Dragon's Island and other stories</i>. Waterville, Me.: Five Star. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0786243147" title="Special:BookSources/0786243147">0786243147</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=Jack&amp;rft.aulast=Williamson&amp;rft.btitle=Dragon%27s+Island+and+other+stories&amp;rft.date=2002&amp;rft.genre=book&amp;rft.isbn=0786243147&amp;rft.place=Waterville%2C+Me.&amp;rft.pub=Five+Star&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources"><span title="This citation requires a reference to the specific page or range of pages in which the material appears. (January 2014)">page&#160;needed</span></a></i>]</sup></span></li>
<li id="cite_note-121"><span class="mw-cite-backlink"><b><a href="#cite_ref-121">^</a></b></span> <span class="reference-text"><cite class="citation book">Stableford, Brian M. (2004). <a rel="nofollow" class="external text" href="https://books.google.com/?id=nzmIPZg5xicC&amp;pg=PR9&amp;dq=Jack+Williamson+Dragon%27s+Island+genetic+engineering&amp;q"><i>Historical dictionary of science fiction literature</i></a>. p.&#160;133. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780810849389" title="Special:BookSources/9780810849389">9780810849389</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.aufirst=Brian+M.&amp;rft.aulast=Stableford&amp;rft.btitle=Historical+dictionary+of+science+fiction+literature&amp;rft.date=2004&amp;rft.genre=book&amp;rft_id=https%3A%2F%2Fbooks.google.com%2F%3Fid%3DnzmIPZg5xicC%26pg%3DPR9%26dq%3DJack%2BWilliamson%2BDragon%2527s%2BIsland%2Bgenetic%2Bengineering%26q&amp;rft.isbn=9780810849389&amp;rft.pages=133&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=38" title="Edit section: Further reading">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><cite class="citation book">Harrington, Vile, Pandha (2008). <a rel="nofollow" class="external text" href="https://books.google.com/?id=7D54wqngF1QC&amp;printsec=frontcover#v=onepage&amp;q&amp;f=false"><i>Viral Therapy of Cancer</i></a>. Hoboken, N.J.: Wiley. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0470019220" title="Special:BookSources/0470019220">0470019220</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.au=Harrington%2C+Vile%2C+Pandha&amp;rft.btitle=Viral+Therapy+of+Cancer&amp;rft.date=2008&amp;rft.genre=book&amp;rft_id=https%3A%2F%2Fbooks.google.com%2F%3Fid%3D7D54wqngF1QC%26printsec%3Dfrontcover%23v%3Donepage%26q%26f%3Dfalse&amp;rft.isbn=0470019220&amp;rft.place=Hoboken%2C+N.J.&amp;rft.pub=Wiley&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></li>
<li><cite class="citation book">Thorne, Kirn, Liu (2011). <i>Oncolytic Viruses: Methods and Protocols (Methods in Molecular Biology)</i>. New York: Humana Press. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1617793396" title="Special:BookSources/1617793396">1617793396</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.au=Thorne%2C+Kirn%2C+Liu&amp;rft.btitle=Oncolytic+Viruses%3A+Methods+and+Protocols+%28Methods+in+Molecular+Biology%29&amp;rft.date=2011&amp;rft.genre=book&amp;rft.isbn=1617793396&amp;rft.place=New+York&amp;rft.pub=Humana+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></li>
<li><cite class="citation book">Sinkovics (2005). <i>Viral therapy of human cancers</i>. New York: Dekker. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0824759133" title="Special:BookSources/0824759133">0824759133</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOncolytic+virus&amp;rft.au=Sinkovics&amp;rft.btitle=Viral+therapy+of+human+cancers&amp;rft.date=2005&amp;rft.genre=book&amp;rft.isbn=0824759133&amp;rft.place=New+York&amp;rft.pub=Dekker&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit&amp;section=39" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li>A number of oncolytic viruses were discussed on Columbia University Professor <a href="/wiki/Vincent_Racaniello" title="Vincent Racaniello">Vincent Racaniello</a>'s "This week in virology" podcast, including episodes on <a rel="nofollow" class="external text" href="http://www.twiv.tv/2011/03/13/twiv-124-viruses-that-make-you-better/">myxoma virus</a>, <a rel="nofollow" class="external text" href="http://www.twiv.tv/2011/05/01/twiv-131-a-reostat-for-cancer/">reovirus</a>, <a rel="nofollow" class="external text" href="http://www.twiv.tv/2011/07/17/twiv-142-viral-oinkotherapy/">picornavirus</a>, <a rel="nofollow" class="external text" href="http://www.twiv.tv/2011/11/06/twiv-156-armed-and-targeted-killer-meta-analysis/">poxvirus</a>, and <a rel="nofollow" class="external text" href="http://www.twiv.tv/2014/08/17/twiv-298/">measles virus</a>.</li>
</ul>
<div role="navigation" class="navbox" aria-labelledby="Emerging_technologies" style="padding:3px">
<table class="nowraplinks hlist collapsible collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="text-align: center;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Emerging_technologies" title="Template:Emerging technologies"><abbr title="View this template" style="text-align: center;;;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Emerging_technologies" title="Template talk:Emerging technologies"><abbr title="Discuss this template" style="text-align: center;;;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Emerging_technologies&amp;action=edit"><abbr title="Edit this template" style="text-align: center;;;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div id="Emerging_technologies" style="font-size:114%"><a href="/wiki/Emerging_technologies" title="Emerging technologies">Emerging technologies</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="text-align: center;">
<div><a href="/wiki/Technology" title="Technology">Technology</a></div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Fields</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Agriculture" title="Agriculture">Agriculture</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Agricultural_robot" title="Agricultural robot">Agricultural robot</a></li>
<li><a href="/wiki/Closed_ecological_system" title="Closed ecological system">Closed ecological systems</a></li>
<li><a href="/wiki/Cultured_meat" title="Cultured meat">Cultured meat</a></li>
<li><a href="/wiki/Genetically_modified_food" title="Genetically modified food">Genetically modified food</a></li>
<li><a href="/wiki/Precision_agriculture" title="Precision agriculture">Precision agriculture</a></li>
<li><a href="/wiki/Vertical_farming" title="Vertical farming">Vertical farming</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Architecture" title="Architecture">Architecture</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Arcology" title="Arcology">Arcology</a></li>
<li><a href="/wiki/Building_printing" class="mw-redirect" title="Building printing">Building printing</a>
<ul>
<li><a href="/wiki/Contour_crafting" title="Contour crafting">Contour crafting</a></li>
<li><a href="/wiki/D-Shape" title="D-Shape">D-Shape</a></li>
</ul>
</li>
<li><a href="/wiki/Domed_city" title="Domed city">Domed city</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Biomedical_technology" title="Biomedical technology">Biomedical</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Artificial_uterus" title="Artificial uterus">Artificial uterus</a></li>
<li><a href="/wiki/Ampakine" title="Ampakine">Ampakine</a></li>
<li><a href="/wiki/Brain_transplant" title="Brain transplant">Brain transplant</a></li>
<li><a href="/wiki/Cryonics" title="Cryonics">Cryonics</a>
<ul>
<li><a href="/wiki/Cryoprotectant" title="Cryoprotectant">Cryoprotectant</a></li>
<li><a href="/wiki/Cryopreservation" title="Cryopreservation">Cryopreservation</a></li>
<li><a href="/wiki/Vitrification" title="Vitrification">Vitrification</a></li>
<li><a href="/wiki/Suspended_animation" title="Suspended animation">Suspended animation</a></li>
</ul>
</li>
<li><a href="/wiki/De-extinction" title="De-extinction">De-extinction</a></li>
<li><a href="/wiki/Genetic_engineering" title="Genetic engineering">Genetic engineering</a>
<ul>
<li><a href="/wiki/Gene_therapy" title="Gene therapy">Gene therapy</a></li>
</ul>
</li>
<li><a href="/wiki/Head_transplant" title="Head transplant">Head transplant</a></li>
<li><a href="/wiki/Isolated_brain" title="Isolated brain">Isolated brain</a></li>
<li><a href="/wiki/Life_extension" title="Life extension">Life extension</a>
<ul>
<li><a href="/wiki/Strategies_for_Engineered_Negligible_Senescence" title="Strategies for Engineered Negligible Senescence">Strategies for Engineered Negligible Senescence</a></li>
</ul>
</li>
<li><a href="/wiki/Nanomedicine" title="Nanomedicine">Nanomedicine</a></li>
<li><a href="/wiki/Nanosensor" title="Nanosensor">Nanosensors</a></li>
<li><a href="/wiki/Personalized_medicine" title="Personalized medicine">Personalized medicine</a></li>
<li><a href="/wiki/Regenerative_medicine" title="Regenerative medicine">Regenerative medicine</a>
<ul>
<li><a href="/wiki/Stem-cell_therapy" title="Stem-cell therapy">Stem-cell therapy</a></li>
<li><a href="/wiki/Tissue_engineering" title="Tissue engineering">Tissue engineering</a></li>
</ul>
</li>
<li><a href="/wiki/Robot-assisted_surgery" title="Robot-assisted surgery">Robot-assisted surgery</a></li>
<li><a href="/wiki/Synthetic_biology" title="Synthetic biology">Synthetic biology</a>
<ul>
<li><a href="/wiki/Synthetic_genomics" title="Synthetic genomics">Synthetic genomics</a></li>
</ul>
</li>
<li><a href="/wiki/Virotherapy" title="Virotherapy">Virotherapy</a>
<ul>
<li><strong class="selflink">Oncolytic virus</strong></li>
</ul>
</li>
<li><a href="/wiki/Medical_tricorder" title="Medical tricorder">Tricorder</a></li>
<li><a href="/wiki/Whole_genome_sequencing" title="Whole genome sequencing">Whole genome sequencing</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Displays</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Next_generation_of_display_technology" title="Next generation of display technology">Next generation</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Field_emission_display" title="Field emission display">FED</a></li>
<li><a href="/wiki/Ferro_Liquid_Crystal_Display" class="mw-redirect" title="Ferro Liquid Crystal Display">FLCD</a></li>
<li><a href="/wiki/Interferometric_modulator_display" title="Interferometric modulator display">iMoD</a></li>
<li><a href="/wiki/Laser_video_display" title="Laser video display">Laser</a></li>
<li><a href="/wiki/Laser-powered_phosphor_display" title="Laser-powered phosphor display">LPD</a></li>
<li><a href="/wiki/OLED" title="OLED">OLED</a></li>
<li><a href="/wiki/Organic_light-emitting_transistor" title="Organic light-emitting transistor">OLET</a></li>
<li><a href="/wiki/Quantum_dot_display" title="Quantum dot display">QD-LED</a></li>
<li><a href="/wiki/Surface-conduction_electron-emitter_display" title="Surface-conduction electron-emitter display">SED</a></li>
<li><a href="/wiki/Telescopic_pixel_display" title="Telescopic pixel display">TPD</a></li>
<li><a href="/wiki/Thick-film_dielectric_electroluminescent_technology" title="Thick-film dielectric electroluminescent technology">TDEL</a></li>
<li><a href="/wiki/Time-multiplexed_optical_shutter" title="Time-multiplexed optical shutter">TMOS</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Screenless" title="Screenless">Screenless</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Bionic_contact_lens" title="Bionic contact lens">Bionic contact lens</a></li>
<li><a href="/wiki/Head-mounted_display" title="Head-mounted display">Head-mounted display</a></li>
<li><a href="/wiki/Head-up_display" title="Head-up display">Head-up display</a></li>
<li><a href="/wiki/Optical_head-mounted_display" title="Optical head-mounted display">Optical head-mounted display</a></li>
<li><a href="/wiki/Virtual_retinal_display" title="Virtual retinal display">Virtual retinal display</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Other</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Autostereoscopy" title="Autostereoscopy">Autostereoscopy</a></li>
<li><a href="/wiki/Flexible_display" title="Flexible display">Flexible display</a></li>
<li><a href="/wiki/Holographic_display" title="Holographic display">Holographic display</a>
<ul>
<li><a href="/wiki/Computer-generated_holography" title="Computer-generated holography">Computer-generated holography</a></li>
</ul>
</li>
<li><a href="/wiki/Multi-primary_color_display" title="Multi-primary color display">Multi-primary color display</a></li>
<li><a href="/wiki/Ultra-high-definition_television" title="Ultra-high-definition television">Ultra HD</a></li>
<li><a href="/wiki/Volumetric_display" title="Volumetric display">Volumetric display</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Electronics</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Electronic_nose" title="Electronic nose">Electronic nose</a></li>
<li><a href="/wiki/E-textiles" title="E-textiles">E-textiles</a></li>
<li><a href="/wiki/Flexible_electronics" title="Flexible electronics">Flexible electronics</a></li>
<li><a href="/wiki/Molecular_electronics" title="Molecular electronics">Molecular electronics</a></li>
<li><a href="/wiki/Nanoelectromechanical_systems" title="Nanoelectromechanical systems">Nanoelectromechanical systems</a></li>
<li><a href="/wiki/Memristor" title="Memristor">Memristor</a></li>
<li><a href="/wiki/Spintronics" title="Spintronics">Spintronics</a></li>
<li><a href="/wiki/Thermal_copper_pillar_bump" title="Thermal copper pillar bump">Thermal copper pillar bump</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Energy</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Production</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Airborne_wind_turbine" title="Airborne wind turbine">Airborne wind turbine</a></li>
<li><a href="/wiki/Artificial_photosynthesis" title="Artificial photosynthesis">Artificial photosynthesis</a></li>
<li><a href="/wiki/Biofuel" title="Biofuel">Biofuels</a></li>
<li><a href="/wiki/Carbon-neutral_fuel" title="Carbon-neutral fuel">Carbon-neutral fuel</a></li>
<li><a href="/wiki/Concentrated_solar_power" title="Concentrated solar power">Concentrated solar power</a></li>
<li><a href="/wiki/Fusion_power" title="Fusion power">Fusion power</a></li>
<li><a href="/wiki/Home_fuel_cell" title="Home fuel cell">Home fuel cell</a></li>
<li><a href="/wiki/Hydrogen_economy" title="Hydrogen economy">Hydrogen economy</a></li>
<li><a href="/wiki/Methanol_economy" title="Methanol economy">Methanol economy</a></li>
<li><a href="/wiki/Molten_salt_reactor" title="Molten salt reactor">Molten salt reactor</a></li>
<li><a href="/wiki/Nantenna" class="mw-redirect" title="Nantenna">Nantenna</a></li>
<li><a href="/wiki/Photovoltaic_pavement" class="mw-redirect" title="Photovoltaic pavement">Photovoltaic pavement</a></li>
<li><a href="/wiki/Space-based_solar_power" title="Space-based solar power">Space-based solar power</a></li>
<li><a href="/wiki/Vortex_engine" title="Vortex engine">Vortex engine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Storage</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Lithium_iron_phosphate_battery" title="Lithium iron phosphate battery">Beltway battery</a></li>
<li><a href="/wiki/Compressed_air_energy_storage" title="Compressed air energy storage">Compressed air energy storage</a></li>
<li><a href="/wiki/Flywheel_energy_storage" title="Flywheel energy storage">Flywheel energy storage</a></li>
<li><a href="/wiki/Grid_energy_storage" title="Grid energy storage">Grid energy storage</a></li>
<li><a href="/wiki/Lithium%E2%80%93air_battery" title="Lithium–air battery">Lithium–air battery</a></li>
<li><a href="/wiki/Molten_salt_battery" title="Molten salt battery">Molten salt battery</a></li>
<li><a href="/wiki/Nanowire_battery" title="Nanowire battery">Nanowire battery</a></li>
<li><a href="/wiki/Research_in_lithium-ion_batteries" title="Research in lithium-ion batteries">Research in lithium-ion batteries</a></li>
<li><a href="/wiki/Silicon%E2%80%93air_battery" title="Silicon–air battery">Silicon–air battery</a></li>
<li><a href="/wiki/Thermal_energy_storage" title="Thermal energy storage">Thermal energy storage</a></li>
<li><a href="/wiki/Electric_double-layer_capacitor" title="Electric double-layer capacitor">Ultracapacitor</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Other</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Smart_grid" title="Smart grid">Smart grid</a></li>
<li><a href="/wiki/Wireless_power" class="mw-redirect" title="Wireless power">Wireless power</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">
<div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Information_and_communications_technology" title="Information and communications technology">IT and<br />
communications</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Ambient_intelligence" title="Ambient intelligence">Ambient intelligence</a>
<ul>
<li><a href="/wiki/Internet_of_Things" class="mw-redirect" title="Internet of Things">Internet of Things</a></li>
</ul>
</li>
<li><a href="/wiki/Artificial_intelligence" title="Artificial intelligence">Artificial intelligence</a>
<ul>
<li><a href="/wiki/Applications_of_artificial_intelligence" title="Applications of artificial intelligence">Applications of artificial intelligence</a></li>
<li><a href="/wiki/Progress_in_artificial_intelligence" title="Progress in artificial intelligence">Progress in artificial intelligence</a></li>
<li><a href="/wiki/Machine_translation" title="Machine translation">Machine translation</a></li>
<li><a href="/wiki/Machine_vision" title="Machine vision">Machine vision</a></li>
<li><a href="/wiki/Semantic_Web" title="Semantic Web">Semantic Web</a></li>
<li><a href="/wiki/Speech_recognition" title="Speech recognition">Speech recognition</a></li>
</ul>
</li>
<li><a href="/wiki/Atomtronics" title="Atomtronics">Atomtronics</a></li>
<li><a href="/wiki/Carbon_nanotube_field-effect_transistor" title="Carbon nanotube field-effect transistor">Carbon nanotube field-effect transistor</a></li>
<li><a href="/wiki/Cybermethodology" title="Cybermethodology">Cybermethodology</a></li>
<li><a href="/wiki/Optical_disc#Fourth-generation" title="Optical disc">Fourth-generation optical discs</a>
<ul>
<li><a href="/wiki/3D_optical_data_storage" title="3D optical data storage">3D optical data storage</a></li>
<li><a href="/wiki/Holographic_data_storage" title="Holographic data storage">Holographic data storage</a></li>
</ul>
</li>
<li><a href="/wiki/General-purpose_computing_on_graphics_processing_units" title="General-purpose computing on graphics processing units">GPGPU</a></li>
<li>Memory
<ul>
<li><a href="/wiki/Programmable_metallization_cell" title="Programmable metallization cell">CBRAM</a></li>
<li><a href="/wiki/Ferroelectric_RAM" title="Ferroelectric RAM">FRAM</a></li>
<li><a href="/wiki/Millipede_memory" title="Millipede memory">Millipede</a></li>
<li><a href="/wiki/Magnetoresistive_random-access_memory" title="Magnetoresistive random-access memory">MRAM</a></li>
<li><a href="/wiki/Nano-RAM" title="Nano-RAM">NRAM</a></li>
<li><a href="/wiki/Phase-change_memory" title="Phase-change memory">PRAM</a></li>
<li><a href="/wiki/Racetrack_memory" title="Racetrack memory">Racetrack memory</a></li>
<li><a href="/wiki/Resistive_random-access_memory" title="Resistive random-access memory">RRAM</a></li>
<li><a href="/wiki/SONOS" title="SONOS">SONOS</a></li>
</ul>
</li>
<li><a href="/wiki/Optical_computing" title="Optical computing">Optical computing</a></li>
<li><a href="/wiki/Quantum_computing" title="Quantum computing">Quantum computing</a></li>
<li><a href="/wiki/Quantum_cryptography" title="Quantum cryptography">Quantum cryptography</a></li>
<li><a href="/wiki/Radio-frequency_identification" title="Radio-frequency identification">RFID</a>
<ul>
<li><a href="/wiki/Chipless_RFID" title="Chipless RFID">Chipless RFID</a></li>
</ul>
</li>
<li><a href="/wiki/Software-defined_radio" title="Software-defined radio">Software-defined radio</a></li>
<li><a href="/wiki/Three-dimensional_integrated_circuit" title="Three-dimensional integrated circuit">Three-dimensional integrated circuit</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Manufacturing</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/3D_printing" title="3D printing">3D printing</a></li>
<li><a href="/wiki/Claytronics" title="Claytronics">Claytronics</a></li>
<li><a href="/wiki/Molecular_assembler" title="Molecular assembler">Molecular assembler</a></li>
<li><a href="/wiki/Utility_fog" title="Utility fog">Utility fog</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Materials_science" title="Materials science">Materials science</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Aerogel" title="Aerogel">Aerogel</a></li>
<li><a href="/wiki/Amorphous_metal" title="Amorphous metal">Amorphous metal</a></li>
<li><a href="/wiki/Artificial_muscle" title="Artificial muscle">Artificial muscle</a></li>
<li><a href="/wiki/Conductive_polymer" title="Conductive polymer">Conductive polymer</a></li>
<li><a href="/wiki/Femtotechnology" title="Femtotechnology">Femtotechnology</a></li>
<li><a href="/wiki/Fullerene" title="Fullerene">Fullerene</a></li>
<li><a href="/wiki/Graphene" title="Graphene">Graphene</a></li>
<li><a href="/wiki/High-temperature_superconductivity" title="High-temperature superconductivity">High-temperature superconductivity</a></li>
<li><a href="/wiki/Superfluidity" title="Superfluidity">High-temperature superfluidity</a></li>
<li><a href="/wiki/Linear_acetylenic_carbon" title="Linear acetylenic carbon">Linear acetylenic carbon</a></li>
<li><a href="/wiki/Metamaterial" title="Metamaterial">Metamaterials</a>
<ul>
<li><a href="/wiki/Metamaterial_cloaking" title="Metamaterial cloaking">Metamaterial cloaking</a></li>
</ul>
</li>
<li><a href="/wiki/Metal_foam" title="Metal foam">Metal foam</a></li>
<li><a href="/wiki/Multi-function_structure" title="Multi-function structure">Multi-function structures</a></li>
<li><a href="/wiki/Nanotechnology" title="Nanotechnology">Nanotechnology</a>
<ul>
<li><a href="/wiki/Carbon_nanotube" title="Carbon nanotube">Carbon nanotubes</a></li>
<li><a href="/wiki/Molecular_nanotechnology" title="Molecular nanotechnology">Molecular nanotechnology</a></li>
<li><a href="/wiki/Nanomaterials" title="Nanomaterials">Nanomaterials</a></li>
</ul>
</li>
<li><a href="/wiki/Picotechnology" title="Picotechnology">Picotechnology</a></li>
<li><a href="/wiki/Programmable_matter" title="Programmable matter">Programmable matter</a></li>
<li><a href="/wiki/Quantum_dot" title="Quantum dot">Quantum dots</a></li>
<li><a href="/wiki/Silicene" title="Silicene">Silicene</a></li>
<li><a href="/wiki/Superalloy" title="Superalloy">Superalloy</a></li>
<li><a href="/wiki/Synthetic_diamond" title="Synthetic diamond">Synthetic diamond</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Military_technology" title="Military technology">Military</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Antimatter_weapon" title="Antimatter weapon">Antimatter weapon</a></li>
<li><a href="/wiki/Caseless_ammunition" title="Caseless ammunition">Caseless ammunition</a></li>
<li><a href="/wiki/Directed-energy_weapon" title="Directed-energy weapon">Directed-energy weapon</a>
<ul>
<li><a href="/wiki/Laser" title="Laser">Laser</a></li>
<li><a href="/wiki/Maser" title="Maser">Maser</a></li>
<li><a href="/wiki/Particle-beam_weapon" title="Particle-beam weapon">Particle-beam weapon</a></li>
<li><a href="/wiki/Sonic_weapon" title="Sonic weapon">Sonic weapon</a></li>
<li><a href="/wiki/Coilgun" title="Coilgun">Coilgun</a></li>
<li><a href="/wiki/Railgun" title="Railgun">Railgun</a></li>
</ul>
</li>
<li><a href="/wiki/Plasma_weapon" title="Plasma weapon">Plasma weapon</a></li>
<li><a href="/wiki/Pure_fusion_weapon" title="Pure fusion weapon">Pure fusion weapon</a></li>
<li><a href="/wiki/Stealth_technology" title="Stealth technology">Stealth technology</a></li>
<li><a href="/wiki/Vortex_ring_gun" title="Vortex ring gun">Vortex ring gun</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Neuroscience" title="Neuroscience">Neuroscience</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Artificial_brain" title="Artificial brain">Artificial brain</a>
<ul>
<li><a href="/wiki/Blue_Brain_Project" title="Blue Brain Project">Blue Brain Project</a></li>
</ul>
</li>
<li><a href="/wiki/Brain%E2%80%93computer_interface" title="Brain–computer interface">Brain–computer interface</a></li>
<li><a href="/wiki/Electroencephalography" title="Electroencephalography">Electroencephalography</a></li>
<li><a href="/wiki/Mind_uploading" title="Mind uploading">Mind uploading</a>
<ul>
<li><a href="/wiki/Brain-reading" title="Brain-reading">Brain-reading</a></li>
<li><a href="/wiki/Neuroinformatics" title="Neuroinformatics">Neuroinformatics</a></li>
</ul>
</li>
<li><a href="/wiki/Neuroprosthetics" title="Neuroprosthetics">Neuroprosthetics</a>
<ul>
<li><a href="/wiki/Visual_prosthesis" title="Visual prosthesis">Bionic eye</a></li>
<li><a href="/wiki/Brain_implant" title="Brain implant">Brain implant</a></li>
<li><a href="/wiki/Exocortex" title="Exocortex">Exocortex</a></li>
<li><a href="/wiki/Retinal_implant" title="Retinal implant">Retinal implant</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Future_of_robotics" class="mw-redirect" title="Future of robotics">Robotics</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Home_automation" title="Home automation">Domotics</a></li>
<li><a href="/wiki/Nanorobotics" title="Nanorobotics">Nanorobotics</a></li>
<li><a href="/wiki/Powered_exoskeleton" title="Powered exoskeleton">Powered exoskeleton</a></li>
<li><a href="/wiki/Self-reconfiguring_modular_robot" title="Self-reconfiguring modular robot">Self-reconfiguring modular robot</a></li>
<li><a href="/wiki/Swarm_robotics" title="Swarm robotics">Swarm robotics</a></li>
<li><a href="/wiki/Uncrewed_vehicle" title="Uncrewed vehicle">Uncrewed vehicle</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Outline_of_space_science" title="Outline of space science">Space science</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Space_launch" title="Space launch">Launch</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Fusion_rocket" title="Fusion rocket">Fusion rocket</a></li>
<li><a href="/wiki/Non-rocket_spacelaunch" title="Non-rocket spacelaunch">Non-rocket spacelaunch</a>
<ul>
<li><a href="/wiki/Mass_driver" title="Mass driver">Mass driver</a></li>
<li><a href="/wiki/Orbital_ring" title="Orbital ring">Orbital ring</a></li>
<li><a href="/wiki/Space_elevator" title="Space elevator">Space elevator</a></li>
<li><a href="/wiki/Space_fountain" title="Space fountain">Space fountain</a></li>
<li><a href="/wiki/Space_tether" title="Space tether">Space tether</a></li>
</ul>
</li>
<li><a href="/wiki/Reusable_launch_system" title="Reusable launch system">Reusable launch system</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Spacecraft_propulsion" title="Spacecraft propulsion">Propulsion</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Beam-powered_propulsion" title="Beam-powered propulsion">Beam-powered propulsion</a></li>
<li><a href="/wiki/Ion_thruster" title="Ion thruster">Ion thruster</a></li>
<li><a href="/wiki/Laser_propulsion" title="Laser propulsion">Laser propulsion</a></li>
<li><a href="/wiki/Plasma_propulsion_engine" title="Plasma propulsion engine">Plasma propulsion engine</a>
<ul>
<li><a href="/wiki/Helicon_double-layer_thruster" title="Helicon double-layer thruster">Helicon thruster</a></li>
<li><a href="/wiki/Variable_Specific_Impulse_Magnetoplasma_Rocket" title="Variable Specific Impulse Magnetoplasma Rocket">VASIMR</a></li>
</ul>
</li>
<li><a href="/wiki/Project_Orion_(nuclear_propulsion)" title="Project Orion (nuclear propulsion)">Project Orion</a></li>
<li><a href="/wiki/Nuclear_pulse_propulsion" title="Nuclear pulse propulsion">Nuclear pulse propulsion</a></li>
<li><a href="/wiki/Solar_sail" title="Solar sail">Solar sail</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Other</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Interstellar_travel" title="Interstellar travel">Interstellar travel</a></li>
<li><a href="/wiki/Propellant_depot" title="Propellant depot">Propellant depot</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Outline_of_transport" title="Outline of transport">Transport</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Aviation" title="Aviation">Aerial</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Adaptive_compliant_wing" title="Adaptive compliant wing">Adaptive compliant wing</a></li>
<li><a href="/wiki/Worldwide_Aeros_Corp" title="Worldwide Aeros Corp">Aeroscraft</a></li>
<li><a href="/wiki/Backpack_helicopter" title="Backpack helicopter">Backpack helicopter</a></li>
<li><a href="/wiki/Delivery_drone" title="Delivery drone">Delivery drone</a></li>
<li><a href="/wiki/Flying_car_(aircraft)" title="Flying car (aircraft)">Flying car</a></li>
<li><a href="/wiki/High-altitude_platform" class="mw-redirect" title="High-altitude platform">High-altitude platform</a></li>
<li><a href="/wiki/Jet_pack" title="Jet pack">Jet pack</a></li>
<li><a href="/wiki/Pulse_detonation_engine" title="Pulse detonation engine">Pulse detonation engine</a></li>
<li><a href="/wiki/Scramjet" title="Scramjet">Scramjet</a></li>
<li><a href="/wiki/Spaceplane" title="Spaceplane">Spaceplane</a>
<ul>
<li><a href="/wiki/Skylon_(spacecraft)" title="Skylon (spacecraft)">Skylon</a></li>
</ul>
</li>
<li><a href="/wiki/Supersonic_transport" title="Supersonic transport">Supersonic transport</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Land_transport" title="Land transport">Land</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Airless_tire" title="Airless tire">Airless tire</a>
<ul>
<li><a href="/wiki/Tweel" title="Tweel">Tweel</a></li>
</ul>
</li>
<li><a href="/wiki/Alternative_fuel_vehicle" title="Alternative fuel vehicle">Alternative fuel vehicle</a>
<ul>
<li><a href="/wiki/Hydrogen_vehicle" title="Hydrogen vehicle">Hydrogen vehicle</a></li>
</ul>
</li>
<li><a href="/wiki/Autonomous_car" title="Autonomous car">Driverless car</a></li>
<li><a href="/wiki/Ground_effect_train" title="Ground effect train">Ground effect train</a></li>
<li><a href="/wiki/Maglev" title="Maglev">Maglev train</a></li>
<li><a href="/wiki/Personal_rapid_transit" title="Personal rapid transit">Personal rapid transit</a></li>
<li><a href="/wiki/Vactrain" title="Vactrain">Vactrain</a>
<ul>
<li><a href="/wiki/ET3_Global_Alliance" title="ET3 Global Alliance">ET3 Global Alliance</a></li>
<li><a href="/wiki/Hyperloop" title="Hyperloop">Hyperloop</a></li>
</ul>
</li>
<li><a href="/wiki/Vehicular_communication_systems" title="Vehicular communication systems">Vehicular communication systems</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;"><a href="/wiki/Pipeline_transport" title="Pipeline transport">Pipeline</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Pneumatic_tube" title="Pneumatic tube">Pneumatic transport</a>
<ul>
<li><a href="/wiki/Automated_vacuum_collection" title="Automated vacuum collection">Automated vacuum collection</a></li>
<li><a href="/wiki/Foodtubes" title="Foodtubes">Foodtubes</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Other</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anti-gravity" title="Anti-gravity">Anti-gravity</a></li>
<li><a href="/wiki/Cloak_of_invisibility" title="Cloak of invisibility">Cloak of invisibility</a></li>
<li><a href="/wiki/Digital_scent_technology" title="Digital scent technology">Digital scent technology</a></li>
<li><a href="/wiki/Force_field_(fiction)" title="Force field (fiction)">Force field</a>
<ul>
<li><a href="/wiki/Plasma_window" title="Plasma window">Plasma window</a></li>
</ul>
</li>
<li><a href="/wiki/Immersion_(virtual_reality)" title="Immersion (virtual reality)">Immersive virtual reality</a>
<ul>
<li><a href="/wiki/VirtuSphere" title="VirtuSphere">VirtuSphere</a></li>
</ul>
</li>
<li><a href="/wiki/Magnetic_refrigeration" title="Magnetic refrigeration">Magnetic refrigeration</a></li>
<li><a href="/wiki/Phased-array_optics" title="Phased-array optics">Phased-array optics</a></li>
<li><a href="/wiki/Quantum_technology" title="Quantum technology">Quantum technology</a>
<ul>
<li><a href="/wiki/Quantum_teleportation" title="Quantum teleportation">Quantum teleportation</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Topics</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Collingridge_dilemma" title="Collingridge dilemma">Collingridge dilemma</a></li>
<li><a href="/wiki/Differential_technological_development" title="Differential technological development">Differential technological development</a></li>
<li><a href="/wiki/Ephemeralization" title="Ephemeralization">Ephemeralization</a></li>
<li><a href="/wiki/Exploratory_engineering" title="Exploratory engineering">Exploratory engineering</a></li>
<li><a href="/wiki/Fictional_technology" title="Fictional technology">Fictional technology</a></li>
<li><a href="/wiki/Proactionary_principle" title="Proactionary principle">Proactionary principle</a></li>
<li><a href="/wiki/Technological_change" title="Technological change">Technological change</a>
<ul>
<li><a href="/wiki/Technological_unemployment" title="Technological unemployment">Technological unemployment</a></li>
</ul>
</li>
<li><a href="/wiki/Technological_convergence" title="Technological convergence">Technological convergence</a></li>
<li><a href="/wiki/Technological_evolution" title="Technological evolution">Technological evolution</a></li>
<li><a href="/wiki/Technological_paradigm" title="Technological paradigm">Technological paradigm</a></li>
<li><a href="/wiki/Technology_forecasting" title="Technology forecasting">Technology forecasting</a>
<ul>
<li><a href="/wiki/Accelerating_change" title="Accelerating change">Accelerating change</a></li>
<li><a href="/wiki/Moore%27s_law" title="Moore's law">Moore's law</a></li>
<li><a href="/wiki/Technological_singularity" title="Technological singularity">Technological singularity</a></li>
<li><a href="/wiki/Technology_scouting" title="Technology scouting">Technology scouting</a></li>
</ul>
</li>
<li><a href="/wiki/Technology_readiness_level" title="Technology readiness level">Technology readiness level</a></li>
<li><a href="/wiki/Technology_roadmap" title="Technology roadmap">Technology roadmap</a></li>
<li><a href="/wiki/Transhumanism" title="Transhumanism">Transhumanism</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="text-align: center;">
<div>
<ul>
<li><img alt="Category" src="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/16px-Folder_Hexagonal_Icon.svg.png" title="Category" width="16" height="14" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/24px-Folder_Hexagonal_Icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/32px-Folder_Hexagonal_Icon.svg.png 2x" data-file-width="36" data-file-height="31" /> <b><a href="/wiki/Category:Emerging_technologies" title="Category:Emerging technologies">Category</a></b></li>
<li><img alt="List-Class article" src="//upload.wikimedia.org/wikipedia/en/thumb/d/db/Symbol_list_class.svg/16px-Symbol_list_class.svg.png" title="List-Class article" width="16" height="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/d/db/Symbol_list_class.svg/23px-Symbol_list_class.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/d/db/Symbol_list_class.svg/31px-Symbol_list_class.svg.png 2x" data-file-width="180" data-file-height="185" /> <b><a href="/wiki/List_of_emerging_technologies" title="List of emerging technologies">List</a></b></li>
</ul>
</div>
</td>
</tr>
</table>
</div>


<!-- 
NewPP limit report
Parsed by mw1300
Cached time: 20161211073155
Cache expiry: 2592000
Dynamic content: false
CPU time usage: 0.984 seconds
Real time usage: 1.058 seconds
Preprocessor visited node count: 8329/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 358377/2097152 bytes
Template argument size: 8495/2097152 bytes
Highest expansion depth: 12/40
Expensive parser function count: 5/500
Lua time usage: 0.547/10.000 seconds
Lua memory usage: 4.7 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  888.657      1 - -total
 72.27%  642.234      1 - Template:Reflist
 43.90%  390.126     80 - Template:Cite_journal
 14.47%  128.594     11 - Template:Fix
 10.90%   96.885      7 - Template:Citation_needed
  8.48%   75.397     11 - Template:Delink
  5.58%   49.553      6 - Template:Navbox
  5.22%   46.432     21 - Template:Category_handler
  4.41%   39.214      3 - Template:Page_needed
  3.57%   31.738      1 - Template:Emerging_technologies
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1723667-0!*!0!!en!4!* and timestamp 20161211073154 and revision id 754177403
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Oncolytic_virus&amp;oldid=754177403">https://en.wikipedia.org/w/index.php?title=Oncolytic_virus&amp;oldid=754177403</a>"					</div>
				<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Biotechnology" title="Category:Biotechnology">Biotechnology</a></li><li><a href="/wiki/Category:Emerging_technologies" title="Category:Emerging technologies">Emerging technologies</a></li><li><a href="/wiki/Category:Experimental_cancer_treatments" title="Category:Experimental cancer treatments">Experimental cancer treatments</a></li><li><a href="/wiki/Category:Virotherapy" title="Category:Virotherapy">Virotherapy</a></li><li><a href="/wiki/Category:Viruses" title="Category:Viruses">Viruses</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Wikipedia_articles_needing_page_number_citations_from_January_2014" title="Category:Wikipedia articles needing page number citations from January 2014">Wikipedia articles needing page number citations from January 2014</a></li><li><a href="/wiki/Category:Articles_needing_more_detailed_references" title="Category:Articles needing more detailed references">Articles needing more detailed references</a></li><li><a href="/wiki/Category:Pages_using_ISBN_magic_links" title="Category:Pages using ISBN magic links">Pages using ISBN magic links</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_January_2014" title="Category:Articles with unsourced statements from January 2014">Articles with unsourced statements from January 2014</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_October_2016" title="Category:Articles with unsourced statements from October 2016">Articles with unsourced statements from October 2016</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_October_2014" title="Category:Articles with unsourced statements from October 2014">Articles with unsourced statements from October 2014</a></li><li><a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">CS1 maint: Multiple names: authors list</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_May_2012" title="Category:Use dmy dates from May 2012">Use dmy dates from May 2012</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Oncolytic+virus" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Oncolytic+virus" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Oncolytic_virus"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Oncolytic_virus"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Oncolytic_virus" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Oncolytic_virus&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Oncolytic_virus&amp;action=history"  title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search Wikipedia" title="Search Wikipedia [f]" accesskey="f" id="searchInput"/><input type="hidden" value="Special:Search" name="title"/><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton"/><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton"/>							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Oncolytic_virus" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Oncolytic_virus" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Oncolytic_virus&amp;oldid=754177403" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Oncolytic_virus&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="https://www.wikidata.org/wiki/Q1560099" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Oncolytic_virus&amp;id=754177403" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Oncolytic+virus">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Oncolytic+virus&amp;returnto=Oncolytic+virus&amp;oldid=754177403&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Oncolytic_virus&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-de"><a href="https://de.wikipedia.org/wiki/Onkolytische_Viren" title="Onkolytische Viren – German" lang="de" hreflang="de" class="interlanguage-link-target">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="https://es.wikipedia.org/wiki/Virus_oncol%C3%ADticos" title="Virus oncolíticos – Spanish" lang="es" hreflang="es" class="interlanguage-link-target">Español</a></li><li class="interlanguage-link interwiki-it"><a href="https://it.wikipedia.org/wiki/Virus_oncolitici" title="Virus oncolitici – Italian" lang="it" hreflang="it" class="interlanguage-link-target">Italiano</a></li><li class="interlanguage-link interwiki-ja"><a href="https://ja.wikipedia.org/wiki/%E8%85%AB%E7%98%8D%E6%BA%B6%E8%A7%A3%E6%80%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9" title="腫瘍溶解性ウイルス – Japanese" lang="ja" hreflang="ja" class="interlanguage-link-target">日本語</a></li><li class="interlanguage-link interwiki-pl"><a href="https://pl.wikipedia.org/wiki/Wirus_onkolityczny" title="Wirus onkolityczny – Polish" lang="pl" hreflang="pl" class="interlanguage-link-target">Polski</a></li><li class="interlanguage-link interwiki-fi"><a href="https://fi.wikipedia.org/wiki/Onkolyyttinen_virushoito" title="Onkolyyttinen virushoito – Finnish" lang="fi" hreflang="fi" class="interlanguage-link-target">Suomi</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Q1560099#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 11 December 2016, at 07:31.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="https://wikimediafoundation.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-cookiestatement"><a href="https://wikimediafoundation.org/wiki/Cookie_statement">Cookie statement</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Oncolytic_virus&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="https://wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="/static/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x" width="88" height="31"/></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":63,"wgHostname":"mw1209"});});</script>
	</body>
</html>
